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ABSTRACT 
Uncaria tomentosa, also known as cat’s claw, is an indigenous herb which 
originates from the Amazon River basin and has proven to be highly effective via case 
report and limited epidemiological evaluation in the pallative treatment of a number of 
inflammatory conditions. The herb is particularly preferred on the American market due 
to its various uses for healing, which provides the impetus for this research. The herb is 
being used to treat osteoarthritis and claims have been made for its ability to: enhance the 
repair of deoxyribonucleic acid (DNA), support joint health and improve immune 
function, enable normal division of cells, and, thus, prevent proliferation of cancer. 
Various studies have illustrated impacts on: cell death, inducible nitric oxide synthase 
(iNOS gene) expression induced by lipopolysaccharide, the activation of TNFα, and NF-
kB, the formation of nitrates, and also the production of hormone prostaglandin (PGE2) 
(Hardin, 2007; Sandoval et al., 2000; & Valerio & Gonzales, 2005). In this study, its 
impact on lymphocytes (immunity) and potential long-term use implications to 
osteoarthritis are explored.  
The purpose of this study was to examine the association of cat’s claw at various 
dosages on lymphocyte proliferation and nitric oxide expression in osteoarthritis patients.  
This has implications for both the long-term safe use of the herb and provides valuable 
information for osteoarthritis patients who may be currently using pharmaceutical 
prescriptions to manage the condition. Osteoarthritis patients may have concerns about 
side effects of those prescription medications and may be considering use of this herb to 
supplement or replace prescription medications. Further, a brief survey of key 
demographics often associated with the etiology of osteoarthritis was used to explore any 
possible relationships between these established risk factors and lymphocyte proliferation 
and nitric oxide expression at differing treatments of cat’s claw exposure.  
A total of 25 participants between ages 35 to 65 years old, with osteoarthritis, 
were recruited as a convenience sample through distributed flyers and outreach at 
physical therapy centers. Participants having any other immunological diseases were 
excluded from participation as were individuals taking immunosuppressive drugs. This 
study was designed using in-vitro cell culture techniques on cases serving as their own 
controls at the 0 ppm dosage level. Additional treatment groups included 10, 100, 150, 
250, and 450 ppm of pharmaceutical grade cat’s claw herb.  This was done under both a 
mitogen stimulated and non-stimulated treatment condition in standard micro-cell well 
plates.  Following incubation, the cells were analyzed through flow cytometry for 
proliferation counts and through additional assay tagged procedures and flow cytometry 
for nitric oxide expression.  
While descriptive findings illustrate some strong directional tendencies between 
various demographic factors and cell proliferation/nitric oxide expression and simple 
linear regression illustrated a difference in means, more advanced ANOVA did not 
illustrate significance.  ANOVA tests examining the relationship between decreased 
lymphocyte proliferation and decreased nitric oxide expression at the various treatment 
levels did not illustrate a significant relationship. Therefore, the exact biomolecular 
mechanism of action for cat’s claw herb is not through these modalities. Given the small 
sample size of this study and trends in the data, larger samples exploring the full panel of 
both pro and anti-inflammatory cytokines associated with osteoarthritis should be 
conducted.  It also suggests the possibility that the herb may be having direct effects on 
pain receptors which should also be investigated. 
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Osteoarthritis (OA) is a chronic disease where the joints of the affected person 
degenerate leading to adult disability. It is a condition which affects the entire joint by 
degrading articular cartilage. Articular cartilage is a combination of collagen, water, 
proteoglycans, and chondrocytes. Chondrocyte components control the cell matrix of the 
cartilage by turnover of the matrix (Sandell & Aigner, 2001). The destruction of the 
cartilage leads to friction and fibrotic conversion of articulating cartilage in synovial 
joints such as the knees, hips, hands, and lower spine region, resulting in pain and 
stiffness in the joints; which undermines the individual's mobility (Dieppe & Lohmander, 
2005).  Since osteoarthritis is not curable, the only option offered in contemporary 
medical care is its management.  
Osteoarthritis is the most common type of arthritis that weakens the whole joint. 
According to the Centers for Disease Control and Prevention, 52.5 million adults around 
the world have arthritis. The number of osteoarthritis patients in the United States 
increased from 21 million in 1990 to 26.9 million in 2005 (CDC, 2017). In the United 
States, U.S. health care costs for this condition where an estimated $82.4 billion per year 
(Tanna, 2004). 
Pharmacological therapy such as non-steroidal anti-inflammatory drugs 
(NSAIDs), Cyclooxygenase-2 (COX-2) inhibitors and Viscosupplements-Hyaluronic 




side effects of non-steroidal anti-inflammatory drugs (NSAIDs) can lead to 
gastrointestinal and cardiovascular problems and steroid use is associated with 
hypertension, neurological and psychological effects (Slipman, 2008).  The side effect 
associated with COX-2 inhibitors is gastrointestinal toxicity, while hyaluronate is 
associated with hypertension upon long term consumption (Mukherjee, Nissen & Topol, 
2001).  
Complementary and alternative supplements are increasingly being used to 
diversify the health care and medication options for osteoarthritis patients. This allows 
for improved healthcare outcomes by minimizing drug side effects (Synovitz & Larson, 
2012). People use alternative supplements, particularly natural herbs, to treat or improve 
the management of some diseases, such as osteoarthritis, that they perceive are 
ineffectively tackled using conventional methods. Cat’s claw is one of the alternative 
supplements that has been used to treat osteoarthritis symptoms (Johnson, Sohn, Inman, 
Bjeldanes, & Rayburn, 2013). 
Cat's claw, which is scientifically known as Uncaria tomentosa, has been 
historically used to treat and prevent inflammatory disorders, particularly osteoarthritis 
(Khanna et al. 2007). Traditionally, it has been used to treat chronic viral infections, 
bacterial infections, numerous inflammatory and immunological disorders, asthma, 
dysentery, cancers, arthritis, and as a birth control agent (Heitzman, Neto, Winiarz, 
Vaisberg, & Hammond, 2005). Nutraceuticals, including food or products containing 
cat’s claw, can be used to prevent and modify symptoms in osteoarthritis patients. So, 




This in-vitro study will examine the impact of cat’s claw (Uncaria tomentosa), a herbal 
treatment, that is reported to provide anti-inflammatory benefits, without major side 
effects, to identify effect differences between exposed and non-exposed cells on  nitric 
oxide stress, and lymphocyte characteristics proliferation. Using quantitative research 
methodology, the aim is to compile the data and information that would assist in 
increasing existing knowledge and awareness, and encourage further research which will 
assist in exploring the potential of cat’s claw in treating osteoarthritis patients. 
A total of 25 participants between ages 35 to 65 years old, with osteoarthritis, 
were selected as a convenience sample by invitation and distributed flyers. Participants 
were excluded who hand other immunological diseases or major immunological 
stressors, except osteoarthritis, and who were using drugs that altered the immune 
response. This study is designed using an in-vitro, self-control approach. Each 
participant’s lymphocytes serving as their own control at the 0 ppm treatment level. The 
remaining cells were treated with cat’s claw at 10, 100, 150, 250 and 450 ppm. 
Osteoarthritis is among the highest-ranking musculoskeletal disease accounting 
for 50% of disease burden in this category. Osteoarthritis of the knee is expected to 
become the fourth major cause of disability in women (Jordan et al., 2003). Destruction 
of the articular cartilage occurs when catabolic enzymes release and decrease the 
production of chondrocytes which ultimately breaks down the matrix. During the 
breakdown of the matrix, inflammatory cytokines are released such as Interleukin-1 (IL-
1), Interleukin-17 (IL-17), Interleukin-18 (IL-18), Interleukin-15 (IL-15), Interleukin-6 




Poniatowski, & Szukiewicz, 2014). According to Hardin (2007), nitric oxide (NO) and 
Nuclear factor-kappa-beta (NF-ĸB) are also released during the breakdown of the matrix. 
Hardin (2007) describes NF-ĸB as a biomolecule which, “regulates genes involved in the 
inflammatory process. NF-ĸB regulates the production of matrix metalloproteases 
(MMPs) by chondrocytes. During injury, chondrocytes release MMPs, which degrades 
the matrix” (2007, p.26). 
According to Tanna (2004), prevalence rates of osteoarthritis are varied across the 
world. Overall, osteoarthritis affects 13.9% of adults aged 25 years and older and 33.6% 
of adults aged 65+. In the United Kingdom, an estimated 10% to 15% of adults above the 
age of 60 have osteoarthritis. In Canada, it is estimated that over 4 million people have 
arthritis. Over 41 million people out of 321 million people have arthritis in the U.S. 
(American Public Health Association, 2016). The healthcare cost of osteoarthritis is 
estimated at $82.4 billion each year in the United States and $18 billion per year in 
Canada (See Figure 1). 
 
Figure 1: Number of population with osteoarthritis compared to a total number of 





According to Miller and colleagues (2005), osteoarthritis is usually a very painful 
joint condition affecting millions of people in the world. Patients with osteoarthritis 
suffer from pain and loss of function. The management of osteoarthritis is aimed at 
reducing pain, inflammation, slow degradation of cartilage, and improving function. 
Prevention of osteoarthritis includes non-pharmacological treatment, pharmacological 
treatment, intra-articular treatment, and surgical treatment (Tanna, 2004).  
Non-pharmacological treatment of osteoarthritis includes education, exercise, 
nutrition, weight loss, and physical aides such as knee braces (Jordan et al. 2003). 
Effective education techniques such as individualized education, group education, and 
patient coping skills was found to be 20% as effective as NSAIDs in reducing joint pain 
(Walker-Bone, Javaid, Arden, & Cooper, 2000). According to Tanna (2004), the effect of 
exercise on osteoarthritis is considered the most significant intervention. Exercise 
improves motion, joint flexibility, and muscle strength and endurance. Weight loss 
reduces pain and the risk of developing symptomatic osteoarthritis in women (Tanna, 
2004).  
Pharmacological therapy controls pain and improves function. However, it does 
not provide a cure and can produce side-effects from drug therapy (Gamble, Wyeth-
Ayerst, Johnson, Searle & Beecham, 2000). For example, paracetamol and 
acetaminophen are used in pain management but provide no cure. Non-steroidal anti-
inflammatory drugs (NSAIDs) are recommended for patients who are unresponsive to 




Corticosteroids and glucocorticoids are used in management of knee arthritis to reduce 
inflammation of swollen joints. Viscosupplements such as hyaluronan and hylan G-F 20 
are also used in management of knee osteoarthritis (Goldberg et al., 2002). However, the 
side effects of Non-steroidal anti-inflammatory drugs (NSAIDs) can lead to 
gastrointestinal and cardiovascular problems, while those of steroidal origin lead to 
increased hypertension and neurological and psychological effects (Slipman, 2008). In 
addition, the side effects associated with COX-2 inhibitors is the gastrointestinal toxicity 
while hyaluronate is associated with hypertension upon long term consumption 
(Mukherjee et al., 2001).  
The prevalence of osteoarthritis, lack of cure from pharmacological therapy, and 
therapy’s adverse effect on the patient, among other issues, have increased the interest on 
the part of patients to use complementary and alternative supplements. Cat’s claw is one 
of the identified alternative supplements that has been used for the treatment of many 
health conditions including osteoarthritis and rheumatoid arthritis (Vitetta, Cicuttini, & 
Sali, 2008). In 1997, cat’s claw herb ranked as the seventh most important herb in the 
U.S. as an alternative supplement (Chauhan, Singh, Bajaj, & Chauhan, 2015). According 
to Schulman and Dean (2006), cat’s claw is possibly effective in reducing the pain and 
stiffness in patients’ joints, improving function, and reducing the need to use 
pharmacological treatment.  
It is hypothesized that the bio-pharmacological activities of cat’s claw results 
from the presence of many secondary metabolites. Cat's claw contains two different 




Carbone, de Dioz Zuniga Quiroz, De Simone, & Pizza, 2004). The most active 
constituent alkaloid in cat's claw is pentacyclic oxindole. It appears to have an immune 
regulating factor that produces immunomodulatory and anti-inflammatory effects through 
some, as yet, unspecified means (Vitetta, Cicuttini, & Sali, 2008). Pentacyclic alkaloids 
can stimulate white blood cells to surround and destroy pathogens through phagocytosis 
(Talbott, 2003). Pentacyclic alkaloids from cat's claw extract was tested clinically for 24 
weeks in a double-blind of 40 patients with active rheumatoid arthritis. Placebo versus 
cat’s claw extract of 60 mg showed a reduction in the tender joints in patents with RA 
(53.2% vs 24.1%). The study reported minor side effects such as diarrhea and dyspepsia 
in three subjects (0.0075%). The extract was considered to be well tolerated (Mur, 
Harting, Eibl, & Schirmer, 2002). Another study showed that the ingestion of freeze-
dried cat’s claw relieves knee pain experienced during physical activities within four 
weeks of treatment (Piscoya et al., 2001). 
According to available animal toxicological studies, cats’ claw has not been 
associated with severe toxicity from oral intake. However, it could have side effects such 
as mild diarrhea, constipation, mild lymphocytosis, or digestive upset (Kuhn & Winston, 
2008). The use of cat’s claw should be avoided during pregnancy or by those wishing to 
have children because of its traditional use as a contraceptive (Valerio & Gonzales, 
2005). It should also be avoided for children under three years old because of its 
unknown pharmacokinetics and toxicity in that age cohort (Vitetta, Cicuttini, & Sali, 
2008).  It is clear that individuals are utilizing cat’s claw to self-medicate for 




research and the need to understand precise biomolecular mechanisms of its action, this 
study on the impacts of cat’s claw to innate immunity (lymphocytes) is timely. 
Purpose of the Study 
According to Vitetta and other researchers (2008), there is a need for studies 
which test the effectiveness of the recommended doses of cat’s claw because the precise 
biomolecular action and interactions with immunity are not entirely clear. While past 
studies have shown that cat’s claw is a possible treatment for some health conditions 
including osteoarthritis, more understanding is needed.  
This alternative supplement has proved to be a potential palliative treatment with 
minimal adverse effects for most users, a solution that the current medical treatment has 
not been able to offer (Rosenbaum, O"Mathuna, Chavez & Shields, 2010). In fact, 
pharmacological treatment increased the risk of gastrointestinal toxicity, hypertension, 
congestive heart failure, and liver injury (Tanna, 2004). If the effective mechanisms of 
action can be further elucidated, this would assist in reducing doubts about the 
mechanisms of action for the alternative supplement and the safety of its long-term use, 
perhaps increasing the number of patients treated using the alternative.  In regard to long-
term use side effects, cat’s claw has mild to moderate gastrointestinal effects that have 
been reported such as nausea, diarrhea, gas, and bloating (Kuhn & Winston, 2008). 
However, studies to date do not discuss its impact on lymphocyte suppression and long-







Osteoarthritis remains one of the greatest challenges faced by the global health 
system.  The disease features in the list of the top five causes of disability, especially for 
people with family history of arthritis, the elderly and professional sports players. 
Globally, osteoarthritis sufferers increased from 10.5 million in 1990 to 17.1 million in 
2010 (Cross et al., 2014). The annual estimated costs for direct and indirect osteoarthritis-
related treatments is $128 billion, including drugs, non-pharmacological procedures, and 
surgeries (Fuller‐Thomson, Stefanyk, & Brennenstuhl, 2009). Such costs are greater in 
developing countries where members do not have access to information about the 
disease. Therefore, understanding the pathophysiology of osteoarthritis plays a leading 
role in minimizing its adverse impacts.    
Osteoarthritis attacks the joint causing chronic pain, stiffness, and swelling. It 
often degenerates the entire articular cartilage. This is a specialized connective tissue 
comprising collagen, water, chondrocytes, and proteoglycans that provides a surface for 
smooth articulation as an individual walks, runs, or stretches (Leung, Rainsford, & Kean, 
2013). Normal joints move easily, the opposing articular surface does not create friction 
and distribute the load unevenly across the tissues; unlike in patients with osteoarthritis. 
The proper joint functioning relies on its biomechanical properties. The joints have 
several composites, such as subchondral bones, connective tissues, ligaments, cartilage 
surfaces, and capsule. The bone plates define the shape whereas the articular surface 




functions such as synthesis and absorption of enzymes and other chemicals during 
movements. The ligaments control the mechanical stability and flexibility while the 
synovial membrane secretes the enzymes (cytokines, growth factors) and hyaluronic acid 
(McAlindon et al., 2014).   
Osteoarthritis destroys the cartilage in the synovial joints, such as in the hands, 
knees, and spinal cord, which in turn leads to pain and stiffness (Omoigui, 2007). 
Osteoarthritis ranks among the most prevalent musculoskeletal diseases accounting for 
50% of disease burdens in this category. Researchers believe that the incidences of 
osteoarthritis will increase significantly and have greater effects on U.S. society as the 
baby boomer generations are reaching middle and old age.  Not all countries experience 
the same prevalence rates as the Centers of Disease Control and Prevention’s (CDC) 
statistics show that over 52.2 adults have arthritis globally and prevalence is not 
consistent, the U.S. having one of the higher rates. For example, the number of the United 
States’ citizens with this chronic type of arthritis increased from less than 21 million in 
1990 to 27 million in 2005 (CDC, 2017).  
Overall, 13.9% of adults aged between 25 and 64 years old and 33.6% (12.4 
million) aged above 65years old have osteoarthritis (CDC, 2017). Similarly, between 10 
and 15% of United Kingdom citizens are osteoarthritis patients, while about 4 million 
(11%) Canadians have the condition. Consequently, osteoarthritis places a heavy burden 
on a country’s health care system. Given that osteoarthritis cure and cause are not known, 





This chronic disease is not curable. However, patients who comply with the 
recommended treatment and management plan report better health outcomes than their 
counterparts that may lack access to proper medical care. As such, these management 
procedures aim at reducing inflammation, pain, and slowing the degradation of cartilage. 
Pharmacological therapy such as non-steroidal anti-inflammatory drugs (NSAIDs) and 
viscosupplements-Hyaluronic acid help such patients in pain management (Allen & 
Golightly, 2016; Man & Mologhianu, 2014).  
Osteoarthritis is also associated with regular hospitalizations and mortality. It 
constitutes the majority or arthritis related hospitalizations (69.9%) accounting for 814, 
900 hospitalizations in 2006. (Lethbridge-Cejku, Helmick, & Popovic, 2003). 
Osteoarthritis sufferers with comorbidities such as cardiovascular disease and dementia 
experience death rates that are more than 1.6 times higher than those for individuals 
without the osteoarthritis co-diagnosis (Silverwood et al., 2015). Individuals with 
osteoarthritis incur substantial expenses in related procedures, such as hip and knee joint 
replacement procedures. According to Kurtz and his partners (2011), the statics reveal 
that knee replacement surgeries tripled in the U.S. between 1990 and 2003. The 
percentage of female patients who underwent knee replacement surgeries was 62.4% and 





Pathophysiology of Osteoarthritis 
As explained by Hardin (2007), the disease is a common degenerative joint 
condition that affects over 20 million adults in the U.S.. Research reports that by the time 
individuals reach the age of 40 years, about 90 percent of them are expected to have 
radiographic properties in joints that bear weight which is an indication of osteoarthritis 
(Hardin, 2007). Degenerative joint disease is reported to affect some or all of the 
metacarpophalangeal, interphalangeal, spine, cervical as well as 
carpometatarsophalangeal joints (Hardin, 2007; Malemud, Islam, & Haqqi, 2003). On the 
other hand, the secondary category of such diseases can be seen in any joint due to acute 
or chronic articular trauma. Also, several factors such as biomechanical, proteases, and 
pro-inflammatory mediators influence the pathophysiology of osteoarthritis. In the past, 
researchers viewed osteoarthritis in terms of cellular inflammation that resulted from the 
increase in leukocytes in the affected joint. The scholars categorized the condition with 
other rheumatoid arthritis that resulted whenever the number of leukocytes exceeded 
1000 cells per milliliter (Allen & Golightly, 2015). 
However, recent studies indicate that synovial inflammation characterizes 
osteoarthritis. The inflammation in osteoarthritis does not only occur through nitric oxide 
inflammatory pathways but is also triggered, impacted or moderated by chemokines and 
cytokines (Silverwood et al., 2015).  The proinflammatory mediators trigger the 
manufacturing of proteolytic enzymes that degrades the extracellular matrix. Also, 
mechanical factors, wear and tear, and excessive joint loading all play significant roles in 




In simple terms, osteoarthritis is a disease that attacks the cartilage, a viscoelastic tissue 
that controls movement and other functions of the joints. The cartilage has three 
components including the cellular, liquids, and solid phase portions that account for 1-
2%, 70% - 80%, and 20% - 30% respectively of the tissue. When cells are injured the 
breakdown of the articular cartilage cell matrix releases cytokines (catabolic mediators). 
Examples of cytokines include: Interleukin-1 (IL-1), tumor necrosis factor alpha (TNFα), 
and also nitric oxide (NO), and they are all triggered by the inflammatory cells, 
synoviocytes, chondrocytes and fibroblasts (Hardin, 2007; Malemud et al., 2003). It is 
essential to note that joint injury is a complicated event that usually involves acute trauma 
of the cartilage. After cartilage injury various effects arise such as cell death (apoptosis, 
necrosis, or even both), production of cartilage proteoglycans, and also increased 
sensitivity to cytokines (Hardin, 2007). Due to the inflammatory response upon the 
release of nitric oxide and inflmmatory cytokines there is increased water content in  
tissues leading to swelling, pain and eventually, decreased mechanical functionality. As 
further elaborated by Hardin (2007), the pathophysiology of this form of arthritis 
involves continuous injury which is followed by repair, and over time, there is failure to 
repair, and lastly, there is the destruction of the cartilage. 
The cellular constituents mainly include the chondrocytes while the solid phase 
contains substances such as collagen and proteoglycans. According to Lahm et al. (2010) 
collagen has relatively slow turnover. On the other hand, proteoglycan exhibits rapid 
turnover. Normal joints maintain this matrix as they balance the degradation and anabolic 




motivating the cells to synthesize transforming growth factor ß (TGFß). Besides, 
promoting the matrix synthesis TGFß minimizes cartilage destruction by inhibiting the 
production of IL-1 and tissue inhibitors metalloproteinases (TIMPs). Cartilage also 
produces fibroblast growth factor and Insulin-like growth factor (B-FGF and IGFs) to 
assist in the repair process (Fang, Xu, Li, & Zhao, 2016).  
On the contrary, this is not the case in the osteoarthritis patient as the matrix 
degradation exceeds the anabolic enzyme synthesis, thereby resulting in a decrease in 
collagen and proteoglycans. Chondrocytes, in turn, synthesize more proteoglycan and 
collagen molecules to restore the equilibrium (Lahm et al., 2010). However, the enhanced 
cartilage degradation often outpaces the attempts to achieve reversal of matrix loss. 
Consequently, erosion, cracking, and fibrillation occur at the cartilages’ superficial layer. 
As the degradation progresses to the deeper layers, the patient’s condition worsens. This 
will also be evident through clinically noticeable symptoms, such as swelling of the joints 
and excessive pain during movement (Leung et al., 2013).   
 According to Garlanda, Dinarello, and Mantovani (2013), inflammatory 
cytokines, such as Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-15 (IL-15), 
Interleukin-17 (IL-17), Interleukin-18 (IL-18), and tumor necrosis factor alpha (TNFα), 
are released during the matrix breakdown. These cytokines induce the synovial cells to 
synthesize the MMPs and proteoglycan which inhibit type II collagen and proteoglycans 
synthesis. For example, IL-1 has been found not to stimulate cartilage destruction but to 




Nitric oxide, a pro-inflammatory ion, can also cause apoptosis (cell death with 
minimal inflammation) through a mutation in mitochondria. Nitric oxide components 
have been observed to cause fragmentation of DNA, the dysfunction of mitochondria, 
remodeling of cytoskeletal tissue, and induce the release of cytochrome C. All these 
factors lead to the development of apoptosis. This process demonstrates the pleiotropic 
(multiple actions) effects of nitric oxide (Vuolteenaho, Moilanen, Knowles, & Moilanen, 
2007).   
Moreover, the cytokines produce nitric oxide (NO) and NF-ĸB, as well as 
promote chondrocyte apoptosis that further supports cartilage deterioration (Kashyap, 
Carter, Sauer, & Chen, 2013) In this case, NF-ĸBs are chemicals that regulate the 
production of matrix metalloproteases (MMPs). In other words, the chondrocytes often 
create MMPs that degrades the matrix during an injury. The synovial cells and 
chondrocytes produce MMPs that are categorized as collagenases, gelatinases, and 
stromelysins. The joint synthesizes the substances as inactive enzymes regulated or 
activated through a process known as enzymatic cleavage (Kashyap et al., 2013). Having 
been activated, the MMPs lose the ability to resist against plasma-derived (alpha-2-
macrglubulin) and tissue inhibitors (TIMPS). According to Man and Mologhianu (2014), 
osteoarthritis enhances the MMPs synthesis to such a high level that it overwhelms the 
inhibitors, thereby, resulting in net degradation. It is clear that excess or deficiency in the 





Osteoarthritis Effects on Other Joint Tissues and Bones 
Several recent studies have revealed that osteoarthritis does not only affect the 
cartilage but the entire joint. Martel-Pelletier and Pelletier (2010) found that the articular 
cartilage degradation involves several cellular changes, biomechanical processes, bone 
remodeling, the formation of marrow lesions, and synthesis of enzymes by the synovium 
cells.  
Subchondral Bone 
This is the bone that lies just below the articular cartilage. Cortical bone joins the 
articular cartilage via a zone called calcified cartilage. Subchondral bone maintains 
healthy bone by reabsorbing excess secretions and forming new bones (Martel-Pelletier 
& Pelletier, 2010). However, the osteoarthritis process usually interferes with these 
functions. It can cause sclerosis and bone marrow lesions. The inflammation may also 
thicken the subchondral bone plate. The MMPs do not only modify the trabecular bone 
architecture, but also inhibit the development of the new bones along the joint margins. 
Osteoarthritis patients have high bone resorption indices that indicate the loss of the bone 
(Lahm et al. 2010). The synovial fluids in such joints come into contact with the bone 
marrow that, in turn, causes bone cysts to form (Ondrouch, Prague, & Czechoslovakia, 
1963). Lahm et al. (2010) note that the osteoarthritis affected subchondral bone produces 
a type of collagen, type I, which stimulates abnormal mineralization. The normal bone α1 
and α2 type I collagen chains ratio averages are 2.4:1, while affected bones ratios vary 
between 4:1 and 17:1. This abnormal mineralization pattern adversely affects the 




Bone Marrow Lesions 
The articular cartilage destruction is significantly associated with bone marrow 
abnormalities. The damage impacts negatively the formation of the bone marrow as well 
as bone marrow necrosis and fibrosis. The abnormalities accentuate the cartilage loss. 
Martel-Pelletier and Pelletier (2010) found that the cartilage loss is always higher in joint 
areas with high bone marrow lesions. The defective bone marrow is also responsible for 
cysts that block the synovial fluids from synthesizing important anabolic enzymes.  
Risk Factors 
Aging  
Osteoarthritis is more common among the elderly than the young. Doctors 
previously perceived osteoarthritis as an inevitable condition of old age. According to 
McAlindon and colleagues (2014), physicians previously hypothesized that frequent 
movements over the life course wore out the articular cartilage. In contrast, recent studies 
have indicated that regular, active physical exercise minimizes the chances of cartilage 
degeneration.  However, age is also known to bring about degenerative joint 
transformation, which leads to wearing out of joints (Scharstuhl et al., 2007).  Cartilage 
repair is likely to deteriorate as one grows old. The regressive joint transformation 
prevents normal healing process in the joints after wear-and-tear, which in turn leads to 
an increased risk of suffering osteoarthritis.  
Researchers have also dedicated their time to exploring differences between 
osteoarthritis cartilages and non-arthritic, aging joint tissues (Aftab, Siddiqui, Babur, & 




cartilages. However, these collagens are more predominant in osteoarthritis suffers than 
normal, aging cartilages. Moreover, a significant difference exists in the liquid phase and 
chemical components, such as the ratio of keratin sulfate to chondroitin sulfate. Möller et 
al., (2016) found that osteoarthritis patients are more likely to have chondroitin sulfate 
epitope 846 and carboxy propeptide which is normally found in fetal and neonatal 
cartilages. This means that old age increases the chances of osteoarthritis, but not all 
older adults have the disease.    
Abnormal Loading and Repetitive Injury 
The joints can withstand normal physiologic loads. Occupations which produce 
excessive joint loading may initiate or accelerate latent disease processes. Heavy manual 
labor, trauma, obesity and weight problems are leading risk factors of osteoarthritis. 
Moreover, higher body mass is medically associated with low metabolism. The low rate 
of metabolism in obese people is believed to increase the chances of progression of 
osteoarthritis in people who are predisposed to the disease (Roubenoff, 2000). Fat tissue 
in the body is known to trigger the release of particular hormones that alter growth 
factors. An excess of fat tissue in the body exposes joints to increased chances of 
developing osteoarthritis. Excess fat tissue may also trigger the advancement of 
osteoarthritis in patients who already have the disease (Messier et al., 2004).  
Individuals in occupations that require heavy load bearing on joints such as 
manual laborers, floor cleaners, those self-employed in construction, professional 
sportsmen, truck/taxi drivers, and farmers experience higher rates of hip and knee 




colleagues (2014), also note that cumulative trauma such as microfracture can stimulate 
enzymatic activity or cause wear and tear, consequently causing an imbalance between 
the degradation and repair of the cartilage. Further, the accumulation of joint debris from 
wear may alter the ability of the synovial cells to maintain homeostasis. For example, 
retired athletes, soccer, football, and rugby players record high incidences of knee 
osteoarthritis due to the numerous cruciate ligament injuries they suffer during the course 
of their careers.  
Injuries cause trauma to bones and joints by causing degeneration of cartilage, 
ligament injuries, and dislocated joints. Trauma on vital joints such as knees, which are 
weight-bearing joints, particularly from anterior cruciate ligament (ACL) tear and strain, 
may lead to osteoarthritis (Shrier, 2004). Joint injuries, mainly in weight-bearing joints, 
affect muscles, bursas, and ligaments surrounding the joint area. In severe and repeated 
cases of joint injury, cartilage may tear and menisci may wear-out. Continuous injuries 
around the same area lead to accumulation of dead and damaged cells, which trigger 
inflammatory processes causing the swelling of joints. Repetitive damage of cartilage 
results in inflammation that increases the chance of suffering from osteoarthritis. 
According to Muthuri, McWilliams, Doherty, and Zhang (2011), bodily injuries, 
particularly to articulating joints, may lead to rupture of blood vessels and clots around 
the joint. It reduces the free circulation of blood in and out of the joints, leading to 





The injuries cause subluxation of the joint as well as abnormal load distribution. 
In this case, subluxation refers to the altering of the collagen fibrils and ligaments. As a 
result, the tendons stiffen, thereby, decreasing the joint flexibility. Similarly, 
osteoarthritis risks among obese people with a body mass index of between 30 and 35 is 
four times higher than other individuals (Aftab et al., 2015).   
Genetic Factors 
Family history plays a significant role in the risk of developing osteoarthritis. The 
disease has been associated with the presence of several genes, such as those responsible 
for extracellular matrix proteins. Generally speaking, most osteoarthritis patients have 
strong body builds, wide geometrical bone measurement, and high bone mineral density 
(Kerkhof et al., 2014; Nevitt et al., 1995). This means that all the young people who 
inherit these traits from their parents are at a significant disadvantage. In fact, family and, 
thus, genetic factors have been found to be present in about 65% of all osteoarthritis cases 
(Manek, Hart, Spector, & MacGregore, 2003). Individuals from families with a history of 
other forms of arthritic and auto-immune diseases where arthritis symptoms predominate, 
such as lupus, ankylosing spondylitis, rheumatoid, and psoriatic arthritis, are at 
significantly higher risk of osteoarthritis than the general population. Individuals with 
endocrine problems, such as hemochromatosis and Wilson's disease, also fall under the 
disadvantaged group. The conditions often affect the blood supply along the joints and 
trigger buildup of toxic materials around the articular cartilage (Allen & Golightly, 2015).  
Hemophilia, which is a genetic bleeding condition, causes bleeding from minor 




reduced blood circulation to the joints. Recurrent bleeding and reduced blood circulation 
in the joints cause the degeneration of joint tissue and cartilage. It results in osteoarthritis 
of the joints in this population (Fernández-Moreno, Rego, Carreira-Garcia, & Blanco, 
2008).  
Gender  
Gender also plays a key role in osteoarthritis prevalence. Several studies suggest 
that more senior women suffer from the disease than senior men. Issa and Sharma (2006) 
found that the prevalence increases after in women after they reach menopause. The 
researchers attribute the increasing risk to the loss of estrogen. Estrogen prevents 
cartilage inflammation and women lose this protection after menopause when estrogen 
levels drop. Roman-Blas, Castañeda, Largo, and Herrero-Beaumont (2009), explain that 
research has produced compelling evidence on estrogen deficiency’s effects on the joint. 
For example, estrogen often impairs the secretion of type II collagen. Leung and his team 
(2013), confirm the findings that indicate that the osteoarthritis prevalence rate was 
higher in men below 45 years old than women in the same age range. However, 
osteoarthritis incidence is significantly higher in females above 55 years than in their 
male peers. The study showed that women were 2.6 times more likely to develop hand 
osteoarthritis after their 50th birthday than men of the same age. The difference is 
attributed to the decline in estrogen levels. Therefore, hormonal therapy may be effective 
for treating this group of senior women, but comes with increasing risk of heart attack 
and stroke, especially as aging continues (Leung et al., 2013).  Further, women have 




men. For example, researchers have observed that females playing soccer are three to 
four times more likely to experience joint problems as their male counterparts (Shrier, 
2004).   
Child birth is also believed to increase the risk of suffering osteoarthritis in 
women. With each birth, the risk of suffering knee and hip osteoarthritis increases by 
eight and two percent respectively. The wide alignment of women’s hips creates 
instability in the knee joints, which increases the chances of cartilage degeneration of the 
knee joints over the course of multiple pregnancies. This makes females more likely to 
develop osteoarthritis of the knee (Prieto-Alhambra et al., 2014). 
Lifestyle 
Diet, the level of physical activity, smoking, and drinking, play key roles in 
developing and living with osteoarthritis. Micronutrient deficiencies such as vitamins C, 
D, and K have been found to trigger arthritis. Leung and his partners (2013), cite that a 
lack of Vitamin C in feeding studies with mice caused chondrocytes to degenerate at a 
faster rate than in mice that were provided with adequate vitamin C. Similarly, humans 
who consume adequate Vitamin C and D achieve increases in bone density which lowers 
the progression of osteoarthritis. Furthermore, Vitamin K supports the coagulation 
process that regulates cartilage mineralization and may reduce the risk of developing 
osteoarthritis (Leung et al., 2013). 
Environment and Osteoarthritis 
Environmental toxins such as chemical pollutants, heavy metals, and pesticides 




Some of these toxins bioaccumulate in the body and lead to on-going, low-grade 
inflammation. (Spector & MacGregor, 2004). Dust, fibers, and prolonged smoking also 
lead to inflammation of joints and deterioration of joint tissues, which result in severe 
pain and reduced flexibility (Meggs, 1993). Additionally, Zeman et al. (2014) found an 
association between drinking water nitrate level and complaints of arthritis in an in vivo 
study of 150 individuals. Low- level nitrate exposure below 10 mg/L is not considered 
acutely lethal to humans but the research found that people consuming well water as their 
primary drinking water source below 10 ppm had osteoarthritis complaint, poorer health, 
lower recreational activity, muscle, and nerve pain. The effect became pronounced at the 
5ppm level of nitrate-nitrogen in the drinking water (P = .0150, f = 6.0533; Zeman et al., 
2011). 
According to Keysor et al. (2009), cold weather has been identified as a cause of 
stiffness and reduced flexibility in patients suffering from acute osteoarthritis. However, 
the cold helps comfort inflammation, which reduces pain and numbness on painful joints. 
Heat, on the other hand, has also been discovered to be therapeutic to patients suffering 
from osteoarthritis. Heat helps reduce stiffness around joints by increasing blood flow, 
hence making joints more flexible, thereby increasing a patient’s mobility (Dieppe & 
Lohmander, 2005).  
Food allergy and intolerance have been associated with osteoarthritis (Haugen et 
al., 1991). Most patients suffering from the disease are sensitive and allergic to foods 
such as eggplants, white potatoes, sweet pepper, tomatoes, and hot peppers. This group of 




et al., 2004). They also contain alkaloids, which affect metabolism of calcium in the body 
and cause inflammations in joints. Patients suffering from osteoarthritis are believed to 
experience a reduction in pain and inflammation after these foods are removed from their 
diets (Wetherell et al., 2004). Furthermore, fibrin, the mesh-like protein that helps to heal 
wounds after injury, is often produced by the body in the event of inflammation in joints. 
Fibrin has been proven to be a strong gauge of inflammatory joint disease. Deposits of 
fibrin are a conspicuous feature of arthritis (Gregory, Sperry, & Wilson, 2008).  
Omega 6 fatty acids used in excess cause inflammation, which leads to production 
of fibrin. Fibrin is fundamental to the processes that produce the majority of arthritis pain. 
Alternatively, proteolytic enzymes ease pain associated with osteoarthritis by moderating 
the response of lymphocytes. As people grow old, their production of proteolytic 
enzymes decreases, creating more pain for those with osteoarthritis (Yelland et al., 2006). 
Proteolytic enzymes eat away fibrin and other scar tissues, which prevent natural anti-
inflammatory processes from decreasing inflammation in osteoarthritic joints. 
Proteolytic enzymes help fight inflammatory tissues, boost cardiovascular and 
immune functions of the body, and dissolve scars (Kullich, 2012). In that manner they 
ease pain caused by osteoarthritis. For example, bromelain, a substance that is found in 
pineapples is proven to help in the production of proteolytic enzymes. It assists in 
removing toxins from the body, reducing, and preventing inflammation in the body as 
well as decreasing swelling in the body. Another dietary substance and spice, turmeric 
has anti-oxidant powers, which ease pain and inflammation. It shuts down the COX2 




enzyme found in unripe papayas, helps replenish proteolytic enzymes in the body. Citrus 
bioflavonoids act as anti-oxidants in the body and enhance quick and effective absorption 
of vitamin C. They inhibit elastase and collagenase enzymes, which aid in the 
degeneration of cartilage tissue at the articular surfaces of the joints. Finally, citrus 
bioflavonoids help joints remain healthy and flexible and protect against free-radical 
damage in the joints.   
Impacts of Osteoarthritis 
Osteoarthritis has multiple and adverse social, financial, and psychological 
impacts on patients and their families. Since the pain level from osteoarthritis is not 
predictable, osteoarthritis restricts the patient from social activities. According to Vignon 
et al. (2006), virtually all the people suffering from osteoarthritis complain about distress 
due to the loss of ability to control their lives. At first, individuals experience physical 
challenges while participating in intense activities such as sports (Vignon et al., 2006). 
Eventually, the individuals begin to experience more painful episodes during light 
movements. This, in turn, leads to sleep disturbance and distress, sleep disturbance being 
a major predictor of poor physical and mental health outcomes. On the other hand, 
quality of sleep is positively correlated with positive treatment outcomes. A study by 
Vitiello, Rybarczyk, Von Korff, and Stepanski, (2009) has shown that osteoarthritis 
patients who sleep at least four and half hours per night cope better with the disease than 
their counterparts getting less sleep. Further, those having careers in sports or those that 
are involved in heavy manual labor may lose their source of living. Understandably, the 




in part due to the inability of these households to absorb the increased medical costs and 
loss of primary income. Further, most of these manual labor occupations outside of 
professional sports are broadly characterized by poor compensation and lack of benefits, 
such as health insurance, life isurace, and retirement benefits. Consequently, these 
individuals’ health and wellbeing deteriorates, thereby, exposing them to other chronic 
co-morbidities, such as psychological distress and heart diseases (Hootman, Macera, 
Helmick, & Blair, 2003). 
Socially, patients with low self-esteem suffer more from chronic morbidity than 
their peers who quickly form and maintain social support relationships. Phyomaung et al., 
(2014) found that pessimistic individuals with osteoarthritis withdraw from 
recommended management procedures more readily, for example, they do not like 
performing light exercises and healthy physical activities such as walking and yoga. This 
can lead to high pain prevalence and increased dissatisfaction with life. According to 
Katon, Lin, and Kroenke (2007), stress for osteoarthritis patients increases with the 
intensity of pain, unmet psychological needs, physical disability and decreasing financial 
security. This is intensified with age as depression levels among older patients with 
osteoarthritis are higher (Sale, Gignac & Hawker, 2008). Therefore, caregivers should 
prioritize such disadvantaged patients’ psychological needs. Around 15% of the people 
with osteoarthritis experience depression and anxiety, with 8-10% of that among the 
elderly patients exclusively. Further complicating increased functional disability on the 
part of elderly patients is a reduced quality of life, and increased risk of falls that are 




Being in pain may trigger stress or depression in patients. However, if a patient 
suffering osteoarthritis suffers co-morbidities as well, pain associated with the disease often 
increases. Surveys that have been done by medical researchers have revealed that people with 
mild osteoarthritis who are also experiencing stress or depression, due to their condition, feel 
twice as much reported pain as individuals not experiencing stress and/or depression (Yudoh 
et al., 2005). When the two conditions, osteoarthritis and depression, overlap, the pain is 
multiplied. Medical studies reveal that osteoarthritis-related pain in the knee is often 
associated with stress or depression. The latter leads to reduced muscle conditioning. It 
becomes a vicious cycle which translates into increased pain associated with osteoarthritis 
and makes the patients stay isolated from other people; it worsens their depression condition 
and so on (Mishra et al., 2012). The latter increases the progression of osteoarthritis in 
patients. 
Further complicating disease management, the higher the negative emotions are, 
the lower is the patient’s ability to adhere to chronic disease management plans. 
Phyomaung et al., (2014), demonstrated that anxiety results in greater pain episodes than 
depression following joint surgery. This is attributable to the fact that anxiety reduces the 
quality of life both before and after undergoing surgery. On the other hand, self-efficacy 
is positively correlated with good coping strategies and better chronic disease 
management. Patients with high self-esteem report adhering to treatment and dietary 
plans more closely and honor all their doctors’ appointments. These individuals also 




achieving better post-surgical and chronic disease management outcomes. (Phyomaung et 
al., 2014).  
Clinical Features of Osteoarthritis 
Osteoarthritis patients often suffer from extreme pain accompanied with stiffness. 
The individuals’ discomfort increases during joint use and they feel relieved while 
resting. However, advanced stages cause persistent pain all the time, whether the patient 
is resting or not. According to Dieppe and Lohmander (2005), the loss of cartilage 
cushion results in friction between the bones causing severe pain even during a period of 
inactivity. In other words, the pain cannot be linked to specific stimuli. Swift (2012) 
notes that several studies exploring the brain’s role in pain perception and osteoarthritis 
reveal that the discomfort does not necessarily result from movement, pressure, or 
loading. They hypothesized that the pain may originate from the mechanical irritation of 
the synovial and capsular inflammation or bone sclerosis. As a result, the patient does not 
get enough sleep and struggles to engage in daily activities, such as walking and climbing 
stairs.  
The joints also become tender and may not move freely. This is not only because 
the muscles weaken but also due to the thickening of the synovial membrane. Such 
symptoms often vary with external conditions. That is, some patients experience pain 
during weather changes while others record bad and good spells all year round (Sutton et 
al., 2009). Osteoarthritis symptoms may also depend on the part of the body affected and 
individual risk factors, for example, osteoarthritis of the knees is highly associated with 




weight together with the progressive cartilage degeneration can deform the knees. A 
significant number of patients are forced to go for knee surgery as their conditions hardly 
respond to medications because of the etiological factors involved (Dieppe et at., 1999).  
Osteoarthritis of the fingers is associated with growth or spurs next to the joint. 
According to Tan et al., (2005), patients with osteoarthritis of the hands may develop two 
types of bony enlargement, the Heberden and Bouchard’s node.  This is abnormal bone 
growth that occurs at the end of the fingers, named after Dr. Herberden, a famous British 
physician, while the bony knob at the middle joint of the fingers got the name from Dr. 
Bouchard, a French doctor who made several discoveries about arthritis treatment in the 
1800s(Tan et al., 2005). The fingers also swell and become tender. Similarly, individuals’ 
that develop osteoarthritis of the cervical spine suffer from extreme pain in their necks 
and low back. Swelling in these areas prevents the normal functioning of spinal nerves, 
leading to numbness.  At the same time, the pain intensity varies from one patient to 
another. Swift (2012), found that the pain episodes are often inconsistent, making the 
development of standardized pain scales difficult for osteoarthritis sufferers. Moreover, 
the pain may come either every day or in episodes. Some patients describe the pain as 
intense and sharp while others say that it is dull and aching.  
Diagnostic Procedures 
The diagnosis focuses on the symptoms. The physician should examine the 
affected joints for swelling, tenderness, pain, and any other damage. He/she must 
supplement the physical examinations with imaging (x-rays and Magnetic Resonance 




2013). X-rays will not only reveal the cartilage loss but also show spurs and nodes around 
the joint. X-ray radiography may indicate osteoarthritis evidence before some patients 
develop severe symptoms. MRI also utilizes strong magnetic fields and radio waves to 
depict better details about the joint and the surrounding bone and soft tissues than X-ray.   
Joint fluid analysis, using a needle to withdraw fluids from the affected hip, knee, 
leg, or spine, indicates whether there are inflammation indicators while additional blood 
tests help to determine whether the joint discomfort results from other types of arthritis or 
other diseases.  For example, the blood examination will indicate erythrocyte 
sedimentation or the presence of other antibodies and rheumatoid factors (McAlindon et 
al., 2014).   
Treatment 
Osteoarthritis’ treatment entails a mix of pharmacological, non-pharmacological, 
intra-articular, and surgical procedures. The treatment begins with safe and low-cost 
therapies before advancing to more complex, costly and higher-risk interventions. The 
first treatment should include non-pharmacological activities, such as stress management 
and disease management education, exercise, nutrition, weight loss, and physical aids, 
such as knee braces (Allen & Golightly, 2015).  
Non-Pharmacologic Therapies   
Non-pharmacological interventions include creating physical exercise programs 
and other behavioral therapies aimed at strengthening the joint muscles, easing pain, and 
minimizing other risk factors, such as on-going weight gain problems. Aerobics, jogging, 




healthy body weight. Clinical studies indicate that low impact exercise presents some of 
the most significant intervention measures for living positively with osteoarthritis.  
Individuals who exercise regularly also achieve appropriate weight loss, a factor which 
has been shown to reduce pain for current osteoarthritis suffers and even the risk of 
developing symptomatic osteoarthritis in women. According to Hawkeswood and Reebye 
(2010), losing at least 5% of one’s body weight is adequate to reduce disability. At the 
same time, physical activities improve motion, joint flexibility, and muscle strength and 
endurance. Every loss of 1-kilogram of body weight leads to a reduction of 4 kg load per 
step and 4,800 kg per each kilometer a patient walks (Hawkeswood & Reebye, 2010).   
Behavioral therapy plays a critical role in managing osteoarthritis. Effective 
education techniques, such as individualized and group discussions, equip the patient 
with adequate coping skills for chronic pain and disease management, making the stress 
and disease management process learning processes 20% as effective as pharmacological 
strategies (Walker-Bone et al., 2000). According to Aftab et al., (2015), a sound chronic 
disease and pain management plan will consider each patient’s expectations, the severity 
of the disease, occupation, and social/psychological needs. Pessimistic patients, for 
example, require more counseling sessions than individuals with higher self-esteem and 
more optimistic outlooks. Treatment plans should be collaborative with care providers so 
as to engage the patient in setting appropriate treatment goals (Aftab et al., 2015)  
Both the literature and evidenced based practices document the benefits of 
patient-driven therapies over passive treatment procedures (Hawkeswood & Reebye, 




access to information and fully understand the needs for certain treatments rather than 
when health professionals impose the procedures on them without adequate education. 
Ideally, the first session should focus on informing individuals about osteoarthritis and 
outlining its treatment procedures. The second visit should concentrate on discussions of 
standardized exercise procedures, healthy diets, and other weight loss activities. Leung et 
al., (2013), found that following such a staggered program intervention results in greater 
weight loss and pain relief than traditional non-pharmacologic treatment. The patients 
also benefit from one-to-one interaction with experienced physical therapists and 
nutritionists.  
During interactions with physical therapist’s patients can learn about and access 
joint supportive devices, such as compression wear, braces, canes and walkers. 
Alternatively, the individual can use orthotic shoes that reduce stress on joints and splints 
to stabilize affected areas. Furthermore, the new knowledge gathered through 
consultation with nutritionists helps ensure the patient maintains low-fat food 
consumption and increases Vitamins C, D, and K in their diets. Individuals with severe 
conditions can employ a transcutaneous electrical nerve stimulation device, TENS to 
manage the pain. This equipment disrupts the transmission of the pain stimuli and has 






Several medications help to minimize pain and improve musculoskeletal function 
in osteoarthritis patients. The drugs are categorized as pain management medications, 
nonsteroidal anti-inflammatory drugs (NSAIDS), and joint injections (Garlanda et al., 
2013). For example, NSAIDS and acetaminophen relieve moderate to mild pain. In 
contrast, narcotics are preferable for severe osteoarthritis exacerbations. Like the 
analgesics, it is recommended to administer non-steroidal anti-inflammatory drugs 
(NSAIDs) to patients who are unresponsive to the non-pharmacologic measures because 
of their side effects.  The drugs both reduce pain and minimize inflammation.  Joint 
injections are effective for patients that are allergic to the NSAIDS.  Injecting 
glucocorticoids into arthritic joints reduces osteoarthritis symptoms. Similarly, 
cyclooxygenase-2 (COX-2) inhibitors and glucocorticoids are used in the management of 
knee arthritis to reduce inflammation of swollen joints. Viscosupplements, such as 
hyaluronan and Hylan G-F 20, have similar effects (Wobig et al., 1999).  
However, these medications have several side effects that make long-term use 
unattractive. For example, non-steroidal anti-inflammatory drugs (NSAIDs) often lead to 
gastrointestinal and cardiovascular problems, while steroid use may cause hypertension 
and psychological disorders (Slipman, 2008). Steroid injections lead to increased 
inflammation in joints over the long term; brought about by the crystallization of 
corticosteroid. It further reduces the rate of healing in patients who are suffering from 
osteoarthritis, since their joints remain sore, immunity is suppressed, and the crystals increase 




cause injury to joint tissues and irritate the nerves around the joint (Arroll & Goodyear-
Smith, 2004). They also expose joints to higher chances of infection from bacteria and other 
diseases. This complicates the healing process of osteoarthritis and increases chances of 
advancement of the disease, which exposes the patient to more pain.  
As a result, some physicians and patients are increasingly using complementary 
and alternative supplements to diversify the health care and medication options for 
osteoarthritis treatment. The fact that pharmacological interventions are palliative and not 
curative therapies, as well as various adverse effects of drug treatments, has increased 
interest on the part of patients to use complementary and alternative supplements (March, 
Amatya, Osborne, & Brand, 2010). These supplements mostly include natural herbs. For 
example, S- Adenosylmethionine (SAMe), cat’s claw (Uncaria tomentosa), and capsaicin 
are some of the alternative supplements that have been used to manage osteoarthritis 
symptoms (Kuhn & Winston, 2008; Noureddin, Mato & Lu, 2015). These alternative 
supplements allow for improved healthcare outcomes by eliminating the adverse side-
effects associated with conventional treatment methods (the drugs’ side effects). SAMe 
contains dietary supplements derived from natural foods that claim to be more effective 
than many pain medications (Kuhn & Winston, 2008). Similarly, capsaicin is an herbal 
medicine made from chili peppers. It contains substance “P” which is believed to block 
stimulation and transmission of pain signals normally triggered by inflammatory 
substances in the joints (Noureddin et al., 2015).  Moreover, cat’s claw has been used for 




significant reductions in pain and number of swollen joints in self-report case studies 
(Kuhn & Winston, 2008). 
Surgery  
Given the cost impacts and the risks associated with surgery, this treatment 
modality is reserved for osteoarthritis cases that do not respond to other treatment 
procedures. When surgery is indicated, however, patients should undergo surgery early 
enough to avoid experiencing complications such as, joint deformities and excessive 
muscle loss (Tanna, 2004). The arthroscopic procedure entails removing damaged/torn 
cartilage in the affected joint, irrigation, realignment, and cartilage grafting (Martel-
Pelletier et al., 2016). In joint replacement, the entire joint is removed and an artificial 
one attached to the bone ends. Arthroscopic surgery and joint replacement involve 
extended recovery times, sometimes taking more than six months to achieve the intended 
benefits (Charousset et al., 2008). 
Several complex factors determine osteoarthritis prognosis. Osteoarthritis cannot 
currently be cured, but developing the right attitude and adapting appropriate lifestyle 
changes minimizes the burden of living with osteoarthritis. Although most of the risk 
factors are not avoidable, osteoarthritis patients have the opportunity and responsibility to 
take control of their lives through appropriate lifestyle management and self-care. 
However, such positive outcomes are possible only when physicians and other medical 
practitioners invest adequate resources in patient and public education, raising awareness 
about this disease and its heavy health burden worldwide. Sharing knowledge about 




treatment of the disease over the past few decades. Current patients can access better 
informed and higher-quality health care more cost effectively than ever before.  
Cat’s Claw (Uncaria Tomentosa) 
Uncaria tomentosa, also known as Cat’s Claw, is a woody herb native to South 
and Central America. The common name of the plant is uña de gato, which is a definition 
for several plants in this species. There are more than 30 species of cat’s claw (Uncaria) 
herb known, with the two most commonly used of medicinal interest being, Uncaria 
tomentosa and Uncaria guianensis (Piscoya et al., 2001). In the Western world’s 
tradition, the latter is more popular as compared to the first one, but since both are in the 
same family of Rubiaceae, they share a common ethno medical use. The Uncaria 
tomentosa genus has been the most thoroughly examined within the western research 
community and its variety of uses catalogued. This explains, to some extent, its 
popularity amongst American consumers (Valerio & Gonzales, 2005).  
As further explained by Piscoya et al., (2001), the species cat’s claw is an 
indigenous herb from the Amazon River basin. For many years, the plant has been used 
as a traditional folk supplement, particularly by local natives and their shamans, in 
overcoming various health complaints, especially chronic inflammatory diseases such as 
arthritis (Caon et al., 2014; Piscoya et al., 2001). The reported health benefits of the herb 
have motivated researchers, most notably in the U.S., to study it users’ claims of positive 
health impacts. Findings of the studies conducted to date, generally conclude that the 




proven to be efficient in managing osteoarthritis and supporting joint health (Williams, 
2001). 
Background of Cat’s Claw (Uncaria Tomentosa) Use 
Cat’s claw herb was initially discovered by Arturo Brell, a German researcher of 
natural resources, who moved from Munich to Pozuzo, a small town in the Peruvian 
rainforest (Williams, 2001). The first evidence of the health benefits of cat's claw was 
found when Dr. Brell used it to treat a patient who was suffering from terminal lung 
cancer. After other therapies had failed, the patient started taking the plant’s root tea. As a 
result, he showed remarkable improvement, and after one year, he was cancer-free. The 
plant is a tropical liana, or a perennial vine that is rarely cultivated (Reinhard, 1999). The 
plant is harvested from either primary or secondary (logging) managed forest. The herb is 
known as “cat’s claw” as it has thorns similar in appearance to a cat’s claws. Most of the 
commercial supply of the cat’s claw is from Peru, but other nations are currently 
producing it due to its numerous health benefits and expanding market. 
The plant has far-reaching branches carrying long shoots that have large and oval 
leaves, approximately 10 cm long (Reinhard,1999). During blossoming, inflorescences 
that are panicle-shaped form instead of the usual thorns that are shaped like claws 
(Keplinger, Laus, Wurm, Dierich & Teppner, 1999). The bark, which is removed from 
the vine, is the major part traditionally used, and the outer layer has to be scrapped to 
remove fungal growth, tiny insects and other elements that could degrade the bark. In 
addition, Hoyos et al., (2015), explain that leaves of cat’s claw (Uncaria tomentos)a are 




extracts in standardized amounts and in a way that can be perceived as sustainable. Thus, 
the leaves of cat's claw are most often used for cosmetic, food, and pharmaceutical 
applications (Hoyos et al., 2015; Wagner, 1985). 
Cat’s claw has high concentrations of phytochemicals.  It has over 30 known 
chemical constituents including 17 alkaloids, glycosides, sterol fractions, tannins, 
flavonoids, and related beneficial compounds (Hoyos et al., 2015). Williams (2001), 
noted that researchers tend to attribute the efficacy of the cat’s claw plant to compounds 
known as oxindole alkaloids. However, more recent evidence suggests that water-soluble 
extracts of cat’s claw that have no oxindole alkaloids present were found to contain 
powerful anti-inflammatory as well as antioxidant impacts (Williams, 2001). According 
to a study conducted by Sheng et al., (2005), other compounds known as quinic acid 
esters are considered the active components of water-soluble extracts of the cat’s claw 
plant, and thus, they are responsible for the health effects in human beings. It is clear that 
further research is needed to understand both the active compounds in this herb and its 
precise biomolecular means of achieving its effects. 
Historical and Most Common Uses of Cat’s Claw 
According to Kemper (1999), cat’s claw (Uncaria tomentosa)  has been used by 
the people in the Ashaninka Peruvian rain forest for more than 2000 years. Among the 
historical uses of the cat’s claw plant are: as a general tonic to ward off illnesses, as an 
abortifacient,  to treat inflammatory diseases such as diarrhea, for gastrointestinal tumors, 
gastric ulcers, gonorrhea, rheumatism, acne, arthritis, diabetes, cancer, as well as diseases 




claw is sometimes used in combination with other herbs that are found locally, such as 
chuchuhuasi, in the treatment of arthritis. The Ashaninka also believe that specific 
species of cat’s claw, comprising species that contain pentacyclic oxide alkaloids such as 
Uncaria tomentosa, have a magnificent power that can only be realized by healing priests 
who are highly ranked in that society (Ganzera, Ilias, Khan, & Khan, 2001; Kośmider, 
2017;  Reinhard, 1999; Valerio & Gonzales, 2005). Therefore, there are numerous 
historical health applications of the cat’s claw plant. In that light, the Ashaninka people 
placed great value on the plant due to its diverse applications and purported health 
benefits. 
Today the cat’s claw species is being used in alternative health applications as a 
cancer remedy and immune stimulant besides being considered significant in treating 
inflammatory conditions, such as atopic disorders, arthritis, gastritis and other related 
intestinal conditions, viral infections such as HIV and prostate problems (Kemper, 1999). 
Other medicinal uses of the drug include treatment of chronic fatigue, environmental and 
chemical sensitivities, and also fibromyalgia. The demand for the cat’s claw herb has  
risen dramaticaly since many HIV patients are currently combining cat’s claw with the 
anti-HIV drug (AZT) (Kemper, 1999). Steinberg (1995) also notes that cat’s claw is often 
included in combination treatments with other herbs such as with capsaicin in the, 
“Nikken Anti-Arthritis” cream.  
Antioxidant and Anti-Inflammatory Properties of the Cat’s Claw Herb 
Through laboratory analysis, extracts of cat’s claw have been proven to possess 




(Aguilar et al., 2002; Aquino, DeFeo, DeSimone, Pizza, & Cirino, 1991; Pilarski, 
Zielinski, Ciesiolka, & Gulewicz, 2006). It has been shown that the antioxidant power of 
the cat’s claw herb is greater than that found in many extracts of vegetables, cereals, 
fruits, and also other medicinal herbs. 
As a cardinal sign of many illnesses affecting aging adults, chronic inflammation 
has been effectively managed by use of cat’s claw since it has a powerful anti-
inflammatory factor (Aquino et al., 1991). As explained by Bors et al., (2011), it  is 
believed that cat's claw extracts inhibit the secretion of an inflammatory messenger 
known as TNFa. The messenger is pertinent for setting the stage, not only for acute, but 
also for chronic inflammation. Cat’s claw is also believed to inhibit the activation of NF-
kB that acts as an inflammatory "switch" linked with a variety of diseases including 
cancer (Heitzman et al., 2005; Piscoya et al., 2001). According to a laboratory study 
conducted by European researchers, cat’s claw not only prevents the growth of human 
leukemia cells, but also induces the cells to go through apoptosis (a programmed self-
destruction; Hayakawa & Smyth, 2006; Sheng, Pero, Amiri, & Bryngelsson, 1998). 
Similarly, research conducted by Piscoya et al. (2001) showed that extracts of the 
medicinal herb reduced the experimentally-driven production of PGE2. The hormone is 
believed to mediate inflammation, hence it is linked with chronic inflammatory illnesses 
such as arthritis (Aguilar et al., 2002; Piscoya et al., 2001).  Researchers have also 
explored the effectiveness of the cat's claw herb in the protection of DNA from oxidative 
stress. Mammone et al., (2006), conducted a laboratory study of cultured human skin 




extract of cat’s claw (C-Med-100), greatly reduced the death of skin cells following 
exposure to UV light (Mammone et al., 2006). As elaborated by Mammone et al., (2006), 
the protection was explained by an increase in the repair of the genetic material (DNA) 
attributed to the cat’s claw water extract. 
Cat’s Claw (Uncaria Tomentosa) and Osteoarthritis 
Overview of the Relationship between Cat’s Claw and Osteoarthritis 
Cat's claw use in osteoarthritis treatment is a form of alternative and 
complementary therapy (Vitetta, Cicuttini, & Sali, 2008). There are different reasons for 
using alternative and complementary therapies and supplements among different racial 
and ethnic groups in the U.S. Among those reasons are prohibitive costs associated with 
conventional treatments, a concern conventional treatment might fail to work as the 
patients would expect, cultural ties to traditional cultures using herbal medicine, or 
concern that pharmaceuticals may produce too many side effects (Vitetta, Cicuttini, & 
Sali, 2008).  
Another reason as to why individuals may use complementary supplements is the 
search for greater relief of disability and/or symptoms without the increased likelihood of 
side-effects associated with pharmaceutical treatment. In addition, individuals seek 
complementary supplements such as cat's claw in efforts to reduce the stress linked with 
living with a chronic disease, and hence, to cope better with the illness (Vitetta, Cicuttini, 
& Sali, 2008). There is also the belief that alternative and complementary treatments are 
not only safer, but also more “natural”. The belief is in part influenced by the widespread 




As explained by Vitetta, Cicuttini, and Sali (2008), musculoskeletal diseases are a 
fundamental cause of disability, and arthritis is the most prevalent form of such 
degenerative diseases. The use of the herb to treat a form of arthritis known as 
osteoarthritis has been highly adopted by people in the U.S. and throughout the world. 
Cat’s claw extracts have been associated with properties such as, antioxidant, 
immunomodulatory, and also anti-inflammatory (Vitetta, Cicuttini, & Sali, 2008). The 
pentacyclic oxindole alkaloids are the most researched of the active components in cat’s 
claw extract for anti-inflammatory and immunomodulatory health impacts. Scientists 
report that the alkaloids induce a factor that regulates the immune system (Ahmed, 
Anuntiyo, Malemud, & Haqqi, 2005). It is believed that such properties make cat’s claw 
effective in the osteoarthritis therapy although this is only partially understood. 
Cat’s claw Action in the Treatment of Osteoarthritis 
According to Sandoval et al., (2002), cat’s claw inhibits iNOS gene expression 
that is induced by lipopolysaccharide, cell death, formation of nitrates, production of 
hormone prostaglandin (PGE2), and also the activation of TNFα, and NF-kappaB 
(Hardin,2007; Sandoval et al., 2002). There is also evidence in rat models, that cat’s claw 
stimulates IL-1 and -6 (Hardin, 2007). Further, extracts of cat’s claw (both Uncaria 
tomentosa and guianensis) have been shown to inhibit the redox-sensitive control of gene 
expressesion, suppress apoptosis, TNFα, act to scavenge free radicals, and also 
cryoprotect cells against such oxidants as peroxynnitrite in murine cell line and human 




It seems clear that cat’s claw has powerful antioxidant properties, its alkaloids 
binding with free radicals, stoping redox reactions (oxidation and reduction reactions) 
before they damage other biomolecules (Sandoval-Chacón et al., 1998). According to the 
study (n = 45, ages 45-75) done by Piscoya et al., (2001), TNFα suppression was reported 
to be at treatment levels that are considerably less compared to that required for 
antioxidants. Cat’s claw was also reported to inhibit the activation of NK-kappaB 
(Hardin,2007; Piscoya et al., 2001). Winyard and Blake (1997) conducted a study on 
mice, which explains that NK-kappaB (the transcription factor) is sensitive to redox 
reactions and it thus controls the expression of genes that lead to inflammatory 
degenerative diseases (i.e., osteoarthritis). According to another study conducted by Beg 
and Baltimore (1996), on mouse embryonic fibroblast cells, cat’s claw’s inhibition of NF-
kappaB, is pertinent in osteoarthritis therapy as two widely applied anti-inflammatory 
agents, namely glucorticoids and salicylates, play a role in NF-kappaB suppression. 
Benefits of Using Cat’s Claw (Uncaria Tomentosa)  in the Treatment of Osteoarthritis 
As explained by Vitetta, Cicuttini, and Sali (2008), there are minimal side effects 
associated with the use of cat’s claw to treat osteoarthritis. Use of the herb is associated 
with relative safety as well as modest benefits to tender joints. A number of case studies, 
series and epidemiological studies have documented the efficacy and minimal side-
effects of cat’s claw. Reearchers have reported that the herb appears to be non-toxic and 
that it has no known drug interactions or contraindications (Chrubasik, Roufogalis, & 




 Another benefit associated with the use of the cat’s claw herb in osteoarthritis 
therapy is its ease of standardization, particularly in its commercial preparation (Hardin, 
2007). Hardin (2007) notes that genera Uncaria tomentosa is a bit different from its 
closely related genera Unacari guianensis in that the former has  a higher content of 
alkaloids, hence its effectiveness in the treatment of osteoarthritis. The herb is also being 
increasingly adopted by individuals due to the belief that naturally occurring plants are 
considerably more effective and give satisfactory health results as compared to 
conventional medicines (Vitetta, Cicuttini, & Sali, 2008).  
Cat’s Claw and Implication for Osteoarthritis 
As explained by Vitetta, Cicuttini, and Sali (2008), even though cardiovascular 
diseases and cancer (highest mortality) receive much attention from the medical and 
public health community, rheumatic or musculoskeletal conditions are the main cause of 
morbidity (chronic disease suffering) in the world. Musculoskeletal and immune 
moderated conditions such as, osteoarthritis, fibromyalgia, gout, rheumatic arthritis as 
well as systemic lupus erythematosus (SLE) have substantial impact on health and quality 
of life and also inflict a great economic burden on the economy (Vitetta, Cicuttini, & Sali, 
2008). Arthritis is the most common form of chronic musculoskeletal disease, and by the 
year 2007, it affected about 43 million adults (20.8%) in the U.S.. Another implication of 
the disease is that it is the greatest cause of disability in the U.S.. Osteoarthritis is also the 
most prevalent disorder of the joints in the world (Vitetta, Cicuttini, & Sali, 2008).  
 Osteoarthritis is also one of the most frequent sources of severe pain, disability 




(2008), radiographic evidence of osteoarthritis is seen in most people when they attain the 
age of 65 years and in approximately 80 percent of individuals over 75 years of age. 
Given these considerations, the use of low-cost, herbal therapies to manage this disease 
remains pertinent. Cat’s claw users have considerable faith in the effectiveness of the 
herb to treat osteoarthritis, citing a belief that the herb is safer and natural, and noting the 
fear of side-effects associated with pharmaceutical therapy (Hemingway & Phillipson, 
1974; Vitetta, Cicuttini, & Sali, 2008). Also, most users cite not only short-term, but also 
long-term health benefits as reasons for its use. Similarly, the cost of pharmaceutical 
treatment is higher, compared to using naturally-occurring herbs, hence the increased 
preference of cat’s claw (Vitetta, Cicuttini, & Sali, 2008).  
Health Impacts of Cat’s Claw on Slowing Progression of Osteoarthritis 
Two general properties of cat’s claw, preventing inflammation and oxidation, 
cannot be stressed enough when describing the health benefits of the herb in osteoarthritis 
therapy. As explained by Sandoval et al., (2002), the active chemicals in cat’s claw have 
been identified as sterols, quivonic acid glycosides, and oxindoles. Extracts of cat's claw 
suppress inflammation and thus enable the development of healthy joint function and 
structure. Relievng the inflammation also relieves the pain and feeling of discomfort 
brought about by osteoarthritis.  What remains unclear is the precise biomolecular 
mechanisms by which this effect is achieved.  Whether the herb accomplishes this by 
reduction in lymphocyte proliferation, modulation of cytokines, supression of the 
biomolecular pathways of inflammation and redox reactions or a combination of all these 




According to Hardin (2007), cat’s clawis capable of protecting cartilage. Loss of 
cartilage is a defining feature of osteoarthritis, and it sets in when the rate of cartilage 
breakdown exceeds that of its regeneration. A study done by Miller, Ahmed, Bobrowski, 
and Haqqi (2006) showed that cat’s claw helped to restore Insulin-like growth factor-1 
(which protects joints) levels after cells of human cartilage were subjected to interleukin-
1 beta, an agent that destroys joints (Miller et al., 2006 ). Patients with osteoarthritis 
suffer from immense pain and discomfort due to the destruction of protective cartilage. 
According to Piscoya et al., (2001), cat’s claw’s benefits for relieving osteoarthritis in 
general are due to these powerful anti-inflammatory and antioxidant properties. Cat's 
claw therapy has been used as the sole medication for patients with osteoarthritis, and it 
has also been used along with pharmecutical medications as complementary and or 
alternative treatment (Vitetta, Cicuttini, & Sali, 2008).  
Cat’s Claw and Osteoarthritis: Studies and Research 
Scientists have conducted a number of studies to establish the health benefits of 
cat’s claw in osteoarthritis therapy. Most of the studies revolve around the plant’s 
potential to prevent inflammation and oxidation. Klaus Keplinger conducted the first 
documented research on cat’s claw in the 1970s and 1980s. According to the research by 
Keplinger, cat’s claw is endowed with immune “strengthening” properties which are 
explainable due to the presence of oxindole alkaloids (Keplinter et al., 1999). Another 
study was conducted by Piscoya et al., (2001), to investigate the efficacy and safety of 
freeze-dried cat's claw in osteoarthritis of the knee. Even though the study was assessing 




this genera of the herb has similar anti-inflammatory and antioxidant features as U. 
tomentosa, for treating symptoms of osteoarthritis. Piscoya et al., (2001), showed that 
patients who had pain that was associated with activity as well as patient/medical 
assessment scores were all significantly improved, and that the patients benefited within 
the first week of treatment with cat’s claw extracts. Piscoya et al., (2001) concluded that 
cat’s claw should be considered a significant therapy in alleviation of chronic 
inflammation; hence the herb is highly regarded in South America and now throughout 
the world. 
Miller et al., (2006), assessed the effects of cat’s claw when human cartilage cells 
were subjected to interleukin-1 beta, an agent that triggers erosion of joint cartilage 
matrix. The study concluded that the use of cat’s claw was pertinent in the treatment of 
degenerative diseases as it helped to bring to normal the levels of Insulin-like growth 
factor-1 which slows matrix erosion and helps protect joints (Miller et al., 2006). 
According to the study, cat’s claw was positively associate with the  preservation of 
healthy cartilage in  aging joints (Miller et al., 2006).  
Mur et al., (2002), conducted research to assess the effectiveness of cat’s claw for 
degenerative conditions with a particular focus on rheumatoid arthritis. The disease is 
characterized by multiple immune system modulated systemic effects as well as severe 
joint inflammation and stiffness, the synovial joint impacts also define osteoarthritis. The 
study indicated that the participats experienced significant improvement in swollen and 
painful joints (Mur et al., 2002). Mur et al., (2002) concluded that the improvement in 




fully understand the biomolecular mechanisms of cat’s claw function as rheumatoid 
arthiritis is a condition of autoimmune disfunction.   
Ahmed et al., (2005), explored the biological basis for a number of botanicals 
used in osteoarthritis and rheumatoid arthritis. Among the numerous herbs the researchers 
examined were the two most common genera of cat’s claw, Uncaria tomentosa and 
Uncaria guianensis. They discovered that concentration of pentacyclic oxindole alkaloids 
in each genera provided immunomodulating, antioxidant, and anti-inflammatory effects 
(Ahmed et al., 2005; Kośmider, 2017;Williams, 2001). 
Chrubasik et al., (2007) also conducted a study to explore the proof of 
effectiveness of herbal anti-inflammatory drugs in the therapy for chronic low back pain 
and osteoarthritis. The researchers conducted systematic reviews of various medical 
journals and libraries to obtain data to prove the applicability of herbal drugs that are 
orally administered to treat these degenerative conditions. The authors concluded that use 
of cat’s claw herb was effective due to the presence of naturally occurring alkaloids that 
aid in  fighting inflammation and amelioraiton of low back pain (Chrubasik et al., 2007)  
Hardin (2007), studied the development of osteoarthritis, particularly the 
suppression of collagen fiber degradation by blocking the action of cytokines (NF-kB, 
and TNFα), and also cat’s claw’s antioxidant benefits. The herb action according to 
Hardin can in part be expalined by the ability to slow or prevent the destruction of 
cartilage with at least one cytokine involved in this as well as the well researched 
antiinflammatory and antioxidant actions (Kessler, Davis, Foster, Rompay, Walters, & 




deserves further study in order that its biomolecular actions and long-term safety be 
understood.  
Negative-Side Effects of Cat’s Claw 
Even though cat’s claw herb is associated with numerous health benefits, it still 
has some negative effects. Being a herb, cat’s claw has both desirable and undesirable 
properties associated with the constituent alkoloids providing its effects; hence the 
alkoloid extraction and supplement preparation process should receive utmost 
consideration. The herb contains tetracyclic alkaloids (TOA) which most manufacturing 
companies claim are toxic or harmful to human beings and must be removed from 
supplements for human consumption. Further, cat’s claw also has other beneficial 
oxindole alkaloids known as pentacyclic alkaloids (POA) which must be isolated and 
concentrated at an effective consistent dosage (Caon et al., 2014; Ganzera et al., 2001). 
Further, since not all benefits or uses of cat's claw have been validated by the Food and 
Drug Administration (FDA), usage of the the herb cannot be medically recommended as 
a substitute in place of drugs prescribed by physicians (Caon et al., 2014). 
 Among the most common potential concerns about the use of cat’s claw include 
the fact that it is sold as an herbal and thus, nutritional, supplement with no regulated 
standards of manufacturing overseen by the U.S. FDA in place. Many marketed 
supplements have been found to contain other drugs or toxic metals; hence cat’s claw has 
similar risks when unregulated. Therefore it is essential to purchase herbal supplements 




certification and scientific methods to assure the removal of harmful alkaloids, standard 
dosage of active alkaloids, and minimization of contamination (Scott & Elmer, 2002). 
For most people, cat's claw has been found to be possibly safe when taken orally 
for short periods of time (Cat’s Claw, 2014).  Nonetheless, side effects such as dizziness, 
headache, and vomiting have been reported among some users. Due to a lack of long-
term and pregnancy/lactation studies precautions against using the herb when pregnant or 
during breastfeeding have been issued by researchers and medical authorities (Hardin, 
2007).  It is advisable that pregnant mothers as well as those breastfeeding refrain from 
its intake. It also necessary for women seeking to be pregnant, as well as children who are 
below three years of age, to avoid the use of cat’s claw until there is a full biomolecular 
and long term-use understanding of the pharmacological actions and health impacts of the 
herb (Hardin, 2007; Williams, 2001). The other negative effect of cat’s claw is that it 
might contribute to hyperactivity or pertubations of the immune system (Kemper, 1999). 
As a result, there could be an increase in the symptoms of auto-immune illnesses such as 
lupus (systemic lupus erythematosus) and multiple sclerosis (Kemper, 1999). Therefore, 
any individual with any auto-immune disease should avoid using cat’s claw unless it is 
prescribed by their healthcare provider.  
Researchers suggest that it might also cause bleeding disorders as it has the 
potential to slow blood clotting (Spaulding-Albright, 1997). With such a potential risk, 
there is a concern that the herb is likely to heighten the risk of bleeding or bruising, 
particularly for people with such preexisting bleeding disorders or who may already be 




potential side effect of cat’s claw use is complications during surgery as it might make 
the control of blood pressure and/or bleeding difficult. In that light, patients scheduled for 
surgery are advised to stop taking cat’s claw. Lastly, use of cat’s claw is believed to pose 
side effects to patients with leukemia due to the difficulties it presents in the control of 






METHODOLOGY, RESEARCH HYPOTHESES, QUESTIONS, AND OBJECTIVES 
Given the previous discussion of cat’s claws reported benefits and the limited 
understanding of its biomolecular and immune system actions, the need for additional 
information is clear. Therefore, this study was envisioned to provide additional 
information to the body of knowledge concerning this herb by studying the in vitro 
responses of human lymphocytes from individuals with active osteoarthritis under 
varying treatment levels of cat’s claw. Thus, three null hypotheses and three alternate 
hypotheses were developed to guide this study:  
Null Hypotheses 
H0: Cat’s claw (Uncaria tomentosa) will have no significant difference of effect, from 
individuals with osteoarthritis, within treatments or between exposed and non-exposed 
cells for the following: 
H01: Cat’s claw will have no significant difference between exposed and non-exposed 
cells, nor between treatment gradients on lymphocyte proliferation. 
H02: Cat’s claw will have no significant difference between exposed and non-exposed 
cells, nor between treatments on nitric oxide stress. 
H03: There will be no significant difference between various questionnaire items such as 
demographics, weight, length of disease, medications taken, etc. between exposed and 






H𝑎𝑎: Cat’s claw (Uncaria tomentosa) will have a significant difference of effect on 
lymphocytes, from individuals with osteoarthritis, within or between exposed and non-
exposed cells for the following: 
H𝑎𝑎1: Cat’s claw will have a significant difference on exposed and non-exposed cells by 
treatment gradient on lymphocyte proliferation. 
H𝑎𝑎2: Cat’s claw will have a significant difference between exposed and non-exposed 
cells by treatment gradient on nitric oxide stress. 
Ha3: There will be a significant difference between various questionnaire items such as 
demographics, weight, length of disease, medications taken, etc. between exposed and 
non-exposed cells, nor between proliferation and nitric oxide stress. 
Research Questions 
Several research questions have been developed to guide this study. These include 
the following: (1) Are there differences in lymphocyte proliferation between the different 
treatments? (2) Are there differences in nitric oxide expression between the different 
treatments? (3) Are either proliferation and/or nitric oxide expression significantly 






This study has several objectives. One objective is to monitor the effectiveness of 
cat’s claw at various treatment levels on nitric oxide stress and lymphocyte proliferation. 
Another is to increase awareness and understanding of the possible benefits of natural 
herbs as an alternative to pharmaceutical products as well as identify any potential long-
term use concerns. The third objective is to reduce risks from the use of pharmaceutical 
products, since adverse effects are common, and the long-term efficacy of these drugs is 
variable. And the fourth objective is to improve health and well-being of the population 
by providing further information about the safety and effectiveness of low-cost, minimal 
side-effect alternatives. 
Significance of the Study 
The benefit of cat’s claw has been widely researched. This study is significant for 
several reasons. First, it will increase existing knowledge and awareness about 
osteoarthritis treatment. Secondly, it has the potential to increase awareness and 
understanding of the possible benefits of natural herbs as an alternative to pharmaceutical 
products. Thirdly, it will contribute to the understanding of the biomolecular mechanisms 
of cat’s claw’s effectiveness. Finally, it will aid in the identification of areas for further 







The limitations of the study are as follows:  
1. The sample size of the study is relatively small with only 25 participants.  
2. The research will be done in the lab in vitro versus in vivo. 
3. Participants will self-identify themselves as osteoarthritis patients. 
4. Participants may not be not totally accurate in their responses to the questionnaire.  
Methodology 
 This study was approved by the Institutional Review Board (IRB; See Appendix 
A). This in vitro study examined the effects of different concentrations (treatments at 0, 
10, 100, 150, 250, and 450 ppm) of cat's claw (Uncaria tomentosa) on nitric oxide stress 
and lymphocyte proliferation of individuals with osteoarthritis disease. This was 
accomplished by application of standard cell culture techniques, in vitro and using the 
participant as their own control (0 ppm treatment).  
Study Design 
The study was designed in-vitro (micro-cell well plates) with blood samples taken 
from each participant and processed to extract mononuclear cells. Peripheral blood 
mononuclear cells (PBMCs) consist of lymphocytes and monocytes that are used for 
various experiments, including human immunology, (proliferation studies) production of 
cytokines and nitric oxide expression (Hunziker, Lippuner, Keel, & Shintani, 2015). 
 Following full, informed consent and a prescreening discussion with participants 
to eliminate anyone with preexisting autoimmune disease, a blood draw for each 




(four, 5 ml vials). The blood sample obtained falls within Red Cross guidelines. Blood 
draws were scheduled through the Student Health Clinic (SHC) at University of Northern 
Iowa. Thus, blood was drawn by a qualified phlebotomist. At the time of the blood draw 
a short questionnaire was completed by each participant with sections covering 
demographics and factors known to be associated with immune system function 
(osteoarthritis history, general health, medications, herbs, supplements, smoking history, 
and psychosocial stress) (see Appendix D ). 
In all cases, samples were obtained and transported to the lab, under ice, for 
immediate processing of mononuclear cells (lymphocytes) within the required time frame 
of 2-3 hours. Failure to accomplish this within the required time frame, could have 
affected the results. However, once timely processing was started, the length of the 
experiment did not affect the findings. Mononuclear cells were isolated using cell 
separation techniques involving the use of a Ficoll-Hypaque density-gradient 
centrifugation method, according to standard immunology procedures as detailed by 
Kanof, Smith and Zola (1996; see Appendix J). The viable isolated mononuclear cells 
were processed to obtain counts and viability using a Millipore MUSE Unit 
(7200121194) flow cytometer. The mononuclear cells were then plated into the micro-
cell well plates and treated with different concentrations of USP grade cat’s claw ranging 
from 0, 10, 100, 150, 250, 450 ppm, where 0 ppm indicated untreated control. All 
controls and treatments were then challenged with a mitogen to encourage cell 
proliferation. The cells were then incubated at 35℃ with 5% CO2 level for 48 hours as 




After 48 hours, the cells (both unchallenged and challenged) were evaluated for nitric 
oxide expression using the Millipore MUSE flow cytometer. This allowed the researcher 
to determine the impact of treatment on nitric oxide expression. After and additional 96 
hours, both unchallenged and challenged cells were counted to find total number of 
viable cells by counts and viability test via flow cytometry, allowing the researcher to 
evaluate lymphocyte proliferation as per standard procedures (see Appendix R, S, & T). 
All bio-hazardous waste was properly handled via University of Northern Iowa-
Environmental Health and Safety. MS Excel program and JMP13, SAS Institute software 
were used for analysis of collected data from questionnaire survey, lymphocytes 
proliferation and nitric oxide expression. Data was analyzed by standard statistical 
procedure that included univariate (generating mean, standard deviation, mode, etc.), 
bivariate (for continuous values), and ANOVA analysis (for categorical and continuous 
values; See Figure 2).  Detailed aspects of the study design having bearing on the 











 Participants were selected as a convenience sample by invitation. This was 
accomplished by the distribution of flyers throughout departments at the University of 
Northern Iowa and outreach to local physician’s offices or venues where individuals with 
osteoarthritis could be found (such as, Cedar Valley SportsPlex, Young Men's Christian 
Association (YMCA), and churches). The researcher provided e-mails and phone contact 
information for participants interested in signing-up, and for those selected to participate, 
so they could have questions and concerns addressed. Participation in the study was 
voluntary and the participant could withdraw from the study at any time. This research 
study had 25 participants on or between the ages 35 to 65 years old, with osteoarthritis.  
Participants selected for this study could have no other immunological diseases such as 
Grave’s disease or major immunological stressors, except osteoarthritis, and could not be 
using drugs that would alter the immune response. Participants were excluded from the 
study if they confirmed having diagnosed autoimmune diseases or if they were taking 
immunosuppressive drugs. All participants received a $10.00 Kwik Star gas card per 
blood draw to offset the inconvenience and cost of driving to the UNI Student Health 





Details of Questionnaire Survey 
Participants were given a consent form that described the nature and purpose of 
the study, gave an explanation of the blood draw procedure risks/benefits, as well as 
rights of refusal to participate and confidentiality (See Appendix C).  
The researchers obtained basic demographics and immunological status from 
participants via the questionnaire. The questionnaire was divided into three parts: 
demographic information, medication information, and health information. The 
demographic information section included questions pertaining to age, gender, weight, 
and height. The medication information section had various questions on different 
medications for osteoarthritis such as herbs, vitamins, prescribed medication, and steroid 
injections. In the health information section, there were various questions on different 
health conditions; for instance, blood type, joint pain, joint injury, and a history of 
osteoarthritis in their family. The questionnaire included questions on how long they have 
suffered from osteoarthritis, and how physically limited by the pain they were. A copy of 
the questionnaire used is included as Appendix D. The researcher assumed that the 
information provided by each participant was correct and not biased (See Appendix E for 
the project checklist). 
Laboratory Preparation Prior to Analysis 
 All necessary glassware and equipment was sterilized 24 hours prior to obtaining 
blood samples. Researchers wore lab coats, sterile gloves, head caps, safety glasses, and 
masks before starting any analysis (See Appendix U). All equipment and the sterile hood 




ventilation fan was at high airflow speed at least 15 minutes prior to beginning and was 
treated with UV light for complete sterilization for at least 30 minutes prior to starting 
any analysis. Apparatus that were needed (50ml conical centrifuge tube, 1.5ml centrifuge 
tube, 10 and 5ml sterile pipets, sterile syringe, pipets, pipet tips, and beakers) were placed 
inside the hood. If any new glassware or equipment was needed during laboratory work, 
they were wiped with 99.8% Isopropanol before placing them inside the hood.  
Preparing Chemicals 
For our study we prepared Roswell Park Memorial Institute Medium (RPMI*) 
mixture, RPMI+ mixture, phytohaemagglutinin (PHA), and cat’s claw solution. For a 
detailed description of the preparation of these mixtures see the Appendices as indicated 
in the list below.  
1. Make RPMI* mixture (See Appendix F). 
2. Make RPMI+ mixture (See Appendix G). 
3. Reconstitute Phytohaemagglutinin (PHA; See Appendix H). 
4. Make cat’s claw treatment solutions (See Appendix I). 
Contamination Quality Control/Evaluation 
After 48 hours, we took a quick look at the culture plate under the tissue culture 
scope on the highest magnification. The color should be pale pink to light yellow but 
should not be bright yellow; and there should be no signs of bacteria or fungal 
contamination (See Appendix O, P, & Q).  This was an extra check on the sterile 





The data collected from the questionnaire survey, lymphocytes proliferation, and 
nitric oxide stress was entered into MS Excel program and then imported to JMP 13 
software from SAS institute. Data was analyzed by standard statistical procedures that 





Equipment Quality Control and Assurance 
Muse System Check 
Before running any test using the Millipore MUSE unit (flow cytometer), a 
system check procedure was ran to assure the Muse Unit was providing reliable and 
accurate results. To run the system check procedure, we added 20µl of bead reagent 
(control faux cells) with 380µl of system check diluent in a micro-centrifuge tube; both 
reagents were mixed thoroughly, system check was ran, and the return of standard cell 
counts verified.  
Incubator Cleaning and Disinfecting 
  It is very important to ensure that there is not any contamination in the incubator 
environment.  Between experimental sets the incubator was sterilized with 99.8% 
isopropanol which was then left to dry completely. The humidity tray was filled with 2.5 
liters of reverse osmosis and microfiltered water with a teaspoonful of copper sulphate 
added.  Intermittently between test runs, high temperature disinfection was used to heat 
internal surfaces to 120°C for 4 hours, and then cooled to the programmed temperature of 
37°C before being placed back into service.  
Pipettes Calibration 
  Calibration was required of all pipettes to maintain their accuracy and precision to 
obtain correct volumes of liquids. Calibration/adjustment was completed by the 
manufacturer according to the recommend one year to six months guidelines based on 






This chapter presents the results of data collected via survey and through 
laboratory work conducted on osteoarthritis patients cultured, treated and challenged 
mononuclear cells (lymphocytes). Univariate and bivariate tests were performed on the 
data using JMP13, SAS Institute software explore the impact on the lymphocyte 
proliferation and nitric oxide stress under experimental conditions.  
Demographic Information 
Age and Body Mass Index (BMI) 
This table below indicates the following information about the age and BMI of 
the participants (Table 1). The minimum age was 37 and maximum age was 65 with a 
mean of 56.2, median of 57, and standard deviation of 6.8617296. The BMI of the 
participants ranged from a minimum of 21.63 to a maximum of 49.6 with a mean of 
31.5652, median of 30.54, and standard deviation of 7.2626052. Detailed distribution 
statistics of demographic information can be found in Appendix X1. 
Table 1: Distributions among age, weight, and height 
 
Distributions N Minimum Maximum Mean Median Std. 
Deviation 
Age (years) 25 37 65 56.2 57 6.8617296 





There were a total of 25 participants, including 21 females and four males (Figure3). 
 
 
Figure 3: Gender distribution of study participants 
 
Medication Information 
Herbs, Vitamins, and Pharmaceutical Exposure 
This study included information on participants who were taking herbs, vitamins, 
prescribed medications, and joint steroid injection. Of the 24 participants 20 participants 
did not take any herbs and four participants took herbs (Figure 4). Turmeric was the most 
common herb taken by participants (Figure 5). The detailed distribution statistics of herbs 
are available in Appendix X2. 
Also, this section indicates how many participants were taking vitamins daily. 
Nineteen out of 25 participants were taking vitamins and the remaining six were not 
(Figure 4). The most common vitamins were multivitamin, vitamin D, calcium, and 




Additionally, the study examined if participants were taking any pharmaceutical 
medications or not. Of 25 participants, 22 were taking prescribed medication and three 
were not taking any prescribed medication (figure 4). The top prescribed medications 
used were: cardiovascular, antihistamines, pain relievers (NSAIDs), anti-depressants, and 
anti-inflammatories (NSAIDs; figure 5). Detailed information is provided in Appendix 
X2. 
This graph below indicates the number of participants who took joint steroid 
injections to manage arthritis pain. Eleven participants did not take any joint steroid 
injections and 14 did take joint steroid injections out of a total of 25 (Figure 5). 
 
 







Figure 5: Distributions among common herbs, vitamins, and medications 
 
Health Information 
Cold or Flu, Life Change or Loss, Allergies, and Immunological Diseases 
This study examined the number of participants who have had a cold or flu in the 
past two weeks, any major life change/loss, and any immunological diseases. There were 
a total of 25 participants of which none had had a cold or flu (Table 2). Of the 25 
participants six had experienced a major life change/loss while 19 participants did not 
have any major life change/loss (Table 2).  
Participants were also asked if they had any immunological diseases other than 
osteoarthritis. Of the 25 participants none had had any diagnosed immunological diseases 
other than osteoarthritis (Table 2).  
The table below also shows the number of participants who suffered from 
allergies. Seventeen out of 25 participants suffered from allergies and eight participants 
did not suffer from allergies (Table 2). The highest category of allergies reported was 






Table 2: Health information among participants 




Yes 0 0 17 6 
No 25 25 8 19 
Total 25 25 25 25 
 
 
Figure 6: Common allergies among participants 
 
Osteoarthritis History 
Length of Osteoarthritis  
The participants were asked about the maximum length of time they had 
osteoarthritis. The maximum length of time the participant’s reported having 





Figure 7: Length of osteoarthritis among participants 
 
Family History of Osteoarthritis 
Figure 8, illustrates whether participants had any history of osteoarthritis in their 
family. Twenty participants out of 25 reported having a family history of osteoarthritis. 
Of the family members’ history of osteoarthritis, the most commonly reported relative 
was the mother followed by the father. 
 






The figure below shows the number of participants who had previous injuries in 
the affected joint(s). Ten participants out of a total of 25 previously had injuries and 15 
participants never had any injuries (Figure 9).  The figure below also shows the most 
common injuries among participants. The most common injury was knee injuries 
followed by spine injury, and hip injury (Figure 9; See Appendix X3). 
 
 
Figure 9: Common injuries among participants 
 
Pain Severity 
This table indicates the level and severity of pain experienced in the last 30 days 
among participants. Twelve participants experienced lots of pain and 13 participants 
experienced some pain (Table 3). Also, the figure below points out the areas in which 
participants most often feel the pain. Most participants identify the knees, hands, hip, and 


















Table 3: Pain severity among participants 
Pain Level Participants 
Lots of pain 12 (48%) 










This figure below indicates the number of participants who reported being 
physically active or physically limited by osteoarthritis pain. Twenty out of 25 
participants reported being physically active and five participants were not physically 
active (Figure 11). Additionally, the figure below shows the frequency of participants’ 
physical activities on a weekly basis. The most frequently reported rate for physical 
activity was seven times a week and the least frequent was two times a week (Figure 11). 
 
 








YES NO 2x/week 3x/week 5x/week 6x/week 7x/week
Participants




Lymphocytes Proliferation Statistical Results 
The tables below illustrate bivariate fit tests of lymphocyte proliferation at various 
concentrations of cat’s claw herb 0 ppm, 10 ppm, 100 ppm, 150 ppm, 250 ppm, and 450 
ppm, following stimulation with mitogen, and based on the following factors: age, 
number of prescribed medications, joint steroid injections, length of osteoarthritis, 
physically limited, physically active (workout y/n), pain severity (lots of pain and some 
pain), pain area (hip and knee), family history, and allergies. 
Association of Various Concentrations of Cat’s Claw on Lymphocytes Proliferation 
A bivariate fit test/simple linear regression at control and the various treatment 
levels of cat’s claw compared with demographics was used to examine proliferation 
response. Table 4 illustrates the direction of cell proliferation following stimulation and 
at different treatment dosages based on the mean and the trend of the bivariate fit test. 
Additionally, Table 5 demonstrate statistically significant trends between demographics 
and cat’s claw treatments, trends where the p value was between 0.06 and 0.09 and the 
absolute t was significant at ≤ 0.05.  These trends are reported as the sample size is small 
and future studies may find this useful. 
The findings of Table 4 indicate that when age increased the cell proliferation 
decreased. Also, when the number of prescribed medication increased, the proliferation 
decreased. For those who took joint steroid, the proliferation decreased, while it increased 
in those who did not take joint steroid. Participants who had osteoarthritis for a longer 
time period, and those who were physically limited had a decrease in proliferation. Those 




no association between proliferation and participants who were physically active, 
whereas there was a decrease for those who were not physically active. Regarding pain 
severity, participants who had some pain had proliferation increases while participants 
who had lots of pain, had proliferation decreases. Also, those who had knee pain had 
proliferation increases, while those who had hip pain had proliferation decreases. Where 
there was family history of osteoarthritis, proliferation increased. However, there was a 
decrease where there was no family history of osteoarthritis. Proliferation increased for 
participants who had allergies but decreased for those who had no allergies. None of 
these relationships were statistically significant but are reported due to the small sample 
size of the study. Detailed analyses are provided in Appendix Y. 
The findings of Table 5 illustrate that the number of prescribed medications taken 
at 100 ppm and 150 ppm cat’s claw treatment was associated with lymphocyte 





Table 4: Descriptive trends between demographics, cat's claw treatments and lymphocyte 
proliferation 









Age (D) (D) (D) (D) (D) (D) 
Number of Prescribed 
Medication         
(Increasing Numbers) 
(D) (D) (D) (D) (D) (D) 
Joint Steroid (Yes/No) 
(Taking injections) (D / I) (D / I) (D / I) (D / I) (D / I) (D / I) 
Length of Osteoarthritis 




(D / I) (D / I) (D / I) (D/ I) (D/ I) (D / I) 
Physically Active (Yes/No) (NA/D) (NA/D) (NA/D) (NA/D) (NA /D) (NA/D) 
Pain Severity (Lots of 
Pain/Some Pain)         
(More Severe) 
(D / I) (D / I) (D/ I) (D/ I) (D / I) (D / I) 
Pain Area (Hip/Knee)   
(Hip Pain) 
(D / I) (D / I) (D / I) (D / I) (D / I) (D / I) 
Family History (Yes/No) 
(Positive History) (I / D) (I / D) (I / D) (I / D) (I / D) (I / D) 
Allergies (Yes/No) (I / D) (I / D) (I / D) (I / D) (I / D) (I / D) 





Table 5: Statistically significant associations between demographics, cat’s claw 
treatments and lymphocytes proliferation, bivariate fit. 








100ppm 0.186443 0.135596 3.6667 0.0736 <.0001* 
150ppm 0.323945 0.281692 7.6667 0.0137* <.0001* 
 
Nitric Oxide Expression Statistical Trends 
The tables below illustrate trends in nitric oxide stress at various treatment levels: 
0 ppm, 10 ppm, 100 ppm, 150 ppm, 250 ppm, and 450 ppm based on the following 
factors: age, herbs, vitamins, number of prescribed medications, joint steroid injections, 
length of osteoarthritis, physically limited, physically active (workout), pain severity (lots 
of pain and some pain), pain area (hip and knee), family history, and allergies. 
Association of Various Concentrations of Cat’s Claw on Nitric Oxide Expression 
A bivariate fit/simple linear regression test at various treatment levels of cat’s 
claw compared with demographics was used to examine nitric oxide response of the 
lymphocytes following mitogenic challenge. Table 6 indicates the trends and direction of 
nitric oxide expression following stimulation and at different treatment dosages, while 
Table 7 demonstrates statistically significant relationships at p<0.05.  Trends where the p 
value was between 0.06 and 0.09 and the absolute t was significant at ≤ 0.05 were 




Results indicated that age and various concentrations of cat’s claw exhibited a 
trend toward increased nitric oxide expression at 10 ppm, 100 ppm, 150 ppm, 250 ppm 
and 450 ppm and a decrease at 0 ppm. With regards to the number of the cells that 
expressed the nitric oxide, there was a decrease at all concentration levels for those who 
had osteoarthritis for longer periods of time, except at 150ppm and 450ppm, wherein 
which the trend was toward an increase. 
Participants who took herbs exhibited a trend toward a decrease in number of 
cells that expressed nitric oxide in all different concentrations of cat’s claw, while those 
who did not take any herbs had an increase in the number of cells that expressed nitric 
oxide at 0 ppm and 100 ppm, and no association at 10 ppm, 150 ppm, 250 ppm, and 450 
ppm. For participants who took vitamins, the number of cells that expressed nitric oxide 
decreased at 0 ppm and 100 ppm, and had no association at 10 ppm, 150 ppm, 250 ppm, 
and 450 ppm. There was an increase in the number of cells that expressed nitric oxide at 
all concentration levels for participants who did not take any vitamins. 
A trend was seen when the number of prescribed medications increased the 
number of cells expressing nitric oxide decreased at 0 ppm, 10 ppm, 100 ppm, and 250 
ppm, but increased at 150 ppm and 450 ppm. At all concentrations of cat’s claw, the 
number of cells that expressed nitric oxide increased for participants who had joint 
steroid injections, except at 100 ppm, which had no association, and decreased for those 




Participants who were physically limited had an increase in the number of cells 
that expressed nitric oxide at all concentrations levels, except 0ppm and 100ppm, which 
had no discernable trend. There was no trend between physically active participants and 
the number of cells expressing nitric oxide at all levels of cat’s claw concentrations. 
However, those participants who were not physically active had a decrease in nitric oxide 
expression at all levels of cat’s claw concentration, except at 100 ppm which had no 
discernable trend. For participants who worked out 2 times a week, there was a decrease 
in the number of cells that expressed nitric oxide at all concentrations, except 0ppm and 
100ppm, which had an increase. Those participants who worked out 3 times a week had a 
decrease in the number of the cells that expressed nitric oxide at all concentration levels, 
except at 0ppm, which had an increase, and no observable trend at 10ppm. For those who 
worked out 5 times per week, there was an increase in the number of cells that expressed 
nitric oxide at all concentration levels, except at 0ppm and 150ppm which had a decrease 
and no discernable trend at 450ppm. Additionally, for those who worked out 6 times a 
week, there was an increase in the number of the cells that expressed nitric oxide at 0ppm 
and 450ppm, and a decrease at the other treatment levels. Finally, for those indicating 
they worked out daily, there was an increase in the number of the cells that expressed 
nitric oxide at all concentration levels, except 0 ppm which had no discernable trend. 
In the category of pain severity, the number of cells that expressed nitric oxide 
decreased at all concentration levels for those reporting greater pain severity, except at 
100 ppm, which exhibited an increasing trend of nitric oxide expression. On the other 




had some pain, except at 100 ppm which had a decrease in the number of cells that 
expressed nitric oxide. Participants who had pain in the hip area, had an increase in the 
number of the cells that expressed nitric oxide at 0 ppm, 10 ppm, 150 ppm, 250 ppm, and 
450 ppm, and decreasing trend at 100 ppm. Additionally, there was also an increase in the 
number of cells that expressed nitric oxide at all concentrations of cat’s claw, except at 
100 ppm, which had a decrease, for those who had pain in the knee area.  
The number of the cells expressing nitric oxide exhibited no discernable trend at 
any treatment level for participants who had a positive family history of osteoarthritis, 
except at the 100ppm treatment level which exhibited an increase. For those who had no 
family history of osteoarthritis, there was an increase in nitric oxide expression at all 
treatment levels except for 100 ppm which had a decrease in the number of the cells that 
expressed nitric oxide. In regard to allergies (individuals reporting having allergies), there 
was a decrease in the number of the cells that expressed the nitric oxide at 10 ppm, 150 
ppm, 250 ppm, and 450, and an increase at 100 ppm, with no association at 0 ppm. While 
for those who had no allergies, there was an increase in the number of the cells that 
expressed nitric oxide, except at100 ppm where there was an observable decrease. 
Table 7 illustrates that age, length of osteoarthritis, and how often participants 
worked out, were found to be associated with nitric oxide expression. This illustrates a 
statistically significant bivariate fit at p<0.05 at100 ppm for age, 0ppm and 100ppm for 
the length of osteoarthritis, and 100ppm, 150 ppm, and 450 ppm for how often the 




Table 6: Descriptive trends between demographics, treatment levels, and nitric oxide 
expression 






ppm 450 ppm 
Age (D) (I) (I) (I) (I) (I) 
Length of Osteoarthritis 
(Longer Duration) 
(D) (D) (D) (I) (D) (I) 
Herbs (Yes/No)              
(Taking Herbs) (I/D) (I/NA) (I/D) (I/NA) (I/NA) (I/NA) 
Vitamins (Yes/No)         
(Taking Vitamins) (D/I) (NA/I) (D/I) (NA/I) (NA/I) (NA/I) 
Number of Prescribed 
Medication                 
(Increasing number) 
(D) (D) (D) (I) (D) (I) 
Joint Steroid (Yes/No)    
(Taking Injections)  (I/D) (I/D) 
(NA/ 
NA) (I/D) (I/D) (I/D) 





NA) (I/D) (I/D) (I/D) 
Physically Active (Yes/No) (NA/D) (NA/D) (NA/NA) 
(NA/D
) (NA/D) (NA/D) 
How Often you Workout/ 2x/w (I) (D) (I) (D) (D) (D) 
How Often you Workout/ 3x/w (I) (NA) (D) (D) (D) (D) 
How Often you Workout/ 5x/w (D (I) (I) (D) (I) (NA) 
How Often you Workout/ 6x/w (I) (D) (D) (D) (D) (I) 
How Often you Workout/ 7x/w (NA) (I) (I) (I) (I) (I) 
Pain Area (Hip/Knees)        
(Hip Pain) (D/I) (D/I) (I/D) (D/I) (D/I) (D/I) 
Pain Severity (Lots of 
pain/Some Pain)               
(More Severe) 
(I/D) (I/D) (D/I) (I/D) (I/D) (I/D) 
Family History (Yes/No) 
(Positive History) (NA/I) (NA/I) (I/D) (NA/I) (NA/I) (NA/I) 
Allergies (Yes/No) (NA/I) (D/I) (I/D) (D/I) (D/I) (D/I) 





Table 7: Statistically significant associations between demographics, cat's claw 
treatments and nitric oxide expression, bivariate fit 
 
  








Abs. t test 
Age 100ppm 0.14681 0.109714 3.9576 0.0587 0.1664 
Length of 
Osteoarthritis 
0ppm 0.281584 0.245663 7.8390 0.0111* 0.3548 
100ppm 0.258956 0.221904 6.9890 0.0156* 0.9298 
How Often 
you Workout 
100ppm 0.64926 0.309209 3.0143 0.0036* * 
150ppm 0.425028 0.26075 2.5872 0.0826 * 




Proliferation Response Quotient by Cat’s Claw Treatment 
A quotient of the stimulated and non-stimulated proliferation response was 
conducted to compare the magnitudes of proliferation following stimulation under the 
various treatments and test for statistically significant trends using ANOVA. The findings 
indicate there was no statistically significant association between dosages of cat’s claw 
and proliferation. (See Figure 12; Appendix AA for more detailed information). 
 
Table 8: ANOVA of proliferation response quotient by cat's claw treatments 




R square DF F Ratio P Value 
0ppm 289.244  -57.8 636.32 0.001509 5 0.0435 0.9989 
10ppm 254.468  -92.6 601.54 
100ppm 249.710  -97.4 596.78 
150ppm 207.991  -139.1 555.06 
250ppm 310.985  -36.1 658.06 
450ppm 239.332  -107.7 586.40 
 
 




Nitric Oxide Quotient of Live Cells by Cat’s Claw Dosages 
A quotient of the stimulated and non-stimulated conditions for only live cells was 
conducted to explore the association between live cells’ nitric oxide expression under 
different treatments. The result demonstrated that there was no association between live 
cells’ nitric oxide expression and treatment levels in this sample population. See Figure 
13; Appendix BB). 
Table 9: ANOVA of nitric oxide live cells response quotient by cat's claw treatments 




R square DF F Ratio P Value 
0ppm 1.50174  -1.344 4.3471 0.011101 5 0.3211 0.8997 
10ppm 2.27938  -0.566 5.1247 
100ppm 0.91432  -1.931 3.7596 
150ppm 1.19661  -1.707 4.1006 
250ppm 2.70405  -0.141 5.5494 











Nitric Oxide Quotient of Dead Cells by Cat’s Claw Dosages 
It is important to note the quotient response of stimulated and non-stimulated cells 
which consequently died although they expressed nitric oxide prior to or following their 
death. Thus, an ANOVA was conducted to determine the potential association of the 
dead cells’ nitric oxide expression under different treatments of cat’s claw. There was no 
statistically significant association found between nitric oxide expression by dead cells 
and cat’s claw treatments. (See Figure 14; Appendix CC). 
Table 10: ANOVA of nitric oxide expression, dead cells quotient by cat's claw treatments 




R square DF F Ratio P Value 
0ppm 0.50708  -0.4506 1.4648 0.041547 5 1.2484 0.2897 
10ppm 0.70548  -0.2522 1.6632 
100ppm 1.63780 0.6801 2.5955 
150ppm 0.22405  -0.7336 1.1817 
250ppm 0.27556  -0.6821 1.2333 










Nitric Oxide Quotient of Total Cells (live and dead) by Cat’s Claw Dosages 
The magnitude of response of both live and dead cells’ nitric oxide expression 
was explored together under the various treatments. A quotient of the stimulated and non-
stimulated conditions for the total cells was generated and an ANOVA was ran under the 
various treatments. The results demonstrate that there was no statistically significant 
association between nitric oxide expression from total cells and cat’s claw treatments in 
this test population. See Figure 15; Appendix DD for further details).  
Table 11: ANOVA of nitric oxide response, total cells, quotient by cat's claw treatments 




R square DF F Ratio P Value 
0ppm 2.0147  -90.66 94.69 0.029413 5 0.8728 0.5011 
10ppm 94.9661 2.29 187.64 
100ppm 15.5591  -77.11 108.23 
150ppm 93.1723 0.50 185.84 
250ppm 2.6213  -90.05 95.29 










DISCUSSION, CONCLUSIONS, AND RECOMMENDATIONS 
Discussion 
This chapter discusses the laboratory findings and data derived from 
questionnaire/survey of 25 osteoarthritis sufferers in light of the previously discussed 
literature. It discusses the trends and associations between different levels of cat’s claw 
treatments (0 ppm, 10 ppm, 100 ppm, 150 ppm, 250 ppm, and 450 ppm) lymphocyte 
proliferation, nitric oxide expression, and various questionnaire associated findings.   
Participant questionnaire, completed at the time of the blood draw, gathered 
information pertaining to aging, number and type of prescribed medications, herbs, 
vitamins, joint steroid injections, family history, length of osteoarthritis, allergy, pain 
severity, pain area, physically limiting condition, and physical activity. This was 
analyzed using univariate statistics, bivariate fit, and ANOVA to look for both descriptive 
trends in the data and for statistically significant associations between survey data and 
treatments as well as treatment levels and lymphocyte proliferation and nitric oxide 
expression. Overall, relationships between treatments and proliferation as well as nitric 
oxide expression did not reject the null hypothesis. However, select questionnaire items 
and certain treatment levels did reject the null hypothesis at a p-value of < 0.05. Further, 
some of the results were marginally statistically significant or showed a trend toward 
significance when the p-value and absolute t-value where considered together. Given the 
small sample size, p-values of between 0.06 and 0.09 where the absolute t was significant 




Lymphocytes Proliferation and Osteoarthritis 
Lymphocyte proliferation is the process whereby lymphocytes in the body begin 
to replicate DNA and multiply. It occurs after the cells cross-link antigen/antibody 
receptors, occurring either after the recognition of an antigen in the body or after 
stimulation from a polyclonal activator. It is a fundamental characteristic of the response 
of lymphocytes following antigen stimulation (Hallab, Anderson, Stafford, Glant, & 
Jacobs, 2005). According to Bocelli-Tyndall et al. (2006), lymphocyte proliferation leads 
to T-cell hypo-responsiveness and immunosuppression, which are common 
characteristics of osteoarthritis. The level of lymphocyte proliferation dramatically 
increases in people with osteoarthritis. This study found descriptive statistical trends 
between questionnaire reported items and lymphocyte proliferation, and under specific 
treatment levels, some questionnaire items demonstrated statistically significant 
associations which are further discussed below. 
Nitric Oxide Expression and Osteoarthritis 
Nitric Oxide is a catabolic destructive factor in osteoarthritis. Presence of Nitric 
Oxide (NO) in the bodies of patients with osteoarthritis is exhibited by the presence of 
INOS in the superficial layer of chondrocytes. Nitric Oxide prevents the stimulation of 
collagen synthesis in cartilage. Nitric Oxide causes an increase in the coalescence of 
matrix metalloproteinases, in a cyclic GMP-dependent manner. An increase in the 
synthesis of metalloproteinase leads to damage of the extracellular matrix and cartilage 
breakdown. Nitric Oxide also causes the coalescence of the body’s IL-1-converting 




bio-molecular processes are partly responsible for the pain and inflammation associated 
with the condition. This study found descriptive trends between questionnaire reported 
items and nitric oxide expression, and under specific treatment levels, some questionnaire 
items demonstrated statistically significant associations which are further discussed 
below. 
Aging and Osteoarthritis 
Osteoarthritis is common in people over the age of 60 years old. One in every 12 
individuals over the age of 60 has osteoarthritis (CDC, 2017). According to medical 
research, the probability of developing osteoarthritis increases with age. All participants 
in this study had osteoarthritis, and ranged in age from 36 years old to 65 years old, with 
52% around 50 years old and 36% around 60 years old. This study found a descriptive 
trend of decreasing cell proliferation with increasing age under different levels of cat’s 
claw treatment. For nitric oxide expression, the number of cells expressing nitric oxide 
increased at 10mppm, 100 ppm, 150 ppm, 250 ppm, and 450 ppm, and decreased at 
0ppm. Age was found to be statistically associated with nitric oxide expression at the 100 
ppm treatment level (p<0.05; Bivariate fit, f = 3.9576; Table 7).  Medical research has 
shown that aging is stochastic in nature and is characterized by the accumulation of 
random cell damage in tissues, such as oxidative damage, somatic mutations, and 
accumulation of defective proteins (Fazzalari, Kuliwaba, & Forwood, 2002).  
 Length of osteoarthritis in participants ranged between 3 years to 30 years with a 
mode of 10 years. Results of the study indicated that out of 25 participants, 8% were 




view that there are rare cases of osteoarthritis affecting people below the age of 40 years 
old. In relation to length of osteoarthritis, the study revealed that participants who had 
osteoarthritis for a longer time had a decreasing descriptive trend in proliferation. With 
regards to the number of the cells that expressed nitric oxide, there was a decreasing trend 
at all concentration levels for those who had osteoarthritis for longer periods of time, 
except at 150ppm and 450ppm, which had an increase. Length of osteoarthritis, was 
found to be significantly associated with nitric oxide expression at 0ppm and 100ppm    
(p < 0.05; Bivariate fit, f = 0ppm 7.8390; 100ppm 69890; Table 7) 
BMI and Osteoarthritis 
According to Aspden (2011), obesity is one of the factors that accelerates 
progression of osteoarthritis, mainly in the knee joints. Higher body mass translates to an 
increase in pressure on the main support joints of the body such as hips, ankles, and 
knees, which results in stress and physical strain on these joints. The increased physical 
strain and pressure on knee joints and hips from increased body weight, has been proven 
to cause an increase in severity of the pain associated with knee and hip osteoarthritis. 
Therefore, an increase in body weight enhances the chances of suffering osteoarthritis. 
Twelve percent of participants were normal weight, 68% were overweight, and 20% of 
them were obese confirming the notion that weight is associated with the development 
and progression of osteoarthritis. 
Gender and Osteoarthritis 
According to Paradowski, Bergman, Sundén-Lundius, Lohmander, and Roos 




factors such as child birth, obesity, and estrogen. For example, estrogen, a female 
hormone, is believed to protect cartilage from deteriorating. However, the production of 
estrogen drops precipitously after menopause, leaving women’s cartilage at greater risk 
of inflammation leading to osteoarthritis. Despite intentional recruitment of both genders, 
this study had 84% female participants and 16% male participants confirming the 
perception that women are more susceptible to osteoarthritis than men. 
Herbs and Osteoarthritis 
There are several herbs that contain natural substances which are known to 
regulate pain and inflammation that comes with osteoarthritis. Nonetheless, people are 
often unaware of such herbs, which were mostly used traditionally, to manage 
osteoarthritis conditions (Mckenzie, Baker, Buffinton, & Doe, 1996). In this study 16% 
(4) took herbs to reduce osteoarthritis pain and 80% (20) did not take any herbs, 
indicating a possible lack of awareness about the potential benefits of different herbs. 
Participants who took herbs had a decreasing trend in the number of cells that expressed 
nitric oxide at all treatment levels. However, those who did not take any herbs had an 
increasing trend in the number of cells that expressed nitric oxide at 0 ppm and 100 ppm, 
and no noted trend at 10 ppm, 150 ppm, 250 ppm, and 450 ppm. 
Vitamins and Osteoarthritis 
Vitamins levels such as D and B12 have been found to have a strong association 
with the risk of developing osteoarthritis (Canter, Wider, & Ernst, 2007). Seventy-six 
percent of the participants took some variety of vitamins and 60% took vitamin D, 




bodies stand a three-percent higher chance of osteoarthritis progression (Canter et al., 
2007). Vitamin D is responsible for maintaining healthy calcium and phosphorous levels 
in the body. The latter helps keep teeth and bones strong. Low levels of vitamin D in the 
body leads to soft and brittle bones, weak teeth, and fragile muscles. It increases both the 
chances of developing osteoarthritis and the progression of osteoarthritis. According to 
Canter et al., (2007), women with high levels of vitamin D in their bodies have a 30% 
lower chance of suffering from osteoarthritis.  
In this study 48% of the participants took vitamin B12 which helps the body to 
produce healthy red blood cells. Vitamin B12 also helps lower homocysteine amino acid, 
which is responsible for weak bones and associated with the decline of cartilage between 
bones. Additionally, it decreases inflammation of joints, mainly around the hips, 
shoulders, and knees. A reduction of B12 in the body, therefore, increases the chances of 
the development and pain of osteoarthritis (Canter et al., 2007). For participants who took 
vitamins, there was a trend of decreasing numbers of cells expressing nitric oxide at 0 
ppm and 100 ppm treatment levels, and no apparent trends at 10 ppm, 150 ppm, 250 ppm, 
and 450 ppm. There was an increasing trend in the number of lymphocytes expressing 
nitric oxide at all concentration levels for participants who did not take any vitamins. 
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Osteoarthritis 
Nonsteroidal anti-inflammation (NSAIDs) drugs are the most prescribed 
medications to manage osteoarthritis pain and inflammation.  NSAIDs cause rapid weight 
gain, which may lead to obesity (Wahli & Michalik, 2012). According to medical 




already suffer the disease. Higher body weight causes growing pressure in the knee and 
hip joints, which translates to stress and deterioration of cartilage (Lin, Zhang, Jones, & 
Doherty, 2004)  
NSAIDs are known to cause tingling, numbness and muscle cramps when used to 
treat osteoarthritis. A common side effect of NSAIDs is the retention of fluids around 
joints. The retention of fluids around the joints sometimes leads to edema and causes the 
swelling of knee, shoulder, wrist, hip, and other body joints. Further, it prevents the 
maintenance of healthy cartilage in the body and creates more pressure and stress on the 
joints (Milder, Williams, Ritchie, Lipworth, & Day, 2010). Extra fluids around the joints 
reduces the rate of healing from osteoarthritis. It decreases a patient’s mobility and 
increases their chance of osteoarthritis progression. Forty-eight percent of the participants 
took anti-inflammatory drugs (NSAIDs), indicating that a huge percentage of 
osteoarthritis patients are taking NSAIDs, and are susceptible to their side effects. The 
findings indicated a descriptive trend of increasing overall prescription medicine use and 
decreasing lymphocyte proliferation. The number of prescribed medications at 100 ppm 
and 150 ppm was significantly associated with lymphocyte proliferation (p<0.05; 
Bivariate fit, f = 100ppm 0.0736, 150 ppm 7.6667; Table 5). Further, a descriptive trend 
was observed between the overall number of prescribed medications and a decreasing 
number of cells expressing nitric oxide at 0 ppm, 10 ppm, 100 ppm, and 250 ppm, but 
this trend was reversed at 150 ppm and 450 ppm where the number of cells expressing 




Joint Steroid Injection and Osteoarthritis 
Joint steroid injection is used to treat inflammatory diseases and conditions such 
as osteoarthritis. It is injected directly into joints to treat such conditions. Continuous 
injection of joint steroids causes the thinning of cartilage on bones in the joint regions. 
Thinning cartilage causes bones to rub on each other during movements, which leads to 
severe pain (Arroll & Goodyear-Smith, 2004). Thinning cartilage also advances the 
progression of osteoarthritis and reduces the rate of healing in patients already suffering 
the disease. The steroid injections also cause whitening of the skin around the joint area 
as well as the thinning of ligaments in the joints. Of the 25 participants, 44% took joint 
steroid injections and 56% did not, which translates to more side effects and potential 
increases in joint deterioration. For participants who took joint steroid, there was a 
decreasing trend in lymphocyte proliferation, while it increased in those who did not take 
joint steroid. At all concentrations of cat’s claw, the number of cells that expressed nitric 
oxide increased for participants who had joint steroid injections, except at 100 ppm, 
which had no discernable trend. For those who did not use joint steroid injections a trend 
of decreasing nitric oxide expression was observed, except at 100ppm which had no 
discernable trend. 
Stress, Depression and Osteoarthritis 
Being in pain may trigger stress or depression in patients. However, if a patient 
suffering osteoarthritis suffers these conditions as well, pain associated with the disease often 
increases. Antidepressants have been proven to have adverse psychological and medical 




some of these side effects lead to worsening of the condition. Antidepressants cause 
headaches, nausea, and abdominal pains fatigue, dizziness, and blurred vision. Fatigue and 
dizziness from antidepressants prevents patients suffering from osteoarthritis from 
performing simple physical exercises to keep their joints active and flexible. It leads to 
stiffness in the joints, which limits mobility in patients suffering from osteoarthritis (Fava et 
al., 2006).  
According to Bet, Hugtenburg, Penninx, and Hoogendijk (2013), antidepressants 
may cause an increase in the weight of the person using them. This is dangerous for patients 
suffering from osteoarthritis, as it exerts increased pressure and stress on weight bearing 
joints such as hip and knee joints. Twenty-eight percent of the osteoarthritis patients who 
participated in this study indicated that were taking antidepressants, which could potentially 
worsen their situation. 
Environmental Triggers and Osteoarthritis 
Environmental toxins such as chemical pollutants, heavy metals, and pesticides 
have been medically proven to have an inflammatory effect on the immune response of 
the body (Spector & MacGregor, 2004). Cold weather has been reported to cause 
stiffness and reduced flexibility in patients suffering from acute osteoarthritis (Keysor et 
al., 2009). Also, food allergy and intolerance have been verified to trigger inflammatory 
episodes in osteoarthritis patients (Haugen, Kjeldsen-Krach & Forre, 1991). For example, 
food that contains alkaloids, gluten, omega 6, and proteolytic enzymes, lead to 
inflammation of joints and deterioration of joint tissues, which trigger increased pain and 




&Yelland et al., 2006). In this study, 68% of participants reported environmental allergies 
and 32% did not. Proliferation trends increased for participants who had reported a 
history of allergies but decreased for those who had no allergies. In the area of nitric 
oxide, there was a decrease in the number of the cells that expressed nitric oxide at 10 
ppm, 150 ppm, 250 ppm, and 450, and an increase at 100 ppm, with no association at 0 
ppm. However, for those who had no allergies, there was an increasing trend in the 
number of cells that expressed nitric oxide at all treatment levels, except at100 ppm 
which exhibited a decrease. 
Family History and Osteoarthritis 
According to Loughlin (2011), 60% of osteoarthritis cases report family histories 
of osteoarthritis in close relatives. In this study, 80% of the participants who had 
osteoarthritis had a family history of osteoarthritis while only 20% did not have a family 
history of osteoarthritis; confirming the observation of Loughlin (2011). For participants 
who reported a positive family history of osteoarthritis, there was no observable trend in 
the number of cells expressing nitric oxide at the majority of treatment levels except at 
100ppm which exhibited an increase. For those who had no family history of 
osteoarthritis, there was an increase at all treatment levels, except at 100 ppm which had 
a decrease in the number of the cells that expressed nitric oxide. Where there was family 
history of osteoarthritis, the proliferation trend increased. However, there was a decrease 




Common Pain Areas in Osteoarthritis Patients  
According to Dieppe and Lohmander (2005), knee, hip, hands, and spine are the 
most affected joint areas for osteoarthritis patients. This study supports those findings as 
68% of participants had knee pain, 64% had hand pain, 44% had spine pain, and 60% hip 
pine. Pain is increased by continuous or increased movement, movement over long 
distances, and running. The pain can also be accentuated by carrying heavy loads and 
excess body weight, which exerts more pressure on the weight bearing joints. The level 
of pain reduces with rest, but inflammation can increase, mainly at night. Pain in the hand 
is common in women with osteoarthritis. It is caused by an over-growth of bones in 
finger joints causing finger joints to be painful, red, and swollen. (Dieppe & Lohmander, 
2005).  
The hip region is the second most commonly affected area of osteoarthritis. The 
pain in the hip area is caused by high weight bearing and any extra body weight only 
exacerbates this. The pain in the hip area may extend to the groin region and can make 
walking difficult. Upper cervical and lower lumbar sections of the spine are the most 
common sites of spinal osteoarthritis. It causes pain that runs from the neck down to the 
lower back, pelvis and to the thighs (Van Weeren & de Grauw, 2010; & Dieppe & 
Lohmander, 2005). This pain makes it hard to bend over or sleep in certain positions. 
Participants in this study who had knee pain exhibited a trend of increasing proliferation 
across all treatments, while those who had hip pain exhibited a trend toward decreasing 
proliferation across all treatments. Participants who had pain in the hip area, had an 




ppm, 250 ppm, and 450 ppm, and a decreasing trend at 100 ppm. Additionally, for those 
who predominantly experienced knee pain there was also an increasing trend in the 
number of cells that expressed nitric oxide at all concentrations of cat’s claw, except at 
100 ppm, which showed a decrease. 
Physical Limitation and Osteoarthritis 
Osteoarthritis leads to stiffness of joints and pain, reducing the range of motion in 
affected joints and causing a reduction in the flexibility of the joints. A decreased range 
of motion in the knees and hips inhibits free mobility of a patient, creating significant 
physical limitations (Dillon, Rasch, Gu, & Hirsch, 2006). Forty-eight percent of the study 
participants reported lots of pain while 52% had some pain. Participants who indicated 
they had milder pain exhibited trends of increasing proliferation at all treatment levels, 
while participants who had lots of pain had decreasing trends of proliferation. For 
individuals who indicated that they experienced severe pain, the number of cells that 
expressed nitric oxide exhibited a decreasing trend at all treatment levels of cat’s claw, 
except at 100 ppm where the trend reversed.  For those who experienced milder pain, 
there was an increasing trend at all concentration levels, except at 100 ppm, which 
exhibited a decreasing trend in the number of cells that expressed nitric oxide.  
Osteoarthritis conditions limit patients’ ability to be physically active, since 
increased physical activity only worsens the severity of the pain and may cause swelling 
around the joints. In this sample, 80% of participants were physically limited by the pain. 
Broken cartilage, damaged vessels in the joints, and degeneration of the tissues, cause 




Continuous friction around the joint may result in pain in patients suffering from 
osteoarthritis (Dillon et al., 2006). Therefore, these individuals limit their movement as 
much as possible in order to limit friction that originates from the grinding of joint bones. 
Participants who reported being physically limited had a decreasing trend in proliferation 
at all treatment levels whereas those who were not physically limited had an increasing 
trend in proliferation. Participants who were physically limited had an increasing trend in 
the number of cells that expressed nitric oxide at all concentrations levels, except 0ppm 
and 100ppm, which had no observable trend.    
Physical Activity and Osteoarthritis Patients 
Mild, low-impact aerobic exercise has been proven to be of much help to 
osteoarthritis patients. The exercises increase blood circulation in the body. Repeated 
physical activity and aerobics help burn excess calories, thereby preventing accumulation 
of extra body weight, which increases pressure on joints leading to severe pain in patients 
with osteoarthritis, particularly of the knees, hips and lower spine (Nelson et al., 2007). 
Water aerobics helps to ease pain in sore joints by lowering the temperature around the 
joints and increasing the circulation of blood around the joints. Physical activities help to 
prevent mobility impairment that is associated with osteoarthritis, because they help keep 
muscles and joints healthy and flexible (Haskell et al., 2007). There was no observable 
trend between proliferation or nitric oxide expression for participants who reported being 
physically active, whereas, there was a decreasing trend in proliferation and nitric oxide 
expression for those who were not physically active, except at 100ppm, where there was 




The most frequent regularity (mode) of physical exercise reported by participants 
was three times a week and the least frequent was two times a week. How often 
participants worked out was found to be significantly associated with nitric oxide 
expression at the 450 ppm treatment level (p<0.05; Bivariate fit, f = 100ppm 3.0143, 150 
ppm 2.5872, 450ppm 6.4789; Table 7). For participants who reported exercising less than 
2 times a week, there was a decreasing trend in the number of cells expressing nitric 
oxide at all treatment levels, except 0ppm and 100ppm, which exhibited an increasing 
trend. Those participants who worked out 3 times a week exhibited a decreasing trend in 
the number of the cells that expressed nitric oxide at all treatment levels, except at 0ppm, 
which exhibited an increasing trend. There was no observable trend at 10ppm. For those 
individuals that indicated they worked out 5 times per week there was an increasing trend 
in the number of cells that expressed nitric oxide at all treatment levels, except at 0ppm 
and 150ppm which exhibited a decreasing trend and no observable trend at 450ppm. For 
those who reported working out 6 times a week, there was an increasing trend in the 
number of the cells that expressed nitric oxide at 0ppm and 450ppm, and a decreasing 
trend at the rest of the treatment levels. Finally, for those reporting work outs 7 times per 
week there was an increasing trend in the number of cells that expressed nitric oxide at all 





ANOVA Analysis of Quotient of Proliferation and Nitric Oxide Expression by Cat’s 
Claw Treatment 
Bivariate ANOVA (multiple regression) test was conducted on the quotient of the 
stimulated and non-stimulated conditions for proliferation, nitric oxide live cell, nitric 
oxide dead cell, and nitric oxide total cells (live cell and dead cell) to explore the 
association between these lymphocyte responses and different treatments of cat’s claw. 
The result showed no statistically significant association between proliferation and 
different doses of cat’s claw. There was also no statistically significant association 
between nitric oxide expression and different concentrations of cat’s claw.  
This study accepted the null hypothesis which signifies that there was no 
statistically significant difference between treatment groups for lymphocyte proliferation 
and nitric oxide stress. Bimolecular action of cat’s claw in this sample does not appear to 
be through proliferation nor nitric oxide expression across the treatment range of 10-
450ppm. This does not further elucidate the mechanisms of cat’s claw’s action, but it 
does indicate how it is likely not acting (keeping in mind this is a small sample size). 
Additionally, if this finding holds true at larger sample sizes, by not affecting lymphocyte 
proliferation and nitric oxide expression, it illustrates that cat’s claw does not 
dramatically reduce the ability of the immune system to function in warding off disease. 
It also challenges researchers to continue to explore the broad range of cytokines and 
interleukins whereby cat’s claw may be having its primary impacts.  Or perhaps even to 




Conclusions and Recommendations 
Osteoarthritis is a chronic disease where the joints of affected patients degenerate 
leading to adult disability. It is a condition which affects the entire joint by degrading 
articular cartilage. Osteoarthritis is among the most prevalent of musculoskeletal diseases 
accounting for 50% of disease burden in this category (Jordan et al., 2003). Osteoarthritis 
is usually a very painful joint condition affecting millions of people around the world 
diminishing their quality of life. According to the CDC (2017), 56.3 million adults 
around the world have arthritis and about 41 million in the U.S. Osteoarthritis attacks the 
joint causing chronic pain, stiffness, and swelling. It often degenerates the entire articular 
cartilage. Patients with osteoarthritis suffer from pain and loss of function (Miller et al, 
2005). Since osteoarthritis is not curable, the only option offered by contemporary 
medicine is its management. 
The health care and medication options for osteoarthritis patients are continuously 
being reevaluated. Complementary and alternative supplements are being used to 
diversify options, which allows for improved healthcare outcomes by minimizing drug 
side effects (Synovitz & Larson, 2012). Alternative supplements, particularly natural 
herbs, are used to treat or improve the management of some autoimmune diseases such as 
osteoarthritis. Cat’s claw is one of the alternative supplements that has been used to treat 




There is mounting evidence that individuals with osteoarthrosis risk multiple side 
effects by long-term use of pharmaceutical medications with sometimes even more 
serious outcomes than those caused by the original condition (Slipman, 2008). Further, 
supplement use, and herbal medication use is a strong and growing market of self-care 
(Synovitz & Larson, 2012). Research on the biomolecular action of alternative 
supplements for osteoarthritis has been lacking, therefore more clinical research needs to 
be done to facilitate understanding of the safety and mechanisms of action of these 
supplements.  
There are very few conclusive studies elucidating the biomolecular action of cat’s 
claw, despite being on the market for several decades (Vitetta et al., 2008). In this study it 
was determined that the action of cat’s claw was not through proliferation nor nitric oxide 
modulation across the treatment ranges of 10-450ppm. This indicates that more work 
needs to be done to verify the biomolecular action of cat’s claws’ effectiveness, 
especially in light of studies suggesting that modulation of iNOS induction may be one of 
the mechanisms of action (Hardin, 2007; Sandoval et al., 2000; & Valerio & Gonzales, 
2005). 
Further biomedical studies need to be done on the toxicity and pharmacokinetics 
of cat’s claw in humans, because both of these are poorly understood, and the long-term 
safety of the herb is not well established (Kuhn & Winston, 2008). Likewise, cat’s claw 
use has not been adequately evaluated for pregnant and lactating women, and children 
under three years old (Piscoya et al., 2001; Vitetta, Cicuttini, & Sali, 2008). Further, very 




certified by the Food and Drug Administration (FDA). Finally, research should be done 
to check whether similar compounds from different parts of the plant have the same 
medicinal value for the treatment of osteoarthritis (Sandoval et al., 2002).  It is only by 
fully understanding the biomolecular actions and long-term safety implications of this 
herb that it will be able to be validated for use by the (FDA) for osteoarthritis patients, 
diversifynig their options for treatment and bring a greater degree of health and wellbeng 
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PARTICIPANT INFORMED CONSENT 
Environmental Health Sciences Lab 
CONSENT TO ACT AS A SUBJECT IN AN EXPERIMENTAL STUDY 
TITLE:  In-vitro study of the impact of varying concentrations of cat’s claw (Uncaria 
tomentosa) on osteoarthritis: a cohort study of individual response. 
 
INVESTIGATOR: Noha Fadlalddin 
Doctoral Student at University of Northern Iowa / HPELS    
 
CO-INVESTIGATOR: Dr. Catherine Zeman 
University of Northern Iowa / HPELS  
Office Phone number: 319-273-7090 
Departmental phone number: 319-273-2456 
 
INVITATION TO PARTICIPANT:  I would like to request your participation in a 
research project to be conducted through the University of Northern Iowa, Allied Health 
(Environmental Health focus), Recreation, & Community Services Doctoral program. 
University policy requires participants’ signed consent to participate in research.  The 
following information is provided to help you make an informed decision whether or not 
to participate. 
 
NATURE AND PURPOSE: You are invited to participate as a subject in an investigation 
of the abilities of various compounds to alter human immune responses in vitro (test-tube 
based study). This project will study the effects of different concentrations of cat's claw 
(Uncaria tomentosa) on human immune cells for osteoarthritis disease. Will there be any 
changes at the level of immune cells? If there is any change observed, in what 
concentration? This is a purely experimental toxicology study. There are no immediate 
health implication for the participants. You will at no time be exposed to any cat’s claw 
compound. We will require a sample of your blood to study the effects of different 
concentrations of cat’s claw (Uncaria tomentosa) on your lymphocytes and associated 




any change at the level of pro-inflammatory cytokines and nitric oxide stress when your 
lymphocytes are exposed to Uncaria tomentosa. 
 
EXPLANATION OF PROCEDURES: As a participant in the study we will collect 20-25 
ml of blood (6-8 teaspoons) from the vein at the elbow into a 30 ml syringe in a session 
that will take approximately 10 minutes.  Contact information will be maintained and you 
will remain eligible to be contacted by phone to donate blood, if you are willing, for up to 
4 years.  You must give consent for each occasion.   
 
All blood samples will be used within 4 hours and will not be stored after that time. 
Samples will be identified by numbers to keep general demographic information and 
donor’s identities anonymous from all individuals except the investigator. Any white 
blood cells that are remaining after the immune assays are set up will be autoclaved and 
thus destroyed. 
 
DISCOMFORT AND RISKS:  There are no anticipated adverse effects, except possibly 
minimal discomfort associated with drawing blood or the causation of a bruise, or 
sometimes clot (hematoma). Additionally, there is an unlikely chance that one may get 
light-headed from blood 
drawing. Consequently if one has a history of light-headed, one has to tell phlebotomist 
that one has grown light-headed on previous blood draws. Finally, there is always a small 
risk of infection with a blood draw, although this is highly unlikely. 
 
BENEFITS: This research will not be of any direct benefit to you but you will get to 
contribute to scientific knowledge and further research. You will receive a $10 University 
Book and Supply Gift Card for your participation following each draw. The name of any 
faculty receiving this gift card will have to be submitted to the Office of Business 
Operations for tax purposes. Faculty may refuse the gift card if they do not want their 
name to be submitted. 
 
REFUSAL TO PARTICIPATE: Your participation is completely voluntary.  You are free 
to withdraw from participation at any time or to choose not to participate at all, and that 
by doing so, you will not be penalized or lose benefits to which you are otherwise 





CONFIDENTIALITY: Any information which will identify you will be treated as 
confidential.  While information from this study may be published in an academic journal 
or presented at a scholarly conference, you will not be in any way personally identified. 
 
VOLUNTARY CONSENT: Dr. Zeman has explained all of this to you and has answered 
all of your questions.  Any future questions you have about this research will be answered 
by Dr. Zeman, whom you may call at 319-273-7090 or write to at the School of HPELS, 
The University of Northern Iowa, Cedar Falls, IA 50614.  You may also contact the 
office of the Human Subjects Coordinator, University of Northern Iowa, (319) 273-6148, 
for answers to questions about the research and about the rights of research subjects. 
 
Please indicate your willingness to participate by completing and signing the following: 
 
I am fully aware of the nature and extent of my participation in this project as stated 
above and the possible risks arising from it.  I hereby agree to participate in this project. I 
acknowledge that I have received a copy of this consent statement.  I am 18 years of age 
or older. 
 
 (Signature of participant)      (Date) 
 
(Printed name of participant) 
 
(Signature of investigator)                  (Date) 
 

















Study Title: In-vitro study of the impact of various concentrations of cat’s claw      




3. Weight:  
4. Height: 
 
1. Are you currently taking any Herbs? 
   Yes 
    No 














2. Are you currently taking any vitamins? 
Yes 
No 





3. Are you currently taking any prescribed Medication? 
Yes 
No 






4. Have you taken any joint steroid injection/shot to manage your arthritis 
pain? 
        Yes 
       No 
5. Have you received an immunization in the last 4 weeks?  
  Yes 
       No  







6. Do you become faint during blood draws? 
  Yes 
   No 
7. Do you know your Blood Type? 
   Yes 
   No 
If yes, then please indicate blood type_____________ 
 
8. Have you had a cold or flu in the past two weeks? 
  Yes 
  No 
 
9. Have you had a major life change/loss in last six months? (Death of a loved-
one, new job, job loss, marriage, etc.) 
  Yes 
  No 
 







11. Do you have (knees, hips, hands, spine) injury? 
       Yes 
No                                                     
If yes, explain 
 









Other please stat____________________________________________ 
 
14. Pain severity in the past 30 days 
 No pain                              Some pain                       Lots of pain 
 
15. Any Diagnosed Immunological diseases other than osteoarthritis? 
 
 
16. Is there any history of osteoarthritis in your family? 
                 Yes 
 No 




17. Do you suffer from allergies? 
Yes 
 No 
If yes please describe:  
18. Do you smoke? 
Yes 
No 
If yes, how many per day __________________________ 
 
19.  Are you physically active? 
 Yes 
 No 







Environmental Health Sciences Lab                                                       Participant ID# 
Project Checklist 
In-vitro study of the impact of various concentrations of cat’s claw (Uncaria tomentosa) 
on osteoarthritis: a cohort study of individual response. 
□ Study explained 
□ Verbal consent 
□ Participant questions answered 
□ Appointment made with Student Health Center 
□ Study re-explained at Student Health Center site 
□ Blood draw risks explained 
□ Participant questions answered 
□ Copy of written consent signed 
□ Participant questionnaire completed 
□ Completed blood-draw, vials labeled 
□ Notified WRC lab (call 273-7090 for pick-up) 
□ Transferred samples to WRC lab. 





MAKE RPMI* MIXTURE 
RPMI* mixture included RPMI 1640 medium with GlutaMAX and 100µl/1ml 
Pen Strep.  RPMI 1640 is a growth culture medium that has been used for cells growth 
(Nakabayashi, Taketa, Miyano, Yamane & Sato, 1982). 
Calculation: 
• 100µl/1ml Pen Strep mean that we should add 100µl of Pen Strep in 1ml of RPMI 
1640.  
• 500ml of RPMI 1640 should contain 100*500µl of Pen Strep 
• 50000µl of Pen Strep = 50ml of  Pen Strep 
• So, 500ml of RPMI 1640 should contain 50ml of Pen Strep 
Method: 
1. First, take 500 ml of RPMI 1640 with GlutaMAX. 
2. Now add 50ml of Pen Strep in 500 ml of RPMI 1640 with GlutaMAX. 










MAKE RPMI+ MIXTURE 
 From our RPMI* mixture we made RPMI+ mixture which included RPMI* and 
10% of Fetal Bovine Serum (FBS). FBS is growth factor that provide nutrients for cells 
culture as alternative of human supplements (Bieback. et al, 2009). 
Calculation: 
• 10% of 40ml RPMI* mixture 
• 10/100*40= 4ml of FBS 
Method: 
1. In a 50ml centrifuge tube, add 4ml of FBS in 36ml of RPMI*. 
2. This make 10%  
3. Now we have 10% FBS solution in 40 ml of RPMI* which is RPMI+ mixture 











RECONSTITUTE PHYTOHAEMAGGLUTININ (PHA) 
Phytohaemagglutinin (PHA) has a rapid effect on the cell membrane that help 
synthesize DNA in lymphocytes while the cell culture incubated (Kay, 1968).  
Calculations: 
We have 5mg/ml of powdered PHA to be reconstituted. 
Calculation 1 




From Formula, V2=C1*V1/C2 
V2=5000*1/8 
V2= 625ml of RPMI* 
So we need to add 625ml of RPMI* in PHA and reconstitute it. 
Calculation 2: 
We need 10% of FBS in 625ml RPMI* 




Add 62.5ml of FBS to make total volume of 625ml  
Calculation 3: 
Each cell culture plate need 5.4 ml of PHA mixture 
625/5.4=115 
This mixture is sufficient for 138 individuals 
Method: 
 Reconstitute PHA in mixture of 625 ml RPMI* 
Filter the mixture through 0.2-micron filter  
Then add 10% of FBS  
Take a sterile snap cap and fill the final mixture.  












MAKE CAT’S CLAW SOLUTION 
 We obtained powdered cat’s claw extract from Sigma-Aldrich Company U.S. 
Pharmacopeia certified (See Appendix K & L). To make cat’s claw solution, we prepared 
450 ppm by adding 4.5g of powdered cat’s claw in 10ml of RPMI+. Cat’s claw solution 
was incubated in a water bath at 37°C for 30 minutes. From 450ppm we made 250, 
150,100, and 10ppm. 
Calculation: 
Molecular weight of cat’s claw= 1g 
Converting 10 ml to liter= 0.01 
450/1000*1*0.01 
0.45*1*0.01= 0.0045g 
0.0045g*1000mg= 4.5mg  
Method: 
1. Weigh 4.5mg of cat’s claw and dilute in 10 ml of RPMI+ 
2. Placed our mixture in the water bath and incubated at 37℃ for 30 minutes (Sandoval-
Chacoan, Thompson, Zhang, Liu, & Mannick, 1998, & Lifeline Cell Technology, 2016).  
3. We removed our mixture from the water bath and run through 0.20micron syringe 





4.  Dilute this stock solution into desired concentration such as 10, 100, 150, 250, and 
450ppm. 
Make 450 ppm of cat’s claw in 10ml of RPMI+: 
Therefore, 4.5mg of cat’s claw in 10ml of RPMI+ makes 450 ppm of cat’s claw which is 
the stock solution 
Dilution Factor: 
Formula, C1*V1=C2*V2 
C1= concentration of stock solution 
V1=volume of stock solution needed to make new solution 
C2= Final concentration of new solution 
V2= Final volume of new solution 
From 450ppm solution make different concentrations 










V1= 1.1ml (converting gives 1100µl). Therefore, take 1100µl from stock solution and 
then add 900µl of RPMI+ to make final volume of 2000µl which is equal to 2ml. 




V2= 2ml  
C1*V1=C2*V2 
V1= 150*2/450 
V1= 0.66ml (converting gives 660µl). Therefore, take 660µl from stock solution and then 
add 1340µl of RPMI+ to make final volume of 2000µl which is equal to 2ml 










V1= 0.44ml (converting gives 440µl). Therefore, take 440µl from stock solution and then 
add 1560µl of RPMI+ to make final volume of 2000µl which is equal to 2ml 




V2= 2ml  
C1*V1=C2*V2 
V1= 10*2/450 
V1= 0.04ml (converting gives 40µl). Therefore, take 40µl from stock solution and then 













PREPARATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS 
1. Added 20ml of room temperature of phosphate-buffered saline (PBS) using sterile 
pipet and mix well. 
2. Slowly by using sterile pipet add 3ml of Ficoll-Hypaque per 10ml of blood/PBS 
mixture by holding the centrifuge tube at a 45° angle and place the tip of the pipet 
containing the Ficoll-Hypaque at the bottom of the sample tube. Therefore, added 
12ml of Ficoll-Hypaque to the blood/PBS (3/10*40= 12ml).  
3. Centrifuge 45 minutes at 1300rpm, at 20° C room temperature. 
4. After centrifugation, we had different layers as shown on Figure 16 (See 
Appendix M). 
5. We used sterile pipet to transfer lymphocytes from centrifuge tube into a new 
50ml sterile centrifuge tube. 
6. Several washings occurred; to wash the cells, we added 5ml of hank’s balanced 
salt solution (HBSS) to the lymphocytes and centrifuge for 10 minutes at 1300 
rpm.  
7. We repeated this wash step by removing supernatant, re-suspend lymphocytes by 
adding 5ml of HBSS and centrifuge for 10 minutes at 1300 rpm as before. 
8. Obtain the pellet from the final wash and re-suspend cells in 1ml of RPMI+ 





9. Refer to the MUSE Count and Viability Kit Users Guide, we used 20µl of cell 
suspension volume and added 380µl of count and viability regent volume. Using 
the Muse Procedure, we counted cells and determine count and viability. 
10. Depending on the viable cell concentration, we diluted the cells to the cell 
experimental concentration with RPMI+. 
11.  We added 50µl of cells to each experimental well on the culture plates under 
each experimental condition (lymphocyte proliferation and nitric oxide stress).  
12. Control wells of 0 only received 150µl of RPMI+ per well and 50µl of cells. 
13.  The next steps involve challenging all experimental wells (except control) with 
the agent of concern (cat’s claw herb).  This was followed by adding RPMI+ to 
the non-stimulated wells and PHA to the stimulated wells of each experimental 
plate condition (lymphocyte proliferation and nitric oxide stress). 
14. In the non-stimulated experimental challenge wells, proceed to all wells/cells with 
various cat’s claw concentrations of 10, 100, 150, 250, and 450ppm across all 
three experimental plates a total of 50µl per well and added 100µl of RPMI+ to 
all wells except 0. 
15. In the stimulated experiential challenge wells, proceed to all wells/cells with 
various cat’s claw concentrations of 10, 100, 150, 250, and 450ppm across all 
three experimental plates a total of 50µl per well and added 100µl of PHA to all  






 Control: 50µl cells + 150µl RPMI+ 
 Challenged: 50µl cells + 50µl cat’s claw + 100µl RPMI+ 
• Stimulated: 
 Control: 50µl cells + 100µl PHA + 50µl RPMI+ 
 Challenged: 50µl cells + 50µl cat’s claw + 100µl PHA 






























































SEPARATION OF BLOOD COMPONENTS ON A FICOLL-HYPAQUE GRADIENT 
 
Figure 16: Isolation of whole mononuclear cells from peripheral blood and cord blood 



























PREPARING NITRIC OXIDE TEST 
1. Nitric oxide culture plate used for Nitric Oxide Test using MUSE Unit. 
2. Prepare nitric oxide reagent working solution: for 12 tests, we mixed 1.5µl of 
nitric oxide reagent with 1,498.5µl of 1× assay buffer. 
3. Prepare 7-AAD working solution: for 12 tests, we mixed 30µl of 7-AAD stock 
solution with 1,320µl of 1× assay buffer. 
4. Add 100µl of nitric oxide reagent working solution to each micro-centrifuge tube. 
5. Add 10µl of cell suspension in each micro-centrifuge tube and mix thoroughly. 
6. Incubate samples for 30 minutes in the 37°C incubator with 5% carbon dioxide 
(CO2). 
7. After incubation, we added 90µl of 7-AAD working solution to each tube and mix 
thoroughly. 
8. Incubate at room temperature for 5 minutes, protected from light. 
9. Use muse unit (See Appendix V). 





























































COUNTS AND VIABILITY TEST 
1. We saved those pictures by participant ID number.  
2. Lymphocyte proliferation culture plate used for counts and viability test using 
MUSE Unit. 
3. We added 380µl of count and viability reagent to each micro-centrifuge tube. 
4. Add 20µl of cells suspension to each tube and mix thoroughly. 
5. Incubate for 5 minutes at room temperature. 
6. Use Muse Unit (See Appendix W).  








































TISSUE CULTURE PLATE OF COUNTS AND VIABILITY TEST UNDER THE 
























ASPETIC TECHNIQUE FOR THE LABORATORY WORK 
1. Wear PPE such as Lab coat, sterile gloves, heap cap, and mask before starting 
laboratory work. 
2. Wipe the hood thoroughly with ethanol (70% v/v) and Kim wipes. 
3. Further, sterilize the hood by UV light for about 30 minutes. 
4. Wipe all equipment necessary for laboratory work with ethanol (70% v/v) such as 
pipet aid, sharps container, biohazard waste can, test tube holder and so on. 
5. Place all equipment inside the hood. 
6. During laboratory work if any new glassware or equipment is needed then first 
































X1: Distribution analysis of demographic information 
Age: 
 










100.0% maximum 65 
99.5%  65 
97.5%  65 
90.0%  65 
75.0% quartile 62 
50.0% median 57 
25.0% quartile 51.5 
10.0%  48.2 
2.5%  37 
0.5%  37 
0.0% minimum 37 
   
Mean 56.2 
Std Dev 6.8617296 
Std Err Mean 1.3723459 
Upper 95% Mean 59.032383 










Level Count Probability 
Female 21 0.84000 
Male 4 0.16000 



















100.0% maximum 49.6 
99.5%  49.6 
97.5%  49.6 
90.0%  43.356 
75.0% quartile 33.795 
50.0% median 30.54 
25.0% quartile 26.47 
10.0%  21.714 
2.5%  21.63 
0.5%  21.63 




Std Dev 7.2626052 
Std Err Mean 1.452521 
Upper 95% Mean 34.563056 







X2: Distribution analysis of medication information 





Level Count Probability 
No 20 0.83333 
Yes 4 0.16667 
Total 24 1.000 
 







Level Count Probability 
Apple cider vinegar 1 0.14286 
Cinnamon 1 0.14286 
Cumin 1 0.14286 
Gluten Cutter 1 0.14286 
Gngko biloba 1 0.14286 
Turmeric 2 0.28571 









Level Count Probability 
No 6 0.24000 
Yes 19 0.76000 
Total 25 1.00000 
 




Level Count Prob 
B-Complex 1 0.02381 
Biotin 2 0.04762 
Calcium 6 0.14286 
Chlorophyll 1 0.02381 
Eye Health Vitamin 1 0.02381 
Hair and Nail Vitamin 1 0.02381 
Iron 2 0.04762 
Multivitamin 9 0.21429 
Neurobion 1 0.02381 
Omega XL 1 0.02381 
Omega-3 4 0.09524 
Vitamin B12 2 0.04762 
Vitamin c 1 0.02381 
Vitamin D 8 0.19048 
Vitamin D-3 2 0.04762 









Level Count Probability 
No 3 0.12000 
Yes 22 0.88000 






























List of Medications 
 
Level Count Probability 
Acid Reflex 1 0.01351 
Albiterol 1 0.01351 
Allegra 1 0.01351 
Amlodipine Besylate 1 0.01351 
Aspirin 3 0.04054 
Atenolo 1 0.01351 
Atltace 1 0.01351 
Atorvastatin 2 0.02703 
Benicar 1 0.01351 
Blood pressure medication 1 0.01351 
Bone Maximizer 1 0.01351 
Cholesterol 2 0.02703 
Clarinex D 1 0.01351 
Clonidine HCL 1 0.01351 
Crestor 2 0.02703 
Cymbalta 1 0.01351 
Depakote 1 0.01351 
Dexilant 1 0.01351 
Ditropan 1 0.01351 
Eligard 1 0.01351 
Esther 1 0.01351 
Estradiol 1 0.01351 
Evista 1 0.01351 
Exemestane 1 0.01351 
FiberCon 1 0.01351 
Finasteride 1 0.01351 
Fluoxetine 1 0.01351 
Fluoxitine 1 0.01351 
Fluticason Propionate 1 0.01351 
Furrosemide 1 0.01351 
Gabapentin 1 0.01351 
Generic Cymbalta 1 0.01351 
Generic Plaguenil 1 0.01351 
HCTZ 2 0.02703 
Hydrochlorothiazide 1 0.01351 
Ibuprofen 1 0.01351 
Imitrix 1 0.01351 
Inhaler 1 0.01351 




Level Count Probability 
Levothyroxine 2 0.02703 
Liothyronnie 1 0.01351 
Lipitor 1 0.01351 
Lisinopril 1 0.01351 
Losartan 1 0.01351 
Meloxicam 1 0.01351 
Mevacor 1 0.01351 
Mitrophal 1 0.01351 
Mobic 1 0.01351 
Morphine 1 0.01351 
Ocuvite 1 0.01351 
Omeprazole 1 0.01351 
Pazeo 1 0.01351 
ProAie HFA Albuterol Sulfate 1 0.01351 
Reclast 1 0.01351 
Simthyroid 1 0.01351 
Simvastatin 1 0.01351 
Singulair 2 0.02703 
Synthroid 2 0.02703 
Tamsuloosin 1 0.01351 
Tizidine 1 0.01351 
Trazadone 1 0.01351 
Venlafaxine 1 0.01351 
Xanex 1 0.01351 
Xyzal 1 0.01351 
Zyrtec 1 0.01351 
















Level Count Probability 
No 11 0.44000 
Yes 14 0.56000 
Total 25 1.00000 
 





Level Count Probability 
No 20 0.80000 
Yes 5 0.20000 






X3: Distribution analysis of health information 





Level Count Probability 
No 7 0.28000 
Yes 18 0.72000 






Level Count Probability 
A Negative 1 0.05556 
A Positive 6 0.33333 
AB Positive 1 0.05556 
B Positive 2 0.11111 
O Negative 4 0.22222 
O Positive 4 0.22222 









Level Count Probability 
No 25 1.00000 
Total 25 1.00000 
 
Have you had a major life change/loss in last six months? (Death of a loved-one, new 





Level Count Probability 
No 19 0.76000 
Yes 6 0.24000 










100.0% maximum 30 
99.5%  30 
97.5%  30 
90.0%  23.8 
75.0% quartile 15 
50.0% median 10 
25.0% quartile 6.5 
10.0%  4 
2.5%  3 
0.5%  3 




Std Dev 7.0717749 
Std Err Mean 1.414355 
Upper 95% Mean 14.399085 










Level Count Probability 
No 10 0.40000 
Yes 15 0.60000 
Total 25 1.00000 
 








Level Count Probability 
Left collar bone-double fracture 1 0.03846 
Anterior discectomy w/fusion (cadaver bone) 1 0.03846 
Carpal tunnel surgery 2 0.07692 
Dislocated right subtalar-surgery 1 0.03846 
Hands 1 0.03846 
Hip Injury 2 0.07692 
Hip replacement 1 0.03846 
Het by car from back 1 0.03846 
Injury L12-L16 L2 1 0.03846 
Injury L3, L4, L5, S1 1 0.03846 
Knees Injury 8 0.30769 
Missing backbone 1 0.03846 
Right shoulder injury 1 0.03846 
Rotator cuff 1 0.03846 
Spine injury 2 0.07692 
Thump joint replacement 1 0.03846 
Total 26 1.00000 
 




Level Count Probability 
No 11 0.44000 
Yes 14 0.56000 









Level Count Probability 
Ankles 1 0.01449 
Everywhere 1 0.01449 
Hands 16 0.23188 
Hip 15 0.21739 
Knees 17 0.24638 
Lower back 5 0.07246 
Nick 1 0.01449 
Shoulder 2 0.02899 
Spine 11 0.15942 
















Level Count Probability 
Lots of pain 12 0.48000 
Some pain 13 0.52000 
Total 25 1.00000 
 





Level Count Probability 
No 25 1.00000 














Level Count Probability 
No 5 0.20000 
Yes 20 0.80000 
Total 25 1.00000 
 





Level Count Probability 
Brother 3 0.10714 
Father 6 0.21429 
Grandfather 1 0.03571 
Grandmother 3 0.10714 
Mother 12 0.42857 
Sister 3 0.10714 









Level Count Probability 
No 8 0.32000 
Yes 17 0.68000 
Total 25 1.00000 
 
If yes please describe                         Frequencies 
 
Level Count Probability 
Antibiotics 1 0.04762 
Cats 2 0.09524 
Dust 1 0.04762 
Environmental 5 0.23810 
Food 1 0.04762 
Hay fever 4 0.19048 
Lanolin 1 0.04762 
Medication 2 0.09524 
Penicillin 1 0.04762 
Perch 1 0.04762 
Smoking 1 0.04762 
Sulfa 1 0.04762 









Level Count Probability 
No 25 1.00000 





















Level Count Probability 
No 5 0.20000 
Yes 20 0.80000 
Total 25 1.00000 
 





Level Count Probability 
2X /week 2 0.09524 
3X /week 10 0.47619 
5X /week 4 0.19048 
6X /week 1 0.04762 
7X /week 4 0.19048 





PROLIFIRATION STATISTICAL RESULTS 






RSquare Adj 0.024559 
Root Mean Square Error 886.9519 
Mean of Response 289.2443 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio 
Model 1 1262040 1262040 1.6043 
Error 23 18093724 786684 Prob > F 
C. Total 24 19355764  0.2180 
 
Parameter Estimates 
Term Estimate Std Error t Ratio Prob>|t| 
Intercept 2167.409 1493.423 1.45 0.1602 











RSquare Adj -0.04433 
Root Mean Square Error 0.12638 
Mean of Response 0.942722 
Observations (or Sum Wgts) 18 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio 
Model 1 0.00444631 0.004446 0.2784 
Error 16 0.25555130 0.015972 Prob > F 
C. Total 17 0.25999761  0.4050 
 
Parameter Estimates 
Term Estimate Std Error t Ratio Prob>|t| 
Intercept 0.969164 0.0583 16.62 <.0001* 
Number of 
Medication 










Adj Rsquare 0.01109 
Root Mean Square Error 893.0543 
Mean of Response 289.2443 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Joint Steroid 1 1012206 1012206 1.2692 0.2715 
Error 23 18343558 797546   
C. Total 24 19355764    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
No 11 516.248 269.27 -40.8 1073.3 




















RSquare Adj 0.028808 
Root Mean Square Error 323.3649 
Mean of Response 70.91077 
Observations (or Sum Wgts) 22 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio 
Model 1 169699.2 169699 1.6229 
Error 20 2091296.8 104565 Prob > F 
C. Total 21 2260996.0  0.2173 
 
Parameter Estimates 
Term Estimate Std Error t Ratio Prob>|t| 
Intercept 217.96648 134.4545 1.62 0.1207 
Length of 
Osteoarthritis 










Adj Rsquare 0.008065 
Root Mean Square Error 894.4191 
Mean of Response 289.2443 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Phisically Limited 1 956098 956098 1.1951 0.2856 
Error 23 18399666 799985   
C. Total 24 19355764    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
No 11 509.866 269.68 -48.0 1067.7 
















Adj Rsquare -0.01163 
Root Mean Square Error 903.2555 
Mean of Response 289.2443 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Pain Severity 1 590744 590744 0.7241 0.4036 
Error 23 18765021 815870   
C. Total 24 19355764    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
Lots of pain 12 129.248 260.75 -410.1 668.64 












Adj Rsquare 0.026202 
Root Mean Square Error 886.2044 
Mean of Response 289.2443 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Pain area 1 1292526 1292526 1.6458 0.2123 
Error 23 18063238 785358   
C. Total 24 19355764    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
Hip 15 103.590 228.82 -369.8 576.9 












Adj Rsquare -0.01548 
Root Mean Square Error 904.9742 
Mean of Response 289.2443 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Family History 1 519262 519262 0.6340 0.4340 
Error 23 18836502 818978   
C. Total 24 19355764    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
No 5 1.005 404.72 -836.2 838.23 












Adj Rsquare 0.009235 
Root Mean Square Error 893.8914 
Mean of Response 289.2443 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Allergies 1 977800 977800 1.2237 0.2801 
Error 23 18377964 799042   
C. Total 24 19355764    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
No 8 0.951 316.04 -652.8 654.73 












Adj Rsquare -0.01548 
Root Mean Square Error 904.973 
Mean of Response 289.2443 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Physically 
Active(Work out) 
1 519315 519315 0.6341 0.4340 
Error 23 18836449 818976   
C. Total 24 19355764    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
No 5 0.990 404.72 -836.2 838.21 















RSquare Adj 0.023637 
Root Mean Square Error 811.8501 
Mean of Response 254.4681 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio 
Model 1 1042058 1042058 1.5810 
Error 23 15159314 659101 Prob > F 
C. Total 24 16201372  0.2212 
 
Parameter Estimates 
Term Estimate Std Error t Ratio Prob>|t| 
Intercept 1961.1122 1366.968 1.43 0.1648 
















RSquare Adj -0.01934 
Root Mean Square Error 0.178958 
Mean of Response 0.977889 
Observations (or Sum Wgts) 18 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio 
Model 1 0.02169450 0.021695 0.6774 
Error 16 0.51241327 0.032026 Prob > F 
C. Total 17 0.53410778  0.4226 
 
Parameter Estimates 
Term Estimate Std Error t Ratio Prob>|t| 
Intercept 1.0362959 0.082554 12.55 <.0001* 
Number of 
Medication 












Adj Rsquare 0.01037 
Root Mean Square Error 817.3475 
Mean of Response 254.4681 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Joint Steroid 1 836062 836062 1.2515 0.2748 
Error 23 15365310 668057   
C. Total 24 16201372    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
No 11 460.776 246.44 -49.0 970.58 













RSquare Adj 0.028736 
Root Mean Square Error 268.7397 
Mean of Response 59.12555 
Observations (or Sum Wgts) 22 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio 
Model 1 117092.3 117092 1.6213 
Error 20 1444420.5 72221 Prob > F 
C. Total 21 1561512.8  0.2175 
 
Parameter Estimates 
Term Estimate Std Error t Ratio Prob>|t| 
Intercept 181.27913 111.7415 1.62 0.1204 
Length of 
Osteoarthritis 











Adj Rsquare 0.012757 
Root Mean Square Error 816.3611 
Mean of Response 254.4681 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Phisically Limited 1 873126 873126 1.3101 0.2641 
Error 23 15328246 666445   
C. Total 24 16201372    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
No 11 465.300 246.14 -43.9 974.48 









Summary of Fit 
Rsquare 0.030739 
Adj Rsquare -0.0114 
Root Mean Square Error 826.2898 
Mean of Response 254.4681 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of Squares Mean Square F Ratio Prob > F 
Pain Severity 1 498010 498010 0.7294 0.4019 
Error 23 15703362 682755   
C. Total 24 16201372    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
Lots of pain 12 107.565 238.53 -385.9 601.00 











Adj Rsquare 0.024869 
Root Mean Square Error 811.3377 
Mean of Response 254.4681 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain area 1 1061187 1061187 1.6121 0.2169 
Error 23 15140184 658269   
C. Total 24 16201372    
 
Means for Anova 





Hip 15 86.247 209.49 -347.1 519.6 











Adj Rsquare -0.01761 
Root Mean Square Error 828.8212 
Mean of Response 254.4681 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Family History 1 401646 401646 0.5847 0.4523 
Error 23 15799726 686945   
C. Total 24 16201372    
 
Means for Anova 





No 5 0.966 370.66 -765.8 767.73 











Adj Rsquare 0.005233 
Root Mean Square Error 819.466 
Mean of Response 254.4681 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Allergies 1 756307 756307 1.1263 0.2996 
Error 23 15445065 671525   
C. Total 24 16201372    
 
Means for Anova 





No 8 0.921 289.72 -598.4 600.26 












Adj Rsquare -0.01762 
Root Mean Square Error 828.8239 
Mean of Response 254.4681 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Physically 
Active(Work out) 
1 401544 401544 0.5845 0.4523 
Error 23 15799828 686949   
C. Total 24 16201372    
 
Means for Anova 





No 5 0.998 370.66 -765.8 767.77 














RSquare Adj 0.022413 
Root Mean Square Error 829.899 
Mean of Response 249.7101 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 1067703 1067703 1.5502 
Error 23 15840843 688732 Prob > F 
C. Total 24 16908546  0.2256 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 1977.2271 1397.359 1.41 0.1705 











RSquare Adj 0.135596 
Root Mean Square Error 0.118509 
Mean of Response 1.050278 
Observations (or Sum Wgts) 18 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 0.05149660 0.051497 3.6667 
Error 16 0.22470901 0.014044 Prob > F 
C. Total 17 0.27620561  0.0736 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 0.9602908 0.054669 17.57 <.0001* 
Number of 
Medication 










Adj Rsquare 0.011005 
Root Mean Square Error 834.727 
Mean of Response 249.7101 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Joint Steroid 1 882855 882855 1.2671 0.2719 
Error 23 16025691 696769   
C. Total 24 16908546    
 
Means for Anova 





No 11 461.713 251.68 -58.9 982.35 












RSquare Adj 0.028878 
Root Mean Square Error 241.3969 
Mean of Response 53.26259 
Observations (or Sum Wgts) 22 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 94662.2 94662.2 1.6245 
Error 20 1165448.8 58272.4 Prob > F 
C. Total 21 1260111.0  0.2171 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 163.09496 100.3724 1.62 0.1198 
Length of 
Osteoarthritis 










Adj Rsquare 0.014846 
Root Mean Square Error 833.1045 
Mean of Response 249.7101 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Phisically 
Limited 
1 945095 945095 1.3617 0.2552 
Error 23 15963450 694063   
C. Total 24 16908546    
 
Means for Anova 





No 11 469.059 251.19 -50.6 988.69 













Adj Rsquare -0.01017 
Root Mean Square Error 843.6157 
Mean of Response 249.7101 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain Severity 1 539734 539734 0.7584 0.3928 
Error 23 16368812 711687   
C. Total 24 16908546    
 
Means for Anova 





Lots of pain 12 96.777 243.53 -407.0 600.56 











Adj Rsquare 0.025049 
Root Mean Square Error 828.7792 
Mean of Response 249.7101 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain area 1 1110420 1110420 1.6166 0.2163 
Error 23 15798125 686875   
C. Total 24 16908546    
 
Means for Anova 





Hip 15 77.631 213.99 -365.0 520.3 











Adj Rsquare -0.01963 
Root Mean Square Error 847.556 
Mean of Response 249.7101 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Family History 1 386468 386468 0.5380 0.4707 
Error 23 16522078 718351   
C. Total 24 16908546    
 
Means for Anova 





No 5 1.044 379.04 -783.1 785.15 











Adj Rsquare 0.001432 
Root Mean Square Error 838.7573 
Mean of Response 249.7101 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Allergies 1 727727 727727 1.0344 0.3197 
Error 23 16180818 703514   
C. Total 24 16908546    
 
Means Anova 





No 8 1.000 296.55 -612.5 614.45 












Adj Rsquare -0.01962 
Root Mean Square Error 847.5513 
Mean of Response 249.7101 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Physically 
Active(Work out) 
1 386652 386652 0.5383 0.4706 
Error 23 16521894 718343   
C. Total 24 16908546    
 
Means for Anova 





No 5 0.985 379.04 -783.1 785.08 












RSquare Adj 0.021711 
Root Mean Square Error 653.8796 
Mean of Response 207.9914 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 655287 655287 1.5326 
Error 23 9833845 427558 Prob > F 
C. Total 24 10489133  0.2282 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 1561.3505 1100.982 1.42 0.1696 











RSquare Adj 0.281692 
Root Mean Square Error 0.281042 
Mean of Response 1.090556 
Observations (or Sum Wgts) 18 
 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 0.6055540 0.605554 7.6667 
Error 16 1.2637545 0.078985 Prob > F 
C. Total 17 1.8693084  0.0137* 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 0.7819764 0.129646 6.03 <.0001* 
Number of 
Medication 










Adj Rsquare -0.00581 
Root Mean Square Error 663.0118 
Mean of Response 207.9914 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Joint 
Steroid 
1 378687 378687 0.8615 0.3630 
Error 23 10110445 439585   
C. Total 24 10489133    
 
Means for Anova 





No 11 346.839 199.91 -66.7 760.38 












RSquare Adj 0.028952 
Root Mean Square Error 287.5975 
Mean of Response 63.3105 
Observations (or Sum Wgts) 22 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 134499.8 134500 1.6261 
Error 20 1654246.1 82712 Prob > F 
C. Total 21 1788745.9  0.2169 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 194.22953 119.5825 1.62 0.1200 
Length of 
Osteoarthritis 











Adj Rsquare 0.027918 
Root Mean Square Error 651.8018 
Mean of Response 207.9914 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Phisically 
Limited 
1 717684 717684 1.6893 0.2066 
Error 23 9771449 424846   
C. Total 24 10489133    
 
Means for Anova 





No 11 399.137 196.53 -7.4 805.68 

















Adj Rsquare 0.006404 
Root Mean Square Error 658.9751 
Mean of Response 207.9914 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain area 1 501423 501423 1.1547 0.2937 
Error 23 9987709 434248   
C. Total 24 10489133    
 
Means for Anova 





Hip 15 92.357 170.15 -259.6 444.33 











Adj Rsquare -0.02371 
Root Mean Square Error 668.8857 
Mean of Response 207.9914 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain 
Severity 
1 198746 198746 0.4442 0.5117 
Error 23 10290386 447408   
C. Total 24 10489133    
 
Means for Anova 







12 115.189 193.09 -284.2 514.63 











Adj Rsquare -0.01684 
Root Mean Square Error 666.6389 
Mean of Response 207.9914 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Family 
History 
1 267763 267763 0.6025 0.4455 
Error 23 10221369 444407   
C. Total 24 10489133    
 
Means for Anova 





No 5 1.008 298.13 -615.7 617.74 











Adj Rsquare 0.006671 
Root Mean Square Error 658.8867 
Mean of Response 207.9914 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Allergies 1 504104 504104 1.1612 0.2924 
Error 23 9985029 434132   
C. Total 24 10489133    
 
Means for Anova 





No 8 0.992 232.95 -480.9 482.89 












Adj Rsquare -0.01683 
Root Mean Square Error 666.6364 
Mean of Response 207.9914 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 




1 267838 267838 0.6027 0.4455 
Error 23 10221294 444404   
C. Total 24 10489133    
 
Means for Anova 





No 5 0.979 298.13 -615.7 617.71 












RSquare Adj 0.01769 
Root Mean Square Error 1165.156 
Mean of Response 310.9853 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 1944334 1944334 1.4322 
Error 23 31224517 1357588 Prob > F 
C. Total 24 33168851  0.2436 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 2642.2012 1961.854 1.35 0.1912 










RSquare Adj 0.010348 
Root Mean Square Error 0.124018 
Mean of Response 1.038778 
Observations (or Sum Wgts) 18 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 0.01811447 0.018114 1.1778 
Error 16 0.24608664 0.015380 Prob > F 
C. Total 17 0.26420111  0.2939 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 0.9854071 0.05721 17.22 <.0001* 
Number of 
Medication 











Adj Rsquare 0.00949 
Root Mean Square Error 1170.008 
Mean of Response 310.9853 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Joint 
Steroid 
1 1683697 1683697 1.2299 0.2789 
Error 23 31485154 1368920   
C. Total 24 33168851    
 
Means for Anova 





No 11 603.757 352.77 -126.0 1333.5 

















RSquare Adj 0.028959 
Root Mean Square Error 235.086 
Mean of Response 51.89014 
Observations (or Sum Wgts) 22 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 89877.4 89877.4 1.6263 
Error 20 1105308.2 55265.4 Prob > F 
C. Total 21 1195185.6  0.2168 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 158.91068 97.74833 1.63 0.1197 
Length of 
Osteoarthritis 












Adj Rsquare 0.019392 
Root Mean Square Error 1164.145 
Mean of Response 310.9853 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Phisically Limited 1 1998460 1998460 1.4746 0.2369 
Error 23 31170390 1355234   
C. Total 24 33168851    
 
Means for Anova 





No 11 629.952 351.00 -96.2 1356.1 











Adj Rsquare -0.00938 
Root Mean Square Error 1181.102 
Mean of Response 310.9853 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain Severity 1 1083788 1083788 0.7769 0.3872 
Error 23 32085063 1395003   
C. Total 24 33168851    
 
Means for Anova 





Lots of pain 12 94.273 340.95 -611.0 799.6 











Adj Rsquare 0.021873 
Root Mean Square Error 1162.672 
Mean of Response 310.9853 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain area 1 2077318 2077318 1.5367 0.2276 
Error 23 31091533 1351806   
C. Total 24 33168851    
 
Means for Anova 





Hip 15 75.624 300.20 -545.4 696.6 













Adj Rsquare -0.02459 
Root Mean Square Error 1189.964 
Mean of Response 310.9853 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Family History 1 600529 600529 0.4241 0.5214 
Error 23 32568321 1416014   
C. Total 24 33168851    
 
Means for Anova 





No 5 1.010 532.17 -1100 1101.9 












Adj Rsquare -0.00792 
Root Mean Square Error 1180.248 
Mean of Response 310.9853 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Allergies 1 1130204 1130204 0.8114 0.3771 
Error 23 32038647 1392985   
C. Total 24 33168851    
 
Means for Anova 





No 8 1.038 417.28 -862.2 864.2 












Adj Rsquare -0.02459 
Root Mean Square Error 1189.965 
Mean of Response 310.9853 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Physically 
Active(Work out) 
1 600453 600453 0.4240 0.5214 
Error 23 32568397 1416017   
C. Total 24 33168851    
 
Means for Anova 





No 5 1.030 532.17 -1100 1101.9 












RSquare Adj 0.022888 
Root Mean Square Error 778.1972 
Mean of Response 239.3317 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 946044 946044 1.5622 
Error 23 13928589 605591 Prob > F 
C. Total 24 14874633  0.2239 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 1865.4526 1310.305 1.42 0.1680 












RSquare Adj -0.05053 
Root Mean Square Error 0.17379 
Mean of Response 1.061 
Observations (or Sum Wgts) 18 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 0.00550454 0.005505 0.1823 
Error 16 0.48324946 0.030203 Prob > F 
C. Total 17 0.48875400  0.6751 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 1.0315794 0.08017 12.87 <.0001* 
Number of 
Medication 










Adj Rsquare 0.008544 
Root Mean Square Error 783.8886 
Mean of Response 239.3317 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Joint Steroid 1 741563 741563 1.2068 0.2833 
Error 23 14133070 614481   
C. Total 24 14874633    
 
Means for Anova 





No 11 433.631 236.35 -55.3 922.56 

















RSquare Adj 0.028935 
Root Mean Square Error 251.8907 
Mean of Response 55.55286 
Observations (or Sum Wgts) 22 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 103150.9 103151 1.6257 
Error 20 1268978.4 63449 Prob > F 
C. Total 21 1372129.2  0.2169 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 170.20403 104.7357 1.63 0.1198 
Length of 
Osteoarthritis 
















Adj Rsquare 0.016097 
Root Mean Square Error 780.8967 
Mean of Response 239.3317 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Phisically Limited 1 849240 849240 1.3927 0.2500 
Error 23 14025394 609800   
C. Total 24 14874633    
 
Means for Anova 





No 11 447.260 235.45 -39.8 934.32 











Adj Rsquare -0.01247 
Root Mean Square Error 792.153 
Mean of Response 239.3317 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain Severity 1 441988 441988 0.7044 0.4100 
Error 23 14432646 627506   
C. Total 24 14874633    
 
Means for Anova 





Lots of pain 12 100.938 228.67 -372.1 573.99 











Adj Rsquare 0.022519 
Root Mean Square Error 778.3443 
Mean of Response 239.3317 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain area 1 940775 940775 1.5529 0.2253 
Error 23 13933858 605820   
C. Total 24 14874633    
 
Means for Anova 





Hip 15 80.942 200.97 -334.8 496.68 











Adj Rsquare -0.01859 
Root Mean Square Error 794.5409 
Mean of Response 239.3317 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Family History 1 354845 354845 0.5621 0.4610 
Error 23 14519789 631295   
C. Total 24 14874633    
 
Means for Anova 





No 5 1.056 355.33 -734.0 736.11 











Adj Rsquare 0.003361 
Root Mean Square Error 785.9349 
Mean of Response 239.3317 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Allergies 1 667680 667680 1.0809 0.3093 
Error 23 14206953 617694   
C. Total 24 14874633    
 
Means for Anova 





No 8 1.103 277.87 -573.7 575.92 












Adj Rsquare -0.01858 
Root Mean Square Error 794.537 
Mean of Response 239.3317 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Physically 
Active(Work out) 
1 354987 354987 0.5623 0.4609 
Error 23 14519646 631289   
C. Total 24 14874633    
 
Means for Anova 





No 5 1.009 355.33 -734.0 736.06 









NITRIC OXIDE STATISTICAL RESULTS 






RSquare Adj -0.03892 
Root Mean Square Error 3.222058 
Mean of Response 1.501744 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 1.04818 1.0482 0.1010 
Error 23 238.77807 10.3817 Prob > F 
C. Total 24 239.82625  0.7535 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept -0.209908 5.425202 -0.04 0.9695 










RSquare Adj 0.245663 
Root Mean Square Error 1.758112 
Mean of Response 1.064695 
Observations (or Sum Wgts) 22 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 24.230050 24.2301 7.8390 
Error 20 61.819190 3.0910 Prob > F 
C. Total 21 86.049240  0.0111* 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept -0.692496 0.73102 -0.95 0.3548 
Length of 
Osteoarthritis 










Adj Rsquare -0.0052 
Root Mean Square Error 3.225911 
Mean of Response 1.555192 
Observations (or Sum Wgts) 24 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Herbs 1 9.16918 9.1692 0.8811 0.3581 
Error 22 228.94308 10.4065   
C. Total 23 238.11226    
 
Means for Anova 





No 20 1.83162 0.7213 0.336 3.3276 










Adj Rsquare 0.014427 
Root Mean Square Error 3.138248 
Mean of Response 1.501744 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Vitamins 1 13.30848 13.3085 1.3513 0.2570 
Error 23 226.51778 9.8486   
C. Total 24 239.82625    
 
Means for Anova 





No 6 0.20338 1.2812 -2.447 2.8537 


















RSquare Adj -0.06149 
Root Mean Square Error 2.298633 
Mean of Response 1.13365 
Observations (or Sum Wgts) 18 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 0.080278 0.08028 0.0152 
Error 16 84.539408 5.28371 Prob > F 
C. Total 17 84.619687  0.9034 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 1.2460042 1.06037 1.18 0.2572 
Number of 
Medication 














Adj Rsquare -0.02813 
Root Mean Square Error 3.205284 
Mean of Response 1.501744 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Joint 
Steroid 
1 3.52786 3.5279 0.3434 0.5636 
Error 23 236.29840 10.2738   
C. Total 24 239.82625    
 
Means for Anova 





No 11 1.92554 0.96643 -0.0737 3.9247 












Adj Rsquare -0.0403 
Root Mean Square Error 3.2242 
Mean of Response 1.501744 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Phisically Limited 1 0.73059 0.7306 0.0703 0.7933 
Error 23 239.09567 10.3955   
C. Total 24 239.82625    
 
Means for Anova 





No 11 1.69460 0.97213 -0.3164 3.7056 











Adj Rsquare 0.027171 
Root Mean Square Error 3.117891 
Mean of Response 1.501744 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain area 1 16.23766 16.2377 1.6703 0.2090 
Error 23 223.58859 9.7212   
C. Total 24 239.82625    
 
Means for Anova 





Hip 15 0.84371 0.80504 -0.8216 2.5091 











Adj Rsquare -0.0149 
Root Mean Square Error 3.184602 
Mean of Response 1.501744 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain 
Severity 
1 6.56744 6.5674 0.6476 0.4292 
Error 23 233.25881 10.1417   
C. Total 24 239.82625    
 
Means for Anova 







12 0.96828 0.91932 -0.9335 2.8700 











Adj Rsquare -0.02496 
Root Mean Square Error 3.20034 
Mean of Response 1.501744 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Family 
History 
1 4.25622 4.2562 0.4156 0.5255 
Error 23 235.57004 10.2422   
C. Total 24 239.82625    
 
Means for Anova 





No 5 0.67652 1.4312 -2.284 3.6373 










Adj Rsquare -0.03737 
Root Mean Square Error 3.219652 
Mean of Response 1.501744 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Allergies 1 1.40461 1.4046 0.1355 0.7162 
Error 23 238.42164 10.3662   
C. Total 24 239.82625    
 
Means for Anova 





No 8 1.15621 1.1383 -1.199 3.5110 











Adj Rsquare -0.0228 
Root Mean Square Error 3.196972 
Mean of Response 1.501744 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 




1 4.75179 4.7518 0.4649 0.5021 
Error 23 235.07446 10.2206   
C. Total 24 239.82625    
 
Means for Anova 





No 5 0.62980 1.4297 -2.328 3.5874 











Adj Rsquare 0.084863 
Root Mean Square Error 1.736032 
Mean of Response 0.886805 
Observations (or Sum Wgts) 19 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
How Often 4 17.085823 4.27146 1.4173 0.2793 
Error 14 42.193295 3.01381   
C. Total 18 59.279118    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
2X /week 2 0.64680 1.2276 -1.986 3.2797 
3X /week 9 0.32467 0.5787 -0.916 1.5658 
5X /week 3 2.99533 1.0023 0.846 5.1450 
6X /week 1 0.00000 1.7360 -3.723 3.7234 











RSquare Adj -0.0005 
Root Mean Square Error 8.619956 
Mean of Response 2.279384 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 73.4037 73.4037 0.9879 
Error 23 1708.9838 74.3036 Prob > F 
C. Total 24 1782.3875  0.3306 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 16.603109 14.51402 1.14 0.2644 











RSquare Adj -0.03617 
Root Mean Square Error 0.549659 
Mean of Response 0.474909 
Observations (or Sum Wgts) 22 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 0.0806595 0.080659 0.2670 
Error 20 6.0425063 0.302125 Prob > F 
C. Total 21 6.1231658  0.6110 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 0.373525 0.228547 1.63 0.1178 
Length of 
Osteoarthritis 










Adj Rsquare -0.03233 
Root Mean Square Error 8.940333 
Mean of Response 2.330608 
Observations (or Sum Wgts) 24 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Herbs 1 22.3629 22.3629 0.2798 0.6021 
Error 22 1758.4502 79.9296   
C. Total 23 1780.8131    
 
Means for Anova 





No 20 2.76230 1.9991 -1.384 6.9082 











Adj Rsquare -0.03098 
Root Mean Square Error 8.750244 
Mean of Response 2.279384 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Vitamins 1 21.3517 21.3517 0.2789 0.6025 
Error 23 1761.0358 76.5668   
C. Total 24 1782.3875    
 
Means for Anova 





No 6 0.63483 3.5723 -6.755 8.0246 











RSquare Adj -0.02195 
Root Mean Square Error 0.575124 
Mean of Response 0.479167 
Observations (or Sum Wgts) 18 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 0.2099853 0.209985 0.6348 
Error 16 5.2922732 0.330767 Prob > F 
C. Total 17 5.5022585  0.4372 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 0.2974542 0.265307 1.12 0.2788 
Number of 
Medication 












Adj Rsquare -0.00232 
Root Mean Square Error 8.627787 
Mean of Response 2.279384 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Joint 
Steroid 
1 70.2971 70.2971 0.9444 0.3413 
Error 23 1712.0904 74.4387   
C. Total 24 1782.3875    
 
Means for Anova 





No 11 4.17115 2.6014 -1.210 9.5525 










Adj Rsquare 0.006652 
Root Mean Square Error 8.58907 
Mean of Response 2.279384 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Phisically 
Limited 
1 85.6287 85.6287 1.1607 0.2925 
Error 23 1696.7588 73.7721   
C. Total 24 1782.3875    
 
Means for Anova 





No 11 4.36727 2.5897 -0.990 9.7245 











Adj Rsquare 0.024078 
Root Mean Square Error 8.513401 
Mean of Response 2.279384 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain area 1 115.3936 115.394 1.5921 0.2197 
Error 23 1666.9939 72.478   
C. Total 24 1782.3875    
 
Means for Anova 





Hip 15 0.52520 2.1982 -4.022 5.072 












Adj Rsquare -0.0079 
Root Mean Square Error 8.651737 
Mean of Response 2.279384 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain 
Severity 
1 60.7789 60.7789 0.8120 0.3769 
Error 23 1721.6086 74.8525   
C. Total 24 1782.3875    
 
Means for Anova 







12 0.65650 2.4975 -4.510 5.8231 











Adj Rsquare -0.03645 
Root Mean Square Error 8.773415 
Mean of Response 2.279384 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Family 
History 
1 12.0129 12.0129 0.1561 0.6964 
Error 23 1770.3746 76.9728   
C. Total 24 1782.3875    
 
Means for Anova 





No 5 0.89300 3.9236 -7.224 9.0096 











Adj Rsquare -0.0211 
Root Mean Square Error 8.708226 
Mean of Response 2.279384 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Allergies 1 38.2240 38.2240 0.5041 0.4849 
Error 23 1744.1635 75.8332   
C. Total 24 1782.3875    
 
Means for Anova 





No 8 0.47688 3.0788 -5.892 6.8459 












Adj Rsquare -0.03795 
Root Mean Square Error 8.779773 
Mean of Response 2.279384 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 




1 9.4462 9.4462 0.1225 0.7295 
Error 23 1772.9413 77.0844   
C. Total 24 1782.3875    
 
Means for Anova 





No 5 1.05000 3.9264 -7.072 9.1724 











Adj Rsquare -0.14031 
Root Mean Square Error 0.605977 
Mean of Response 0.489263 
Observations (or Sum Wgts) 19 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
How Often 4 0.6555209 0.163880 0.4463 0.7734 
Error 14 5.1409208 0.367209   
C. Total 18 5.7964417    
 
Means for Oneway Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
2X /week 2 0.246500 0.42849 -0.673 1.1655 
3X /week 9 0.462111 0.20199 0.029 0.8953 
5X /week 3 0.786333 0.34986 0.036 1.5367 
6X /week 1 0.000000 0.60598 -1.300 1.2997 












RSquare Adj 0.109714 
Root Mean Square Error 0.994054 
Mean of Response 0.91432 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 3.910718 3.91072 3.9576 
Error 23 22.727305 0.98814 Prob > F 
C. Total 24 26.638023  0.0587 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept -2.391851 1.673758 -1.43 0.1664 











RSquare Adj 0.221904 
Root Mean Square Error 0.969641 
Mean of Response 0.951045 
Observations (or Sum Wgts) 22 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 6.571034 6.57103 6.9890 
Error 20 18.804067 0.94020 Prob > F 
C. Total 21 25.375101  0.0156* 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 0.0359658 0.403175 0.09 0.9298 
Length of 
Osteoarthritis 










Adj Rsquare 0.049891 
Root Mean Square Error 1.044565 
Mean of Response 0.933667 
Observations (or Sum Wgts) 24 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Herbs 1 2.408900 2.40890 2.2077 0.1515 
Error 22 24.004547 1.09112   
C. Total 23 26.413447    
 
Means for Anova 





No 20 1.07535 0.23357 0.5910 1.5597 











Adj Rsquare 0.010123 
Root Mean Square Error 1.04818 
Mean of Response 0.91432 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Vitamins 1 1.368334 1.36833 1.2454 0.2760 
Error 23 25.269689 1.09868   
C. Total 24 26.638023    
 
Means for Anova 





No 6 0.49800 0.42792 -0.3872 1.3832 











RSquare Adj -0.05903 
Root Mean Square Error 1.23809 
Mean of Response 0.969944 
Observations (or Sum Wgts) 18 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 0.080255 0.08026 0.0524 
Error 16 24.525860 1.53287 Prob > F 
C. Total 17 24.606115  0.8219 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 0.8576064 0.571136 1.50 0.1527 
Number of 
Medication 











Adj Rsquare -0.04084 
Root Mean Square Error 1.074827 
Mean of Response 0.91432 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Joint 
Steroid 
1 0.067227 0.06723 0.0582 0.8115 
Error 23 26.570796 1.15525   
C. Total 24 26.638023    
 
Means for Anova 





No 11 0.855818 0.32407 0.18542 1.5262 











Adj Rsquare -0.04328 
Root Mean Square Error 1.076082 
Mean of Response 0.91432 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Phisically 
Limited 
1 0.005116 0.00512 0.0044 0.9476 
Error 23 26.632908 1.15795   
C. Total 24 26.638023    
 
Means for Anova 





No 11 0.898182 0.32445 0.22700 1.5694 











Adj Rsquare -0.03958 
Root Mean Square Error 1.074171 
Mean of Response 0.91432 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain area 1 0.099640 0.09964 0.0864 0.7715 
Error 23 26.538384 1.15384   
C. Total 24 26.638023    
 
Means for Anova 





Hip 15 0.965867 0.27735 0.39213 1.5396 











Adj Rsquare 0.000147 
Root Mean Square Error 1.053449 
Mean of Response 0.91432 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain 
Severity 
1 1.113676 1.11368 1.0035 0.3269 
Error 23 25.524347 1.10975   
C. Total 24 26.638023    
 
Means for Anova 







12 1.13400 0.30410 0.50491 1.7631 










Adj Rsquare -0.00437 
Root Mean Square Error 1.055825 
Mean of Response 0.91432 




Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Family 
History 
1 0.998401 0.99840 0.8956 0.3538 
Error 23 25.639623 1.11477   
C. Total 24 26.638023    
 
Means for Anova 





No 5 1.31400 0.47218 0.33722 2.2908 










Adj Rsquare -0.01249 
Root Mean Square Error 1.060086 
Mean of Response 0.91432 




Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Allergies 1 0.791048 0.79105 0.7039 0.4101 
Error 23 25.846975 1.12378   
C. Total 24 26.638023    
 
Means for Anova 





No 8 1.17363 0.37480 0.39830 1.9490 











Adj Rsquare -0.04344 
Root Mean Square Error 1.076166 
Mean of Response 0.91432 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 




1 0.000949 0.00095 0.0008 0.9774 
Error 23 26.637075 1.15813   
C. Total 24 26.638023    
 
Means for Anova 





No 5 0.902000 0.48128 -0.0936 1.8976 











Adj Rsquare 0.309209 
Root Mean Square Error 0.759216 
Mean of Response 0.774526 
Observations (or Sum Wgts) 19 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
How Often 4 6.949812 1.73745 3.0143 0.0548 
Error 14 8.069735 0.57641   
C. Total 18 15.019547    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
2X /week 2 1.75000 0.53685 0.599 2.9014 
3X /week 9 0.24100 0.25307 -0.302 0.7838 
5X /week 3 1.33000 0.43833 0.390 2.2701 
6X /week 1 0.00000 0.75922 -1.628 1.6284 












RSquare Adj 0.006676 
Root Mean Square Error 25.73581 
Mean of Response 6.348748 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 769.159 769.159 1.1613 
Error 23 15233.628 662.332 Prob > F 
C. Total 24 16002.787  0.2924 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 52.715332 43.33316 1.22 0.2361 











RSquare Adj -0.04053 
Root Mean Square Error 1.923289 
Mean of Response 1.247 
Observations (or Sum Wgts) 22 
 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 0.673001 0.67300 0.1819 
Error 20 73.980799 3.69904 Prob > F 
C. Total 21 74.653800  0.6743 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 1.5398531 0.7997 1.93 0.0685 
Length of 
Osteoarthritis 










Adj Rsquare -0.03575 
Root Mean Square Error 26.81287 
Mean of Response 6.600988 
Observations (or Sum Wgts) 24 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Herbs 1 148.149 148.149 0.2061 0.6543 
Error 22 15816.464 718.930   
C. Total 23 15964.612    
 
Means for Anova 





No 20 7.71210 5.996 -4.72 20.146 













Adj Rsquare -0.03146 
Root Mean Square Error 26.22514 
Mean of Response 6.348748 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Vitamins 1 184.360 184.360 0.2681 0.6096 
Error 23 15818.427 687.758   
C. Total 24 16002.787    
 
Means for Anova 





No 6 1.51633 10.706 -20.63 23.664 













RSquare Adj -0.05212 
Root Mean Square Error 2.107365 
Mean of Response 1.3575 
Observations (or Sum Wgts) 18 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 0.701039 0.70104 0.1579 
Error 16 71.055782 4.44099 Prob > F 
C. Total 17 71.756821  0.6964 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 1.6895177 0.972137 1.74 0.1014 
Number of 
Medication 












Adj Rsquare 0.010323 
Root Mean Square Error 25.68851 
Mean of Response 6.348748 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Joint Steroid 1 825.100 825.100 1.2503 0.2750 
Error 23 15177.687 659.899   
C. Total 24 16002.787    
 
Means for Anova 





No 11 12.8299 7.7454 -3.19 28.852 
















Adj Rsquare 0.008239 
Root Mean Square Error 25.71555 
Mean of Response 6.348748 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Phisically Limited 1 793.133 793.133 1.1994 0.2848 
Error 23 15209.654 661.289   
C. Total 24 16002.787    
 
Means for Anova 





No 11 12.7031 7.7535 -3.34 28.742 













Adj Rsquare 0.01901 
Root Mean Square Error 25.57552 
Mean of Response 6.348748 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain area 1 958.320 958.320 1.4651 0.2384 
Error 23 15044.467 654.107   
C. Total 24 16002.787    
 
Means for Anova 





Hip 15 1.2935 6.6036 -12.37 14.954 












Adj Rsquare -0.0042 
Root Mean Square Error 25.87631 
Mean of Response 6.348748 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain Severity 1 602.370 602.370 0.8996 0.3527 
Error 23 15400.417 669.583   
C. Total 24 16002.787    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
Lots of pain 12 1.2397 7.4698 -14.21 16.692 












Adj Rsquare -0.03435 
Root Mean Square Error 26.26189 
Mean of Response 6.348748 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Family History 1 139.993 139.993 0.2030 0.6565 
Error 23 15862.794 689.687   
C. Total 24 16002.787    
 
Means for Anova 





No 5 1.61600 11.745 -22.68 25.912 













Adj Rsquare -0.02656 
Root Mean Square Error 26.16286 
Mean of Response 6.348748 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Allergies 1 259.399 259.399 0.3790 0.5442 
Error 23 15743.389 684.495   
C. Total 24 16002.787    
 
Means for Anova 





No 8 1.65313 9.2500 -17.48 20.788 












Adj Rsquare -0.03059 
Root Mean Square Error 26.21414 
Mean of Response 6.348748 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Physically 
Active(Work out) 
1 197.624 197.624 0.2876 0.5969 
Error 23 15805.163 687.181   
C. Total 24 16002.787    
 
Means for Anova 





No 5 0.72560 11.723 -23.53 24.977 











Adj Rsquare 0.26075 
Root Mean Square Error 1.6841 
Mean of Response 1.249579 
Observations (or Sum Wgts) 19 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
How Often 4 29.351747 7.33794 2.5872 0.0826 
Error 14 39.706683 2.83619   
C. Total 18 69.058431    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
2X /week 2 0.61500 1.1908 -1.939 3.1691 
3X /week 9 0.84500 0.5614 -0.359 2.0490 
5X /week 3 0.17333 0.9723 -1.912 2.2587 
6X /week 1 0.00000 1.6841 -3.612 3.6120 












RSquare Adj -0.01688 
Root Mean Square Error 10.21742 
Mean of Response 2.704048 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 62.7972 62.797 0.6015 
Error 23 2401.1016 104.396 Prob > F 
C. Total 24 2463.8988  0.4459 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 15.952568 17.20378 0.93 0.3634 











RSquare Adj 0.084158 
Root Mean Square Error 1.378783 
Mean of Response 0.745818 
Observations (or Sum Wgts) 22 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 5.569528 5.56953 2.9297 
Error 20 38.020868 1.90104 Prob > F 
C. Total 21 43.590395  0.1024 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept -0.096646 0.573296 -0.17 0.8678 
Length of 
Osteoarthritis 










Adj Rsquare -0.03073 
Root Mean Square Error 10.49832 
Mean of Response 2.791008 
Observations (or Sum Wgts) 24 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Herbs 1 34.6354 34.635 0.3143 0.5807 
Error 22 2424.7261 110.215   
C. Total 23 2459.3615    
 
Means for Anova 





No 20 3.32825 2.3475 -1.54 8.197 











Adj Rsquare -0.02446 
Root Mean Square Error 10.25544 
Mean of Response 2.704048 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Vitamins 1 44.8963 44.896 0.4269 0.5200 
Error 23 2419.0025 105.174   
C. Total 24 2463.8988    
 
Means for Anova 





No 6 0.31933 4.1868  -8.342 8.9803 











RSquare Adj -0.05798 
Root Mean Square Error 1.616953 
Mean of Response 0.844667 
Observations (or Sum Wgts) 18 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 0.178848 0.17885 0.0684 
Error 16 41.832594 2.61454 Prob > F 
C. Total 17 42.011442  0.7970 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 0.6769669 0.745908 0.91 0.3776 
Number of 
Medication 











Adj Rsquare 0.005294 
Root Mean Square Error 10.10539 
Mean of Response 2.704048 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Joint 
Steroid 
1 115.1633 115.163 1.1277 0.2993 
Error 23 2348.7355 102.119   
C. Total 24 2463.8988    
 
Means for Anova 





No 11 5.12538 3.0469 -1.178 11.428 











Adj Rsquare 0.005741 
Root Mean Square Error 10.10312 
Mean of Response 2.704048 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Phisically 
Limited 
1 116.2190 116.219 1.1386 0.2970 
Error 23 2347.6798 102.073   
C. Total 24 2463.8988    
 
Means for Anova 





No 11 5.13645 3.0462 -1.165 11.438 











Adj Rsquare 0.026727 
Root Mean Square Error 9.995929 
Mean of Response 2.704048 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain area 1 165.7713 165.771 1.6591 0.2105 
Error 23 2298.1275 99.919   
C. Total 24 2463.8988    
 
Means for Anova 





Hip 15 0.60153 2.5809 -4.738 5.941 











Adj Rsquare -0.00192 
Root Mean Square Error 10.14196 
Mean of Response 2.704048 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain 
Severity 
1 98.1320 98.132 0.9540 0.3389 
Error 23 2365.7668 102.859   
C. Total 24 2463.8988    
 
Means for Anova 







12 0.64192 2.9277 -5.415 6.698 











Adj Rsquare -0.03042 
Root Mean Square Error 10.28519 
Mean of Response 2.704048 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Family 
History 
1 30.8427 30.843 0.2916 0.5944 
Error 23 2433.0561 105.785   
C. Total 24 2463.8988    
 
Means for Anova 





No 5 0.48260 4.5997 -9.033 9.9978 











Adj Rsquare -0.0242 
Root Mean Square Error 10.25414 
Mean of Response 2.704048 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Allergies 1 45.5093 45.509 0.4328 0.5171 
Error 23 2418.3895 105.147   
C. Total 24 2463.8988    
 
Means for Anova 





No 8 0.73725 3.6254 -6.762 8.2369 












Adj Rsquare -0.02479 
Root Mean Square Error 10.25705 
Mean of Response 2.704048 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 




1 44.1377 44.138 0.4195 0.5236 
Error 23 2419.7611 105.207   
C. Total 24 2463.8988    
 
Means for Anova 





No 5 0.04660 4.5871 -9.443 9.5357 











Adj Rsquare 0.048828 
Root Mean Square Error 1.153745 
Mean of Response 0.591474 
Observations (or Sum Wgts) 19 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
How Often 4 6.554508 1.63863 1.2310 0.3422 
Error 14 18.635791 1.33113   
C. Total 18 25.190299    
 
Means for Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
2X /week 2 0.00000 0.8158 -1.750 1.7498 
3X /week 9 0.21456 0.3846 -0.610 1.0394 
5X /week 3 1.61000 0.6661 0.181 3.0387 
6X /week 1 0.00000 1.1537 -2.475 2.4745 











RSquare Adj -0.00106 
Root Mean Square Error 10.84252 
Mean of Response 2.86532 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 114.5766 114.577 0.9746 
Error 23 2703.8833 117.560 Prob > F 
C. Total 24 2818.4599  0.3338 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 20.760872 18.2563 1.14 0.2672 










RSquare Adj -0.04939 
Root Mean Square Error 1.138166 
Mean of Response 0.6515 
Observations (or Sum Wgts) 22 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 0.014992 0.01499 0.0116 
Error 20 25.908453 1.29542 Prob > F 
C. Total 21 25.923446  0.9154 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 0.6077903 0.473248 1.28 0.2137 
Length of 
Osteoarthritis 











Adj Rsquare -0.03078 
Root Mean Square Error 11.22515 
Mean of Response 2.972625 
Observations (or Sum Wgts) 24 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Herbs 1 39.4648 39.465 0.3132 0.5814 
Error 22 2772.0865 126.004   
C. Total 23 2811.5513    
 
Means for Anova 





No 20 3.54610 2.5100 -1.66 8.752 











Adj Rsquare -0.0309 
Root Mean Square Error 11.00293 
Mean of Response 2.86532 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Vitamins 1 33.9750 33.975 0.2806 0.6014 
Error 23 2784.4850 121.065   
C. Total 24 2818.4599    
 
Means for Anova 





No 6 0.79083 4.4919 -8.501 10.083 











RSquare Adj -0.0504 
Root Mean Square Error 1.225248 
Mean of Response 0.680722 
Observations (or Sum Wgts) 18 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio 
Model 1 0.276794 0.27679 0.1844 
Error 16 24.019712 1.50123 Prob > F 
C. Total 17 24.296506  0.6734 
 
Parameter Estimates 
Term Estimate Std 
Error 
t Ratio Prob>|t| 
Intercept 0.8893481 0.565212 1.57 0.1352 
Number of 
Medication 










Adj Rsquare 0.013617 
Root Mean Square Error 10.76275 
Mean of Response 2.86532 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Joint 
Steroid 
1 154.2149 154.215 1.3313 0.2604 
Error 23 2664.2451 115.837   
C. Total 24 2818.4599    
 
Means for Anova 





No 11 5.66727 3.2451 -1.046 12.380 














Adj Rsquare 0.015135 
Root Mean Square Error 10.75446 
Mean of Response 2.86532 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Phisically 
Limited 
1 158.3146 158.315 1.3688 0.2540 
Error 23 2660.1453 115.658   
C. Total 24 2818.4599    
 
Means for Anova 





No 11 5.70427 3.2426 -1.004 12.412 











Adj Rsquare 0.014621 
Root Mean Square Error 10.75727 
Mean of Response 2.86532 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain area 1 156.9262 156.926 1.3561 0.2562 
Error 23 2661.5338 115.719   
C. Total 24 2818.4599    
 
Means for Anova 





Hip 15 0.81967 2.7775 -4.926 6.565 











Adj Rsquare -0.0099 
Root Mean Square Error 10.8903 
Mean of Response 2.86532 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Pain 
Severity 
1 90.6905 90.691 0.7647 0.3909 
Error 23 2727.7694 118.599   
C. Total 24 2818.4599    
 
Means for Anova 







12 0.88292 3.1438 -5.620 7.386 











Adj Rsquare -0.03775 
Root Mean Square Error 11.03941 
Mean of Response 2.86532 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Family 
History 
1 15.4827 15.483 0.1270 0.7248 
Error 23 2802.9773 121.869   
C. Total 24 2818.4599    
 
Means for Anova 





No 5 1.29140 4.9370 -8.922 11.504 










Adj Rsquare -0.02772 
Root Mean Square Error 10.98594 
Mean of Response 2.86532 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Allergies 1 42.5688 42.569 0.3527 0.5584 
Error 23 2775.8912 120.691   
C. Total 24 2818.4599    
 
Means for Anova 





No 8 0.96313 3.8841 -7.072 8.9980 










Adj Rsquare -0.03097 
Root Mean Square Error 11.00329 
Mean of Response 2.86532 
Observations (or Sum Wgts) 25 
 
Analysis of Variance 
Source DF Sum of 
Squares 




1 33.7945 33.794 0.2791 0.6023 
Error 23 2784.6655 121.072   
C. Total 24 2818.4599    
 
Means for Anova 





No 5 0.54000 4.9208 -9.639 10.719 











Adj Rsquare 0.549048 
Root Mean Square Error 0.619204 
Mean of Response 0.557 
Observations (or Sum Wgts) 19 
 
Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
How Often 4 9.936378 2.48409 6.4789 0.0036* 
Error 14 5.367786 0.38341   
C. Total 18 15.304164    
 
Means for Oneway Anova 
Level Number Mean Std Error Lower 95% Upper 95% 
2X /week 2 0.00000 0.43784 -0.939 0.9391 
3X /week 9 0.24789 0.20640 -0.195 0.6906 
5X /week 3 0.60333 0.35750 -0.163 1.3701 
6X /week 1 3.43000 0.61920 2.102 4.7581 















Level Minimum 10% 25% Median 75% 90% Maximum 
0 0.613 0.768 0.964 1.01 1.025 1568 4060 
10 0.455 0.8234 0.97 1.01 1.065 1250 3830 
100 0.919 0.9522 0.975 1 1.17 1102 4000 
150 0.814 0.9562 0.985 1.02 1.155 1025.6 3010 
250 0.733 0.958 0.977 1.02 1.135 947.2 5800 
450 0.931 0.9496 0.985 1.03 1.16 1110 3710 
 
Summary of Fit 
Rsquare 0.001509 
Adj Rsquare -0.03316 
Root Mean Square Error 877.9644 
Mean of Response 258.6218 








Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Dosage 
CC_proliferation 
5 167797 33559 0.0435 0.9989 
Error 144 110998299 770822   
C. Total 149 111166096    
 
Means for ANOVA 





0 25 289.244 175.59 -57.8 636.32 
10 25 254.468 175.59 -92.6 601.54 
100 25 249.710 175.59 -97.4 596.78 
150 25 207.991 175.59 -139.1 555.06 
250 25 310.985 175.59 -36.1 658.06 
450 25 239.332 175.59 -107.7 586.40 
 
Means and Std Deviations 





0 25 289.244 898.05 179.61 -81.5 659.94 
10 25 254.468 821.62 164.32 -84.7 593.62 
100 25 249.710 839.36 167.87 -96.8 596.18 
150 25 207.991 661.10 132.22 -64.9 480.88 
250 25 310.985 1175.60 235.12 -174.3 796.25 




















Level Minimum 10% 25% Median 75% 90% Maximum 
0 0 0 0 0.509 1.165 6.832 13.6 
10 0 0 0 0.38 0.9885 2.384 43.5 
100 0 0 0 0.45 1.535 2.694 3.54 
150 0 0 0.006175 0.42 1.2525 4.81 6.59 
250 0 0 0 0.0602 0.8415 4.854 50.9 
450 0 0 0 0 1.61 3.558 54.6 
 
Summary of Fit 
Rsquare 0.011101 
Adj Rsquare -0.02348 
Root Mean Square Error 7.197172 
Mean of Response 1.915028 








Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Dosage CC 
NO+ 
5 83.1515 16.6303 0.3211 0.8997 
Error 143 7407.2976 51.7993   
C. Total 148 7490.4490    
 
 
Means for ANOVA 





0 25 1.50174 1.4394 -1.344 4.3471 
10 25 2.27938 1.4394 -0.566 5.1247 
100 25 0.91432 1.4394 -1.931 3.7596 
150 24 1.19661 1.4691 -1.707 4.1006 
250 25 2.70405 1.4394 -0.141 5.5494 
450 25 2.86532 1.4394 0.020 5.7106 
 
Means and Std Deviations 





0 25 1.50174 3.1611 0.6322 0.197 2.8066 
10 25 2.27938 8.6178 1.7236 -1.278 5.8366 
100 25 0.91432 1.0535 0.2107 0.479 1.3492 
150 24 1.19661 1.8188 0.3713 0.429 1.9646 
250 25 2.70405 10.1322 2.0264 -1.478 6.8864 












Level Minimum 10% 25% Median 75% 90% Maximum 
0 0 0 0 0 0.03545 1.972 6.44 
10 0 0 0 0 0 3.444 9 
100 0 0 0 0 0.1345 6.83 24.4 
150 0 0 0 0 0.036719 1.40043 2.041958 
250 0 0 0 0 0 1.3594 3.56 
450 0 0 0 0 0 1.1544 3.38 
 
Summary of Fit 
Rsquare 0.041547 
Adj Rsquare 0.008268 
Root Mean Square Error 2.422608 
Mean of Response 0.600107 








Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Dosage-2 5 36.63538 7.32708 1.2484 0.2897 
Error 144 845.14052 5.86903   
C. Total 149 881.77590    
 
 
Means for ANOVA  






0 25 0.50708 0.48452 -0.4506 1.4648 
10 25 0.70548 0.48452 -0.2522 1.6632 
100 25 1.63780 0.48452 0.6801 2.5955 
150 25 0.22405 0.48452 -0.7336 1.1817 
250 25 0.27556 0.48452 -0.6821 1.2333 
450 25 0.25068 0.48452 -0.7070 1.2084 
 
Means and Std Deviations 




0 25 0.50708 1.42734 0.2855 -0.0821 1.0963 
10 25 0.70548 2.15432 0.4309 -0.1838 1.5947 
100 25 1.63780 5.16462 1.0329 -0.4941 3.7697 
150 25 0.22405 0.54646 0.1093 -0.0015 0.4496 
250 25 0.27556 0.93476 0.1870 -0.1103 0.6614 







ANOVA TEST OF NITRIC OXIDE TOTAL CELL (LIVE AND DEAD CELLS) 




Level Minimum 10% 25% Median 75% 90% Maximum 
0 0.445 0.5502 0.825 1.14 2.505 5.102 9.59 
10 0.0448 0.3994 0.6435 0.885 1.615 16.97 2310 
100 0.423 0.5196 0.6745 1.07 2.75 29.88 296 
150 0.000991 0.02608 0.4365 0.906 2.285 393.44 1330 
250 0.0378 0.1272 0.5375 0.746 1.1915 7.694 31.9 
450 0.103 0.3962 0.5055 1.14 2.43 8.472 507 
 
Summary of Fit 
Rsquare 0.029413 
Adj Rsquare -0.00429 
Root Mean Square Error 234.424 
Mean of Response 38.39786 








Analysis of Variance 
Source DF Sum of 
Squares 
Mean Square F Ratio Prob > F 
Dosage -3 5 239815.9 47963.2 0.8728 0.5011 
Error 144 7913463.0 54954.6   
C. Total 149 8153278.8    
 
 
Means for ANOVA 





0 25 2.0147 46.885 -90.66 94.69 
10 25 94.9661 46.885 2.29 187.64 
100 25 15.5591 46.885 -77.11 108.23 
150 25 93.1723 46.885 0.50 185.84 
250 25 2.6213 46.885 -90.05 95.29 
450 25 22.0538 46.885 -70.62 114.73 
 
Means and Std Deviations 





0 25 2.0147 2.119 0.424 1.14 2.89 
10 25 94.9661 461.509 92.302 -95.54 285.47 
100 25 15.5591 59.002 11.800 -8.80 39.91 
150 25 93.1723 320.928 64.186 -39.30 225.64 
250 25 2.6213 6.551 1.310 -0.0829 5.33 
450 25 22.0538 101.060 20.212 -19.66 63.77 
 
